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ABSTRACT OF THE DISSERTATION
The Role of Claudins in Bone Metabolism
by
Fatima Zakariya Alshbool
Doctor of Philosophy, Graduate Program in Pharmacology
Loma Linda University, December 2014
Dr. Subburaman Mohan, Chairperson

Osteoporosis, a major public health problem in the U.S., is characterized by low
bone mass and structural deterioration of bone tissue. Since the imbalance between bone
formation and bone resorption during bone remodeling has been documented to be a
major factor in the pathogenesis of osteoporosis, it is crucial to identify novel genes
and/or novel functions of known genes that regulate the formation and activity of bone
forming osteoblasts and bone resorbing osteoclasts. To this end, recent evidence suggests
a significant role for caudins (Cldns), which comprise a major group of tight junction
proteins, in bone biology and development. This notion is based on our previous studies
which demonstrated that Cldn-18 knockout (KO) mice developed osteopenia phenotype
by increasing bone resorption and osteoclast differentiation. Since Cldn-18 is known to
be predominately expressed in the stomach, and it was globally disrupted in these earlier
studies, in this dissertation we tested the possibility that the osteopenia phenotype in these
mice is due to its disruption in the stomach. We found that loss of Cldn-18 reduced
gastric acidity and serum calcium in adult mice. However, correction of serum calcium
deficit did not rescue the osteopenia phenotype observed in Cldn-18 KO mice, thus
suggesting that increased bone resorption is likely to be due to direct effects of lack of
Cldn-18 on osteoclasts, and not due to gastric pH changes caused by its loss in the
xiv

stomach. Since the Cldn family consists of 27 members, in a separate set of studies, their
expression was examined during osteoblast and osteoclast differentiation. We found that
several Cldns are expressed in bone, in a complex, cell type and differentiation stagedependent fashion. Moreover, of those Cldns found to be expressed, a key member,
namely Cldn-1, was found to be a positive regulator of osteoblast proliferation and
differentiation, and is regulated by several osteoregulatory factors. Collectively, our
studies suggest that Cldns play important non canonical functions in regulating bone cell
signaling, and may lay down the foundation for the development of Cldn-based agents for
diagnosis and therapeutic management of osteoporosis.

xv

CHAPTER ONE
INTRODUCTION
Osteoporosis
Osteoporosis, a major public health problem, is characterized by low bone mass
and structural deterioration of bone tissue resulting in increased bone fragility (Dempster,
2011; Raisz, 2005). According to the National Institutes Consensus Development
Conference, osteoporosis is described as “a skeletal disorder characterized by
compromised bone strength predisposing to an increased risk of fracture. Bone strength
reflects the integration of two main features: bone density and bone quality. Bone density
is expressed as grams of mineral per area or volume and in any given individual is
determined by peak bone mass and amount of bone loss. Bone quality refers to
architecture, turnover, damage accumulation (e.g., microfractures) and mineralization. A
fracture occurs when a failure-inducing force (e.g., trauma) is applied to osteoporotic
bone. Thus, osteoporosis is a significant risk factor for fracture, and a distinction between
risk factors that affect bone metabolism and risk factors for fracture must be made”.
Osteoporosis is considered as a “silent disease” because it remains undetected until bone
fractures occur (Dempster, 2011; Raisz, 2005). It is well known that osteoporosis related
fractures result in both physical and psychological consequences that have a significant
impact on patients’ quality of life, such as decreased functionality, disability, depression,
pain and anxiety (Colon-Emeric & Saag, 2006; Pasco et al., 2005). In addition, fractures
are associated with increased mortality and morbidity, depending on the affected site,
with hip and spine being the most common sites (Dempster, 2011). For instance, the one
year survival post hip fracture is decreased by 10-20%, compared to control population
(Abrahamsen, van Staa, Ariely, Olson, & Cooper, 2009; Panula et al., 2011).
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In the United States, 10 million individuals have already been diagnosed with
osteoporosis, and this number is expected to rise to 14 million by 2020
(http://www.nof.org/ aboutosteoporosis /bonebasics/whybonehealth, 2011). Moreover,
around 34 million Americans have low bone mass and are, therefore, at increased risk of
osteoporosis or an osteoporotic related fracture (http://www.nof.org/aboutosteoporosis
/bonebasics/whybonehealth, 2011). In fact, according to the National Osteoporosis
Foundation, it is expected that one in four men, and one out of every two women will
experience an osteoporosis related fracture during their life. (http://www.nof.org/
aboutosteoporosis/bonebasics /whybonehealth, 2011). As for the economic burden of
osteoporosis, it resides in direct medical cost of osteoporosis related fractures, which
have been estimated in the United States at 13.7-20.3 billion dollars in 2005 (Burge et al.,
2007). By 2025, the expected annual cost for treatment of osteoporosis related fractures is
approximately 25.3 billion dollars (http://www.nof.org/aboutosteoporosis/bonebasics/
whybonehealth, 2011). Collectively, these aforementioned “facts” clearly demonstrate an
urgent need for improving the diagnosis, prevention and treatment of osteoporosis.

Etiology and Risk Factors
It is well established that osteoporosis can result from failure to produce optimal
bone mass during active growth periods and/ or the imbalance between bone formation
and bone resorption during bone remodeling processes (Raisz, 2005). Osteoporosis is a
multifactorial disease, with a number of risk factors implicated in its pathogenesis,
including genetics, gender, age, and environmental factors such as nutrition, and physical
inactivity.
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As for genetic factors, they have been found to play an essential role in the
regulation of bone mineral density variation, as evident from twins and family studies
that suggest a high (50-85%) heritability of bone mineral density (Arden, Baker, Hogg,
Baan, & Spector, 1996; Smith, Nance, Kang, Christian, & Johnston, 1973). In addition,
inter-individual variance of bone formation markers was found to be attributable to
genetic factors in premenopausal twins (Garnero, Arden, Griffiths, Delmas, & Spector,
1996; Harris, Nguyen, Howard, Kelly, & Eisman, 1998). These observations prompted
extensive research efforts in an attempt to identify genes responsible for developing
osteoporosis, by applying either a candidate gene approach or genome wide research
strategy. These studies uncovered several novel single nucleotide polymorphisms (SNPs)
that are associated with low bone mineral density and osteoporosis, including genes
encoding nuclear receptors (e.g., vitamin D and estrogen receptors), and wnt-β-catenin
signaling proteins (e.g., lipoprotein receptor related protein (LRP5) and sclerostin)
(Gennari et al., 2005; Morrison et al., 1994; Richards, Zheng, & Spector, 2012; Urano &
Inoue, 2014). It is noteworthy that genome wide association studies (GWAS) have
identified 62 genome wide significant loci involved in the pathogenesis of osteoporosis,
which indicate that it is a complex disease, regulated by multiple genes (Richards et al.,
2012).
It is well established that gender plays a role in developing osteoporosis, given
that it is more common in women than men (Kling, Clarke, & Sandhu, 2014). In fact, sex
steroids play a significant role in regulating bone metabolism, which is evident in
menopausal women as estrogen deficiency was found to be associated with increased
bone turnover and loss (Raisz, 2005). To this end, the negative effect of estrogen
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deficiency on the skeleton was found to be mediated by multiple mechanisms, such as
enhanced osteoclast differentiation and function, decreased osteoblast differentiation, as
well as increased osteoblast apoptosis (Chow, Tobias, Colston, & Chambers, 1992;
Gohel, McCarthy, & Gronowicz, 1999; Syed & Khosla, 2005; Zallone, 2006).
Interestingly, sex steroids also serve as important regulators of bone health in males.
Estrogen and testosterone were shown to regulate bone mass, and their deficiencies
resulted in bone loss in men (Chin & Ima-Nirwana, 2012; Ohlsson, Borjesson, &
Vandenput, 2012).
Age is considered an important and irreversible risk factor for osteoporosis. Aside
from age dependent decrease in sex hormones, increased bone turnover is considered the
major cause of aging-induced bone loss (Seeman, 2003). In this connection, bone loss is
known to accelerate as people age due to the reduced bone mass being subjected to the
same or perhaps a higher intensity of remodeling; thus the same or larger volume of bone
is removed from an already decreased bone mass (Seeman, 2003). In addition, several
lines of evidence have demonstrated that bone formation is reduced with aging as a
consequence of reduced osteoblasts numberans, life span, impaired differentiation and
function, and enhanced adipocyte differentiation (Kassem & Marie, 2011; Khosla, 2013;
Stringer et al., 2007). There are also a number of secondary causes of age related
osteoporosis, including diseases such as malabsorption, medications such as
corticosteroids, and physical inactivity (Khosla, 2013; Lane & Yao, 2010).
Osteoporosis is also determined by environmental factors such as nutrition,
inadequate physical activity, alcohol, and smoking. Diet is very important for the
development and maintenance of the skeleton. For example, calcium and vitamin D
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deficiency can result in decreased bone mass and increased risk of fracture (Koo &
Walyat, 2013; Murad et al., 2011). Thus, in order to prevent or reduce the risk of
osteoporosis, it is important to eat a healthy balanced diet with adequate calcium and
vitamin D. Additionally, some diseases and medications can contribute to vitamin D and
calcium deficiency such as malabsorptive disorders (Krupa-Kozak, 2014; Targownik,
Bernstein, & Leslie, 2013). As stated before, physical inactivity has a negative impact on
bone; for example, prolonged bed rest may result in a significant bone loss (Bergmann et
al., 2010; Inoue et al., 2000). However, it was found that loading the immobilized tibia
increases periosteal bone formation, and decreases bone loss caused by immobilization
(Bergmann et al., 2010; Inman, Warren, Hogan, & Bloomfield, 1999). In addition,
several studies have documented that mechanical loading increases bone formation
(Kesavan & Mohan, 2010; Kesavan, Mohan, Oberholtzer, Wergedal, & Baylink, 2005).
Consequently, physical activity/exercise is employed as a modality to preserve bone mass
and decrease risk of fractures (Tveit, Rosengren, Nilsson, & Karlsson, 2014). Taken
together, these data suggest that osteoporosis is a complex disease, and is determined by
interplay of a host of genetic and environmental factors.

Pharmacological Management of Osteoporosis
The goal of the therapeutic management of osteoporosis is to decrease bone loss
and reduce the risk of fracture (Hosoi, 2007; Nakamura, 2008). Since osteoporosis results
from an imbalance between bone formation and bone resorption, it is treated by
decreasing bone resorption and/or increasing bone formation (Sweet, Sweet, Jeremiah, &
Galazka, 2009). There are several Food and Drug Administration (FDA) approved anti-
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resorptive drugs such as bisphosphonate, raloxifene, calcitonin, amongst others (Sweet et
al., 2009). Importantly though, it is now known that the long term use of the most
prescribed anti-resorptive agents is associated with an increased risk of jaw osteonecrosis
and atypical fractures (Boyce, 2013). While there are many FDA approved antiresorptive drugs, there is a shortage of anabolic drugs. Teriparatide, a recombinant form
of endogenous human parathyroid hormone (PTH 1-34), is in fact the only FDA
approved bone anabolic agent (Brixen, Christensen, Ejersted, & Langdahl, 2004).
Therefore, in order to identify/meet the need for new anabolic agents, design safer antiresorptive drugs, and advance our knowledge of the pathogenesis of osteoporosis, it is
important to identify novel genes and/or novel function(s) of known genes as well as
(better) understand the related molecular mechanisms regulating osteoblast and osteoclast
functions.

The Skeleton
The skeleton makes up about 20% of our body and consists of about 213 bones
(Chau, Leong, & Li, 2009; Clarke, 2008). The bones of our skeleton provide mechanical
support and motility, protect internal organs, serve as a reservoir for minerals such as
calcium and phosphorus, and provide an environment for hematopoiesis within the
marrow spaces (Chau et al., 2009; Long, 2012). The bone is a dynamic tissue that
continuously undergoes remodeling throughout life (Hadjidakis & Androulakis, 2006).
As for bone remodeling, it is a process by which old bone is removed and replaced by
new bone, in order to maintain the skeletal integrity, strength, and mineral homeostasis
(Hadjidakis & Androulakis, 2006). The remodeling cycle consists of four sequential
phases including: activation, resorption, reversal, and formation (Clarke, 2008) (Fig. 1).
6

Figure 1. Bone remodeling Cycle. The remodeling cycle consists of four sequential
phases including: activation, resorption, reversal, and formation. This process requires a
well-coordinated activity of cells of the osteoblast and osteoclast lineages, in what is
known as the basic multicellular unit (BMU); which carry out resorption of old bone and
formation of new bone, in a sequential manner. Modified from (Persy & D'Haese, 2009)
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Therefore, this process requires a well-coordinated activity of cells of the
osteoblast and osteoclast lineages, in what is known as the basic multicellular unit
(BMU); which carry out resorption of old bone and formation of new bone, in a
sequential manner (Hou et al., 2009). To this end, there are three cell types in bone: 1) the
bone forming osteoblasts; 2) the mechanosensory osteocytes; and 3) the bone resorbing
osteoclasts. These cells are known to communicate with each other, by either direct cellcell contact and/or indirect signaling molecules with the ultimate goal of maintaining
bone homeostasis (Nakahama, 2010). Thus, it is important to understand the molecular
mechanisms and signaling pathways which regulate osteoblast, osteocyte, and osteoclast
functions.

Osteoblasts
As the chief bone forming cells, osteoblasts produce bone matrix proteins such as
type I collagen, alkaline phosphatase (ALP), and osteocalcin (Long, 2012). Osteoblasts
are mononuclear cuboidal cells with well-developed endoplasmic reticulum and a large
Golgi complex supporting its secretory function (Long, 2012). Osteoblasts have also been
found to express numerous genes that are not only essential but also sufficient for the
formation and mineralization of bone (Long, 2012). To this end, ALP is highly expressed
in osteoblasts, and hence ALP activity and staining is widely used to identify
osteoblasts in vitro and even in vivo (Anh, Dimai, Hall, & Farley, 1998). Besides their
role in bone formation, osteoblasts regulate bone resorption by secreting important
factors for osteoclastogenesis, such as the receptor activator of nuclear factor kappa B
ligand (RANKL) (Nakahama, 2010; Proff & Romer, 2009).
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Osteoblast Differentiation
Osteoblasts originate from mesenchymal stem cells, which can also differentiate
into other cell types such as osteoblasts, chondrocytes, adipocytes, fibroblasts, and
myoblasts, depending on the expression of lineage specific transcription factors (Chau et
al., 2009). The selective expression/function of transcription factors at distinct points
during osteoblast differentiation regulates the osteoblastic lineage (Fig. 2). For example,
Runx-2 and osterix (Osx) are considered the key transcription factors required for
osteoblast differentiation (Jensen, Gopalakrishnan, & Westendorf, 2010; Marie, 2008).
Osteoblast differentiation processes are divided into several stages, including
commitment to osteoprogenitors, their expansion, and maturation to functional
osteoblasts; which in turn will be terminated by becoming osteocytes, bone lining cells,
or dying (Fig. 2) (Chau et al., 2009; Jensen et al., 2010). As for the differentiation status
of osteoblasts, it is usually evaluated by the expression level of osteogenic marker genes
including ALP (early-stage marker), type I collagen, bone sialoprotein (BSP), and
osteocalcin (late-stage marker). To this end, osteoblast differentiation and bone formation
are regulated by hormones, growth factors, cytokines, and transcription factors.

Hormones Regulating Osteoblastogenesis
Several hormones have been shown to regulate osteoblast differentiation. For
instance, estrogen exerts an anabolic effect by promoting osteoblastogenesis and
inhibiting osteoblast apoptosis through modulating Runx-2 and wnt signaling (Gohel et
al., 1999; Marie, 2008; Qu et al., 1998). The growth hormone also plays a fundamental
role in regulating skeletal growth, and this role is primarily mediated by insulin like
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Figure 2. Regulation of osteoblast differentiation. Osteoblasts are derived from
mesenchymal stem cell. Runx-2 and osterix (Osx) are considered the key transcription
factors required for osteoblast differentiation and bone formation. The differentiation
processes are divided into several stages, including commitment to osteoprogenitors, their
expansion, and maturation to functional osteoblasts, which in turn will be terminated by
becoming osteocytes, bone lining cells, or dying. The differentiation status of osteoblasts
is usually evaluated by the expression level of osteogenic marker genes including ALP
(early-stage marker), bone sialoprotein (BSP), and osteocalcin (late-stage marker).
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growth factor-I (IGF-I) (Mohan & Kesavan, 2012). As for the parathyroid hormone
(PTH), it stimulates both bone formation and resorption at physiological conditions
(Aslan et al., 2012). The anabolic effects of PTH are mediated by multiple mechanisms,
including increasing the expression and activity of Runx-2 and Osx, suppressing the
expression of adipogenic transcription factors such as PPARγ in osteoprogenitor cells,
and promoting osteoblast survival by activating wnt/β-catenin signaling (Bellido et al.,
2003; Greenfield, 2012; B. L. Wang et al., 2006). Vitamin D3 also regulates bone
formation by activating and/or suppressing several osteoblast genes (Ramasamy, 2006).
For example, it stimulates the production of bone matrix proteins such as ALP and
osteopontin, whereas a separate study has shown that it suppresses Runx-2 (Drissi et al.,
2002; Prince & Butler, 1987; Ramasamy, 2006). Ascorbic acid (AA) is another key
inducer of osteoblastogenesis, and its deficiency results in impaired bone formation and
spontaneous fracture (Mohan et al., 2005). Several studies have shown that the addition
of AA to cultured osteoblast-like cells stimulates the initial disposition of collagenous
extracellular matrix proteins followed by induction of osteoblastogenic markers genes
(Harada, Matsumoto, & Ogata, 1991; Mohan et al., 2005; Xing, Pourteymoor, & Mohan,
2011). Thus, it is clear that AA is essential for osteoblast formation and function.

Growth Factors Regulating Osteoblastogenesis
A number of growth factors have been demonstrated to be involved in regulating
osteoblast differentiation and bone formation such, as bone morphogenetic proteins
(BMPs), transforming growth factor-β (TGF-β), fibroblast growth factors (FGF), IGF-I,
and wnts , amongst others.
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BMPs, a subfamily of TGF-β superfamily, are one of the major transducers of
osteoblast differentiation and bone formation (Chau et al., 2009). Furthermore, previous
in vitro and in vivo studies have shown that the anabolic effects of BMPs on bone are
mediated by regulating the expression of Runx-2 and Osx, thereby modulating several
aspects of osteoblast differentiation including osteoprogenitor commitment, expansion,
and activity (Chau et al., 2009). Several BMPs, such as BMP-2, -4, -5, -6, and -7, are
known to have a strong osteogenic capacity (Chen, Deng, & Li, 2012). BMPs have also
been found to signal through Smad-dependent and Smad-independent (e.g. MAPK)
pathways, with Smad signaling being mediated by the BMP receptor (Chau et al., 2009;
Chen et al., 2012). TGF-β, which is abundant in bone matrix, is another important growth
factor that is known to promote osteoblast differentiation and activity (Janssens, ten
Dijke, Janssens, & Van Hul, 2005). Specifically, TGF-β has been shown to play
important roles in the proliferation and expansion of osteoprogenitors, and early stages of
osteoblast differentiation. It has been demonstrated that TGF-β regulates Runx-2 through
the canonical Smad-dependent and the non-canonical Smad-independent pathways (Chau
et al., 2009; Chen et al., 2012). IGF-I, is another major growth factor that is locally
produced by bone cells and acts in an autocrine/paracrine manner to regulate
osteoblastogenesis (Mohan & Kesavan, 2012). The anabolic effect of IGF-I is mediated,
in part, by promoting the survival, proliferation, differentiation, and function of
osteoblasts (Tahimic, Wang, & Bikle, 2013). Moreover, it signals through the IGF-I
receptor, which is a tyrosine kinase receptor that activates several intracellular signaling
pathways, such MAPK and PI-3K-AKT (Chau et al., 2009). The wnt family of
glycoproteins is an important regulator of osteoblastogenesis, which acts at several stages
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of osteoblast differentiation (Bodine & Komm, 2006; Yavropoulou & Yovos, 2007).
There are two wnt pathways known to play important roles during the various osteoblast
differentiation stages, from commitment to termination, i.e., the canonical β-catenindependent and the non-canonical β-catenin-independent pathway (e.g. JNK and PKC)
(Kubota, Michigami, & Ozono, 2009; Monroe, McGee-Lawrence, Oursler, &
Westendorf, 2012). The canonical wnt/β-catenin signals through frizzled receptor and
LRP5/6 co-receptor thereby inactivating GSK-3β and stabilizing β-catenin. This, in turn,
results in β-catenin nuclear translocation and binding to LEF/TCF transcription factors
and the regulation of the expression of β-catenin target genes (Bodine & Komm, 2006;
Monroe et al., 2012). In addition, wnt signaling promotes osteoblastogenesis by induction
of Runx-2 and Osx, and suppression of adipogenic transcription factors such as PPARγ
(Kubota et al., 2009). The wnt pathway was also found to regulate the expression of
genes involved in modulating osteoblast proliferation and apoptosis (Chau et al., 2009).

Transcription Factors Regulating Osteoblastogenesis
Runx-2, a runt domain-containing transcription factor, is essential for controlling
osteoblast commitment and differentiation (Komori, 2010). This notion is evident by the
finding that targeted deletion of Runx-2 in mice results in complete absence of
osteoblasts and mineralized bone (Komori et al., 1997; Otto et al., 1997). Indeed, Runx-2
haploinsufficiency is associated with a human disease known as cleidocranial dysplasia,
which is characterized by defective bone formation and ossification of cranial bones
(Mundlos et al., 1997). Furthermore, Runx-2 is expressed during all stages of osteoblast
differentiation, is necessary for mesenchymal stem cell commitment towards osteoblast
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lineages, as well as the control of the expression of major osteoblast specific genes,
including type I collagen, osteopontin, BSP, and osteocalcin (Komori, 2010; Marie,
2008). Since the promoter of these aforementioned genes has a Runx-2 regulatory
element, Runx-2 can positively or negatively regulate their expression by interacting with
several transcriptional activators and repressors and other co-regulatory proteins (Marie,
2008). Osx, a zinc finger transcription factor, is also essential for osteoblastogenesis,
given that its deletion in mice resulted in lack of osteoblasts and defective bone formation
(Nakashima et al., 2002; Zhang, 2010). It is believed that Osx is downstream of Runx-2,
as Osx expression was absent in Runx-2 deficient mice, whereas normal levels of Runx-2
were detected in Osx null mice (Jensen et al., 2010; Nakashima et al., 2002). Besides
Runx-2 and Osx, several other transcription factors have been implicated in the
regulation of osteoblast differentiation, including AP-1, ATF4, Dlx-3, Dlx-5, Dlx-6, Fra,
and Msx2 (Jensen et al., 2010). It is thought that these transcription factors have a
facilitating role in osteoblastogenesis, given that no severe phenotype was observed with
their genetic manipulation (Long, 2012).
Taken together, these findings clearly demonstrate that the regulation of
osteoblastogenesis is complex and mediated by several hormones, growth factors, and
transcription factors. Although much progress has been made in this area, our
understanding of the molecular pathways that regulate osteoblast differentiation and
function is still limited. Thus, the identification of novel genes that participate in
regulating osteoblast function(s) is imperative in advancing our understanding of the
mechanisms that regulate bone formation.
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Osteocytes
Osteocytes are the most abundant cells in the skeleton, and comprise up to 9095% of bone cells (Knothe Tate, Adamson, Tami, & Bauer, 2004). They are derived from
osteoblast lineage cells, in which the terminally differentiated osteoblasts become
embedded in the bone matrix (Bonewald, 2011). They express low levels of ALP and
high levels of osteocalcin and casein kinase II, which are considered as molecular maker
genes (Bonewald, 2011). In terms of morphology, osteocytes have distinct dendritic
processes that radiate from their cell body, and connect to each other and different cell
types via gap junctions (Schaffler & Kennedy, 2012). Originally, while they were thought
to be inert cells embedded in the matrix (Bonewald, 2011; Schaffler & Kennedy, 2012), it
has been demonstrated that osteocytes have multiple essential functions. These include:
1) acting as mechanosensory cells; 2) regulating bone formation mainly by secreting
sclerostin, an important inhibitor of wnt signaling; 3) modulating bone resorption by
secreting osteoclastogenic factors ; 4) regulating bone matrix mineralization by inducing
the expression of proteins such as DMP1, PHEX, and MEPE; and 5) participating in
regulation of phosphate and calcium metabolism (Schaffler & Kennedy, 2012).
Collectively, osteocytes seem to be a local key orchestrator of a host of bone functions.

Osteoclasts
Osteoclasts are giant multinucleated cells that are responsible for the removal of
mineralized bone during bone development, homeostasis, and repair (S. K. Lee &
Lorenzo, 2006). They have unique and efficient machinery for dissolving crystalline
hydroxyapatite and degrading organic bone matrix (Vaananen, Zhao, Mulari, & Halleen,
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2000). Resorbing osteoclasts come into contact with bone surface and form Howship`s
lacunae by undergoing cytoskeletal reorganization and cellular polarization (Bruzzaniti &
Baron, 2006). Consequently, these processes result in the formation of three distinct parts
of the plasma membrane: sealing zone, apical membrane (ruffled border), and basolateral
membrane (Vaananen et al., 2000). As for the sealing zone, it anchors the resorbing
osteoclast to bone matrix and seals the resorption lacunae from its surroundings via
integrins (Bruzzaniti & Baron, 2006). A district feature of osteoclasts is their ruffled
border, which consists of multiple finger like projection of plasma membrane facing the
bone matrix (Vaananen et al., 2000). This border serves as the resorbing organelle by
delivering hydrochloric acid to dissolve mineralized components of the bone, and
vesicles containing lysosomal enzymes (e.g. cathepsin K and MMP-9) in order to degrade
organic bone matrix (Vaananen & Laitala-Leinonen, 2008; Vaananen et al., 2000). As for
the acid secretion machinery, it is composed of an electrogenic proton pump (H+ATPase), and a chloride channel in the ruffled border, as well as carbonic anhydrase in
the cytoplasm,which together, maintain the acidic pH (4-5) of the resorption lacunae
(Supanchart & Kornak, 2008). The degraded products are then endocytosed and
transported into the basolateral membrane (Mulari, Vaaraniemi, & Vaananen, 2003). It is
well known that the basolateral membrane is involved in transcytosis and exocytosis of
degraded bone matrix through its functional secretory domain (Mulari et al., 2003; Salo,
Lehenkari, Mulari, Metsikko, & Vaananen, 1997). Moreover, it is involved in receiving
signals from different cytokines and hormones, and in cell-cell interactions with other
bone cells (Vaananen & Laitala-Leinonen, 2008). Of note, tartrate resistant-acid
phosphatase (TRAP) is highly expressed in osteoclasts, and therefore TRAP expression
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and staining is widely used to identify osteoclasts in vitro and in vivo (Takeshita, Kaji, &
Kudo, 2000).

Osteoclast Differentiation
Osteoclast precursors are hematopoietic cells derived from the
monocyte/macrophage lineage (Boyle, Simonet, & Lacey, 2003; Bruzzaniti & Baron,
2006). The process of osteoclast formation is divided into several stages, including
osteoclastic lineage commitment, proliferation, differentiation, survival and fusion (Fig.
3). Each stage is regulated by one or more cytokines and transcription factors. It is well
known that macrophage colony stimulating factor (MCSF) and RANKL are sufficient for
inducing osteoclast differentiation and function (Boyce, 2013; S. K. Lee & Lorenzo,
2006). The differentiation of osteoclasts is usually evaluated by measuring the expression
level of osteoclastogenic marker genes including early-stage markers (e.g., RANK) and
late-stage markers (e.g., TRAP, calcitonin receptor, and cathepsin K) (Boyce, 2013;
Boyle et al., 2003). To this end, research efforts have thus far documented that
osteoclastogenesis is regulated by several hormones, cytokines, transcription factors,
amongst others (Asagiri & Takayanagi, 2007; Boyce, 2013; Yoshida et al., 1990).
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Figure 3. Regulation of osteoclast differentiation. Osteoclasts derive from
monocyte/macrophage lineage hematopoietic cells, and their formation is divided into
several stages, including osteoclastic lineage commitment, proliferation, differentiation,
survival and fusion. Each of these stages is regulated by one or several cytokines and
transcription factor. MCSF and RANKL are sufficient for inducing osteoclast
differentiation and function. The differentiation of osteoclasts is evaluated by measuring
the expression level of marker genes including early-stage markers (e.g., RANK) and
late-stage markers (e.g., tartrate resistant acid phosphatase (TRAP) and cathepsin K
(Ctsk).
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Hormones Regulating Osteoclastogenesis
It is well documented that estrogen is a negative regulator of bone resorption
(Zallone, 2006). The negative effects of estrogen on osteoclastogenesis are complex and
is mediated by several mechanisms, including indirectly modulating the production of
RANKL and osteoprotegerin (OPG; a decoy receptor for RANKL) by osteoblast lineage
cells, directly modulating osteoclast activity and apoptosis, as well as reducing the
production of osteoclastogenic cytokines such as TNF-α and IL-1 (Kameda et al., 1997;
Lorenzo et al., 1998; Zallone, 2006). Vitamin D3 is also considered an inducer of bone
resorption at supraphysiological doses (Ramasamy, 2006; Takahashi, Udagawa, & Suda,
2014). It has been demonstrated that the positive effect of vitamin D3 on
osteoclastogenesis is indirect and mediated by upregulation of RANKL in osteoblast
lineage cells (Ramasamy, 2006). In addition, vitamin D3 has been shown to
downregulate the expression of OPG (Ramasamy, 2006). In contrast, several studies have
shown that vitamin D3 inhibits bone resorption, and this suppressive effect could be
mediated by its direct action on osteoclasts (Sakai et al., 2009; Takahashi et al., 2014;
Takasu et al., 2006). Thus, the effect of vitamin D3 on osteoclastogenesis appears to be
complex and dose dependent. PTH is another calcitropic hormone that enhances
osteoclast formation and function, when it is administered continuously (Ramasamy,
2006). It positively regulates osteoclastogensis by increasing the RANKL/OPG ratio
produced by osteoblasts (Ramasamy, 2006). On the other hand, calcitonin was found to
be a potent inhibitor of osteoclastic bone resorption, whose function is to maintain normal
calcium homeostasis (Naot & Cornish, 2008).

19

Cytokines Regulating Osteoclastogenesis
It is well known that MCSF and RANKL are sufficient for inducing osteoclast
differentiation and function (Boyce, 2013; S. K. Lee & Lorenzo, 2006). MCSF is an
essential osteoclastogenic cytokine secreted by osteoblasts (S. K. Lee & Lorenzo, 2006).
It was found that MCSF was deficient in osteopetrotic mice that are lacking osteoclasts,
and this osteopetrotic phenotype was rescued by MCSF injection or its selective
expression in osteoblasts (Abboud, Woodruff, Liu, Shen, & Ghosh-Choudhury, 2002;
Yoshida et al., 1990). Upon binding to its receptor (c-FMS) that is expressed on
osteoclast precursors, MCSF upregulates the expression of RANK, and stimulates the
proliferation and survival of these cells (Ross & Teitelbaum, 2005). As for RANKL, it is
a member of the tumor necrosis factor (TNF) superfamily, and is a key cytokine for
osteoclast differentiation and activity (S. K. Lee & Lorenzo, 2006). Targeted deletion of
RANKL in mice results in osteopetrotic phenotype (characterized by high bone mass
density) due to lack of osteoclasts (Kong et al., 1999). Moreover, RANKL is produced by
marrow stromal and osteoblastic cells, and binds to its cognate receptor (RANK) that is
expressed on osteoclasts, which in turn activates downstream signaling that is involved in
osteoclastoegenesis. In contrast, OPG is a decoy receptor for RANKL, and is secreted by
marrow and osteoblastic cells to negatively regulate osteoclast differentiation (Boyle et
al., 2003; Lacey et al., 1998). The physiological importance of OPG was demonstrated by
severe osteoporosis developed in OPG deletion mice due to increased osteoclast
differentiation (Bucay et al., 1998). Therefore, the ratio of RANKL/OPG produced by
marrow and osteoblastic cells has either a positive or negative impact on osteoclast
differentiation and bone resorption. In addition to the MCSF/RANKL/OPG axis, several
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other cytokines have been implicated in regulating osteoclast differentiation, such as
TNF-α, IL-1, and IL-6 (Azuma, Kaji, Katogi, Takeshita, & Kudo, 2000; Jimi et al., 1999;
S. K. Lee & Lorenzo, 2006; T. Tamura et al., 1993). These cytokines stimulate
osteoclastogenesis by either exerting direct effects on osteoclasts, or indirect effects by
modulating the MCSF/RANKL/OPG axis (S. K. Lee & Lorenzo, 2006).

Transcription Factors Regulating Osteoclastogenesis
As can been seen in Fig. 3, there are multiple transcription factors involved in the
regulation of different stages of osteoclast formation. The commitment, proliferation, and
survival of osteoclast precursors are mainly regulated by the PU.1 and MITF
transcription factors. Their physiological significance was confirmed by genetic studies
in which osteopetrosis was observed in mice lacking PU.1 or MITF genes (Tondravi et
al., 1997; Weilbaecher et al., 2001). Additionally, PU.1 and MITF has been shown to be
linked to MCSF signaling (Mellis, Itzstein, Helfrich, & Crockett, 2011). Thus, PU.1
upregulates the expression of the MCSF receptor (c-FMS), whereas MITF is activated by
MCSF signaling and promotes macrophage survival by inducing the expression of an
anti-apoptotic protein (Bcl-2) (DeKoter, Walsh, & Singh, 1998; McGill et al., 2002;
Mellis et al., 2011). Moreover, RANK expression was found to be upregulated by the
coordinated activity of PU.1 and MITF, during osteoclast differentiation (Ishii et al.,
2008; Mellis et al., 2011). Activation of RANKL signaling pathways result in induction
of important osteoclastogenic transcription factors, such as NFAT-c1, NFκB, and c-Fos.
NFAT-c1 is the most strongly induced transcription factor by RANKL signaling, and is
in fact considered as a master regulator of osteoclast differentiation (Takayanagi et al.,
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2002). NFATc1-deficient embryonic stem cells fail to differentiate into osteoclasts in
response to RANKL stimulation, and conditional deletion of NFAT-c1 in osteoclasts
results in osteopetrosis (Aliprantis et al., 2008; Takayanagi et al., 2002). Interestingly,
once NFAT-c1 is expressed in osteoclast precursors, it promotes osteoclastogenesis, even
in the absence of RANKL (Takayanagi et al., 2002). Also, NFAT-c1 regulates the
expression of osteoclastogenic genes such as TRAP, integrin, calcitonin receptor, and
cathepsin-k (Crotti et al., 2006; Takayanagi et al., 2002). NFκB and AP-1 are
transcription factors activated by RANKL signaling, are important for osteoclastogenesis,
and regulate common target genes critical for osteoclastogenesis (Asagiri & Takayanagi,
2007). In this connection, targeted deletion of the c-Fos component of AP-1 in mice
resulted in osteopetrosis due to defective osteoclast differentiation (Z. Q. Wang et al.,
1992). Likewise, the osteopetrosis phenotype was observed in the p50/p52 double
knockout (KO) mice as a consequence of osteoclast absence. However, this phenotype
can be rescued by c-Fos or NFAT-c1, suggesting that they are downstream of NFκB
(Iotsova et al., 1997; Yamashita et al., 2007). In summary, the regulation of osteoclast
differentiation is complex and is mediated by sequential expression of several
transcription factors.
Collectively, these findings clearly demonstrate that an combination of hormones,
cytokines, and transcription factors act (in concert) directly and/or indirectly to regulate
osteoclastogenesis. Despite this progress, the detailed molecular pathways that regulate
osteoclast differentiation and function are still poorly understood. Thus, the identification
of novel genes that participate in regulating osteoclast function(s) is imperative in
advancing our understanding of the mechanisms that regulate bone resorption.
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Tight Junctions
Cell-to-cell interaction is important in the development and maintenance of
various biological tissues (Gunzel & Yu, 2013). The cell junctional complex consists of
four types of proteins including gap junctions (e.g. connexins), hemidesmosomes (e.g.
integrins), adherens (e.g. cadherins), and tight junctions (Elkouby-Naor & Ben-Yosef,
2010). In the skeleton, it has been shown that bone cells form a variety of intracellular
junctions (Cheng, Shin, Towler, & Civitelli, 2000; Lecanda et al., 2000), and there is
substantial evidence demonstrating the importance of gap junctions in skeletal
development; for example, connexin 43 deficient mice exhibited reduced bone mineral
density (BMD) and skeletal abnormalities (Lecanda et al., 2000). Regarding tight
junctions, several investigators have documented the ability of bone cells (osteoblasts and
osteocytes) to form tight junctional structures (Prele, Horton, Caterina, & Stenbeck,
2003; Soares, Arana-Chavez, Reid, & Katchburian, 1992; Weinger & Holtrop, 1974).
Tight junctional strands are composed of several types of transmembrane proteins
including occludin, junctional adhesion molecule, tricellulin, and caudins (Cldns)
(Elkouby-Naor & Ben-Yosef, 2010). It was previously reported that occludin is
expressed in osteoblasts and its targeted disruption in mice resulted in cortical bone
thinning and postnatal growth retardation (Saitou et al., 2000; Wongdee et al., 2008). Of
the various tight junction proteins, extensive evidence suggests that Cldns are the primary
proteins responsible for the formation of tight junctional strands, and there is also
evidence showing that they participate in intracellular signaling that controls cell
proliferation and differentiation in a variety of cell types (Elkouby-Naor & Ben-Yosef,
2010; Gunzel & Yu, 2013; Matter, Aijaz, Tsapara, & Balda, 2005; Saitou et al., 1998).
Thus, the focus of these dissertation studies is going to be on Cldns.
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Claudin Structure
The Cldn family of protein molecules consists of 27 members that have been
identified in mouse and human cells, with a molecular weight ranging from 20-34 kDa
(Angelow, Ahlstrom, & Yu, 2008). In terms of structure, Cldns are composed of four
transmembrane domains, two extracellular loops, a short intracellular loop, and cytosolic
amino and carboxy termini (Chiba, Osanai, Murata, Kojima, & Sawada, 2008) (Fig. 4).
While the amino acid sequence of the first and fourth transmembrane domains is highly
conserved among the different Cldns, that of the second and third domains is not (Morita,
Furuse, Fujimoto, & Tsukita, 1999). Structure-function studies revealed that Cldns’ first
extracellular loop contains several charged amino acids, which have been found to play
an important role in determining their paracellular barrier charge selectivity (Colegio,
Van Itallie, McCrea, Rahner, & Anderson, 2002; Elkouby-Naor & Ben-Yosef, 2010). In
addition, the first extracellular loop has two signature sequences including a G-L-W
motif and two highly conserved cysteine, which are thought to confer an important
function in stabilizing the protein structure (Angelow et al., 2008; Gunzel & Yu, 2013;
Gupta & Ryan, 2010). The second extracellular loop is folded in a helix-turn-helix motif
that is involved in Cldn-Cldn interactions, and has been found- in some Cldns- to serve as
a receptor for the colistridium perfringens enterotoxin (Findley & Koval, 2009; K. Fujita
et al., 2000; Morin, 2005; Piontek et al., 2008). Regarding the carboxy terminus, it has
been shown to possess the highest structural diversity among the Cldn family of proteins
(Krause et al., 2008). It also has a PDZ-binding motif that that enables Cldns to interact
with PDZ domain containing proteins such as zonula occludens (ZO)-1/2/3, MUPP1,
PATJ, , amongst others (Angelow et al., 2008; Krause et al., 2008). The interactions
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Figure 4. Schematic representation of Cldns structure. Cldns are composed of four
transmembrane domains (I, II, III, and IV), two extracellular loops (ECL1 and ECL2), a
short intracellular loop, and cytosolic amino and carboxy termini.
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between Cldns and cytoplasmic scaffolding proteins such as ZO are predicted to be
essential for linking the Cldn family of proteins to the cytoskeleton and/or for their
participation in intracellular signaling (Balda & Matter, 2009; Gunzel & Yu, 2013).
Additionally, the carboxy terminus has phosphorylation sites for Ser/Thr, and Tyr
Kinases, which serve regulatory roles by modulating the Cldn’s localization and function
(Angelow et al., 2008).
Recently, several phylogenetic trees and classifications are suggested based on the
structure in various species, which is comprehensively described by Gunzel et al.,
(Gunzel & Fromm, 2012). Based on sequence analysis and functional properties of the
mouse variants, Cldns are classified into two major groups: 1. The “classic” Cldns, which
encompass Cldn 1-10, 14, 15, 17, and 19, based on their close similarities; and 2. The
“non-classic” Cldns, which encompass the remaining Cldns including Cldn-12, -13, -16, 18, -20, -22, and -23, as they seem to be less similar/related (Krause et al., 2008).

Expression and Distribution Profile
Cldns exhibit diverse tissue/cell type-specific patterns of expression (Table 1).
Some tissues/cells such as the epidermis express several Cldns (Brandner et al., 2002),
whereas others, such as Sertoli cells, express one or two Cldns (C. M. Van Itallie &
Anderson, 2006). Interestingly, Cldn expression also varies within the same tissue. For
example, in mouse kidney, at least 15 Cldns are expressed with distinct expression
patterns in every segment of the nephron (Elkouby-Naor & Ben-Yosef, 2010). Thus,
while the proximal tubules express Cldn-1, -2, -10, -11, -12, and -14, the distal tubules
express Cldn-3, -7, -8, -10, and -11 (Elkouby-Naor & Ben-Yosef, 2010).
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Table 1. Cldns tissue distribution and functions.
Cldn
1

Tissue expression
Ubiquitous: Most
epithelial tissues and
vascular endothelial

Canonical function

Non-canonical function

Barrier forming- cation
selective (Inai, Kobayashi, & Shibata,

Cell proliferation (H. Fujita et al.,

1999)

Cell differentiation (Hoshino et al.,

(Gunzel & Yu, 2013)

2011; Pope et al., 2013)
2008)

Cell motility and migration
(during development and in
cancer cells) (Fishwick, Neiderer,
Jhingory, Bronner, & Taneyhill, 2012;
Fortier, Asselin, & Cadrin, 2013; Yoon et
al., 2010)

Cell signaling and regulating
gene expression (Singh et al., 2011;
Suh et al., 2013)

Anti-apoptosis (J. W. Lee et al., 2010;
Y. Liu et al., 2012)

Hepatitis C virus and dengue
virus entry cofactors (Che, Tang, &

2

Typical for epithelial
tissues (Gunzel & Yu,

Pore forming - cation selective
(Amasheh et al., 2002; Yu et al., 2009)

Li, 2013; Meertens et al., 2008)
Cell proliferation (Dhawan et al.,
2011; Wada, Tamura, Takahashi, &

Tsukita, 2012)

2013; Krause et al., 2008)

Cell signaling (Nishida, Yoshida,

3

Epithelial tissues and
vascular endothelium

Barrier forming- cation
selective (Milatz et al., 2010)

Nishiumi, Furuse, & Azuma, 2013)
Cell proliferation (Okugawa et al.,
2012)

Cell motility and migration
(cancer cells) (Agarwal, D'Souza, &

(Gunzel & Yu, 2013)

Morin, 2005)

Gene expression (Shang, Lin,
Manorek, & Howell, 2013)
Apoptosis (Sun et al., 2011)
Angiogenesis (Sun et al., 2011)

Receptor for Clostridium
perfringens enterotoxin
(Veshnyakova et al., 2012)

4

Epithelial tissues
(Gunzel & Yu, 2013)

Predominantly Barrier
forming- cation selective (C.

Cell motility and migration
(normal and cancer cells)

Van Itallie, Rahner, & Anderson, 2001)
Also act as Cl- pore (Hou,
Renigunta, Yang, & Waldegger, 2010)

(Agarwal et al., 2005; Webb, Spillman, &
Baumgartner, 2013)
Gene expression (Shang et al., 2013)
Cell signaling (Kawai et al., 2011)
Angiogenesis (Li et al., 2009)

Receptor for Clostridium
perfringens enterotoxin
(Veshnyakova et al., 2012)

5

Typical for vascular
endothelium, such as
blood brain barrier
(Nitta et al., 2003)

Barrier forming- cation
selective (Fontijn, Rohlena, van

Cell motility and migration
(cancer cells) (Escudero-Esparza,

Marle, Pannekoek, & Horrevoets, 2006;
Wen, Watry, Marcondes, & Fox, 2004)

Jiang, & Martin, 2012a, 2012b)

Some epithelial
tissues (Rahner, Mitic, &
Anderson, 2001)
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6

Embryonic
epithelium (Turksen &

Barrier forming- cation
selective (Sas, Hu, Moe, & Baum,

Troy, 2001)

2008)

Kidney (neonates)

Cell proliferation (Y. F. Liu et al.,
2010; Zavala-Zendejas et al., 2011)
Cell differentiation (Arabzadeh,
Troy, & Turksen, 2006; Hong et al., 2005)

Cell motility and migration
(Cancer cells) (Y. F. Liu et al., 2010;

(Abuazza et al., 2006)
Liver (A. Zheng et al.,
2007)

Zavala-Zendejas et al., 2011)
Apoptosis (Guo et al., 2012)

Co-receptor for hepatitis C
virus (Meertens et al., 2008; A. Zheng et
al., 2007)

7

8

Epithelial tissues

Barrier and pore forming

Cell proliferation (Thuma & Zoller,

(Gunzel & Yu, 2013)

(Alexandre, Jeansonne, Renegar,
Tatum, & Chen, 2007; Alexandre, Lu,
& Chen, 2005; Hou, Gomes, Paul, &
Goodenough, 2006)

2013; Zavala-Zendejas et al., 2011)

Predominantly Barrier
forming- cation selective

Receptor for Clostridium
perfringens enterotoxin (Shrestha

(Angelow, Schneeberger, & Yu, 2007;
Yu, Enck, Lencer, & Schneeberger,
2003)

& McClane, 2013)

Barrier forming- cation
selective (Sas et al., 2008)

Cell proliferation (Zavala-Zendejas

Epithelial tissues
(Gunzel & Yu, 2013)

9

Kidney (neonates)
(Abuazza et al., 2006)
Inner ear (Kitajiri et al.,
2004)
Liver (A. Zheng et al.,
2007)

10 a

Epithelial tissues,
mainly kidney (Gunzel

10 b

Zavala-Zendejas et al., 2011)
Gene expression (J. Y. Zheng et al.,
2003)
Apoptosis (Hoggard et al., 2013;
Thuma & Zoller, 2013)

et al., 2011)

Cell motility (cancer cells)
(Zavala-Zendejas et al., 2011)

Pore forming- anion selective
(C. M. Van Itallie et al., 2006)

& Yu, 2013)

Epithelial tissues,
mainly kidney (Gunzel

Cell motility and migration
(cancer cells) (Thuma & Zoller, 2013;

Co-receptor for hepatitis C
virus (Meertens et al., 2008)
Cell motility and migration
(cancer cells) (Ip, Cheung, Lee, Ho, &
Fan, 2007)

Pore forming- cation selective
(C. M. Van Itallie et al., 2006)

Cell motility and migration
(cancer cells) (Ip et al., 2007)

& Yu, 2013)

11

Sertoli cells (Morita,
Sasaki, Fujimoto, Furuse, &
Tsukita, 1999)

Predominantly Barrier
forming- cation selective (C. M.

Cell proliferation (Tiwari-Woodruff

Van Itallie, Fanning, & Anderson, 2003)

Cell differentiation (Mazaud-Guittot

Oligodendrocyte and
myelin sheath (Morita,

et al., 2001)
et al., 2010)

Cell motility and migration
(cancer cells) (Agarwal et al., 2009)
Apoptosis (Mazaud-Guittot et al.,

Sasaki, et al., 1999)
Inner ear (Kitajiri et al.,
2004)

2010)

Choroid plexus
epithelium
(Wolburg, WolburgBuchholz, Liebner, &
Engelhardt, 2001)

12

Stomach, intestine,
salivary gland,
epidermis, urinary
bladder , and
vascular endothelium

Not well characterized : Pore
forming- cation selective (H.
Fujita et al., 2008)

(H. Fujita et al., 2006;
Gunzel & Yu, 2013)
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Not known

13

Hematopoietic tissues

Not known

Cell proliferation and
differentiation (Thompson et al.,

(Thompson et al., 2010)

Colon and urinary
bladder (H. Fujita et al.,

2010)

2006)

Kidney (neonates)
(Abuazza et al., 2006)

14

Kidney and liver.
(Wilcox et al., 2001)
Inner ear (Kitajiri et al.,
2004)

Barrier forming- cation
selective (Ben-Yosef et al., 2003)

Cell proliferation (Baker et al.,
2013)

Angiogenesis (Baker et al., 2013)
Receptor for Clostridium
perfringens enterotoxin (Shrestha
& McClane, 2013)

15

16

Intestine (H. Fujita et al.,
2006)

Predominantly pore forming cation selective (C. M. Van Itallie

Respiratory tract (F.

et al., 2003)

Wang et al., 2003)

Also acts as Cl- barrier (Colegio

Mammary epithelium

et al., 2002)

(Markov, Kruglova, Fomina,
Fromm, & Amasheh, 2012)
Kidney (Simon et al.,
1999)

Pore forming- cation selective
(Hou et al., 2007; Kausalya et al., 2006)

Mammary epithelium

17

(Markov et al., 2012)
Kidney (Krug et al., 2012)

Cell proliferation (A. Tamura et al.,
2008)

Cell motility and migration
(cancer cells) (Martin, Harrison,
Watkins, & Jiang, 2008)

Pore forming-anion selective

Not Known

(Krug et al., 2012)

18-1

Predominantly in
lung (Tureci et al., 2011)
Kidney (Tureci et al.,

Not known

Not Known

Barrier forming- cation
selective (Jovov et al., 2007)

Cell differentiation (Linares et al.,

Predominantly barrier
forming- anion selective (Hou et

Not known

2011)

Inner ear (Kitajiri et al.,
2004)

18-2

Predominantly in
stomach (Tureci et al.,

2012a)

2011)

Osteoclasts (Linares et
al., 2012a)

Osteoblasts (Kim,

19

Alarcon, Pourteymour,
Wergedal, & Mohan, 2013)
Inner ear (Kitajiri et al.,
2004)
Esophagus (Jovov et al.,
2007)
Kidney (Konrad et al.,
2006; Luk et al., 2004)

Retinal pigment
epithelium (Konrad et al.,

al., 2008)

2006)

(Angelow, El-Husseini, Kanzawa, &
Yu, 2007)

Myelin sheath
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(Miyamoto et al., 2005)
Intestine (A. Tamura et
al., 2008)

Also act as Na barrier

Not known

Not known

Brain capillary
endothelial cells
(Ohtsuki, Yamaguchi,
Katsukura, Asashima, &
Terasaki, 2008)
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21

Intestine, stomach,
liver, and kidney

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

(Gunzel & Yu, 2013)

22
23

Brain capillary
endothelial cells
(Ohtsuki et al., 2008)
Intestine (A. Tamura et
al., 2008)

Brain capillary
endothelial cells
skin,
placenta, stomach ,
and germinal center
B-cells (Gunzel & Yu,
(Ohtsuki et al., 2008)

2013)

24

Intestine, stomach
kidney, and heart
(Gunzel & Yu, 2013)

25

Intestine, stomach,
liver, kidney, heart,
and brain (Gunzel & Yu,
2013)

26

Intestine and brain
(Gunzel & Yu, 2013)

27

Intestine and liver
(Gunzel & Yu, 2013)

30

There is increasing evidence that the expression of Cldns is also developmental
stage specific (Gunzel & Yu, 2013). In mouse jejunum, the expression of several Cldns is
increased or decreased during neonatal development (Holmes, Van Itallie, Rasmussen, &
Anderson, 2006). For example, Cldn-19 expression was detected at birth, peaked at day
14, and then was undetectable by day 28 (Holmes et al., 2006). The expression of several
Cldns during embryonic development has also been investigated. Thus, during mouse
development (between E.7 and E.17), the expression of Cldn-21 and -24 was found to
increase progressively, whereas that of Cldn-26 and -27 decreased (Gunzel & Yu, 2013;
Mineta et al., 2011). There is also increasing evidence that the expression of Cldns
changes in response to pathological conditions such as cancer and inflammation (Kwon,
2013). Several studies have reported up- or down-regulation of Cldns in association with
various cancers (Kwon, 2013). Thus, the known complexity in the expression of patterns
of Cldns in different tissues is consistent with both common and Cldn-specific functions
among various Cldns.
As for Cldn distribution in bone, in older studies several investigators have
documented the ability of bone cells (osteoblasts and osteocytes) to form tight junctional
structures (Prele et al., 2003; Soares et al., 1992; Weinger & Holtrop, 1974). However,
the evidence of the presence of tight junction associated proteins has been recently
confirmed (Wongdee et al., 2008). Specifically, several Cldns including Cldn-1 to-12, -14
to -20, -22, and -23, were reported to be expressed at the mRNA level in rat osteoblasts
(Prele et al., 2003; Wongdee et al., 2008). In fact, immunohistochemical analysis of
decalcified tibial sections revealed that the expression of selected Cldns (Cldn-5, -11, -14,
-15, and -16) was localized at the bone lining cells (inactive osteoblasts) (Wongdee et al.,
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2008; Wongdee, Riengrojpitak, Krishnamra, & Charoenphandhu, 2010). Furthermore, a
cell border localization of Cldn-1 was shown in an osteoblast-like cell line (Hatakeyama
et al., 2008). In another study, Arana-Chavez et al., observed the presence of tight
junctional structures between osteoblasts in early osteogenesis by freeze fracture and
ultrathin section electron microscopy (Arana-Chavez, Soares, & Katchburian, 1995;
Soares et al., 1992). Moreover, Cldn-1, -2, and -6 mRNA expression was found to be
higher in osteoblast like MC3T3-E1 cells compared to osteocyte-like MLO-Y4 cells
(Hatakeyama et al., 2008). By contrast, the expression of Cldn-1 and -2 in rat osteoblasts
was found to be higher in the mineralization stage compared to the proliferation stage,
thus suggesting that the expression levels of Cldn-1 and Cldn-2 in rat osteoblasts may be
differentiation stage dependent (Prele et al., 2003). The observed changes in the
expression profile of Cldns are consistent with the idea that Cldns play an important role
during skeletal development.
While it is well documented that osteoblast lineage cells express Cldns, virtually
little is known about their expression profiles in bone resorbing osteoclasts. Nonetheless,
we recently provided the first evidence that Cldns, specifically Cldn-18 is expressed in
osteoclasts (Linares et al., 2012a). Of the two tissue specific Cldn-18 isoforms, Cldn-181.1 (lung isoform) and Cldn-18-2.1 (stomach isoform), it was found that bone cells
predominantly express the stomach isoform (Linares et al., 2012a). However, it remains
to be determined if other Cldns are expressed in osteoclast line cells and if the Cldns are
important for the formation and activity of multinucleated osteoclasts.
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Regulation of Cldn Expression
Studies have shown that several growth factors, hormones, and cytokines play
important roles in regulating Cldns expression and function. It has been demonstrated
that TGF-β regulates Cldns expression via Smad dependent and Smad independent
pathways in several physiological and pathological states (Gunzel & Yu, 2013).
Furthermore, several inflammatory cytokines (e.g. IL-β, TNF-α, and IFN-γ) were
implicated in modulating the expression of Cldns (Gunzel & Yu, 2013). For instance, it
has been found that TNF-α downregulates barrier-forming Cldns (Cldn-1, -3,-4, -7, and 8) and upregulates pore-forming Cldns (e.g. Cldn-2) in the intestinal epithelium; thereby
increasing epithelial cell permeability (Gunzel & Yu, 2013). In addition, the expression
of intestinal Cldn-2 and Cldn-12 was found to be upregulated by vitamin-D treatment,
and has been implicated to play a role in the paracellular transport of calcium in the
intestinal epithelium (H. Fujita et al., 2008). Several transcription factors have been
reported to regulate Cldn expression, with Snail and Slug being the most extensively
studied. These transcription factors were shown to suppress the expression of various
Cldns by directly binding to their gene promoters (Ikenouchi, Matsuda, Furuse, &
Tsukita, 2003; Ohkubo & Ozawa, 2004; C. M. Van Itallie & Anderson, 2006). For
example, overexpressing Snail was found to downregulate the expression of Cldn-1, -2, 3, -4 and -7 (Gunzel & Yu, 2013; Ohkubo & Ozawa, 2004). Other transcription factors
such as GATA-4, CDX-1, Grhl2, and SP1 have also been reported to regulate Cldn
expression (Gunzel & Yu, 2013). The issue of whether these transcription factors are
involved in mediating the transcriptional effects of growth factors and cytokines on Cldn
expression in target cells remains to be determined.
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In terms of skeletal tissues, little is known about the physiological regulators of
Cldn expression. A study by Hatakeyama et al., reported that Cldn-1, -2, and -6
expression in MC3T3-E1 mouse osteoblasts was upregulated by IGF-I, a key bone
formation regulator (Hatakeyama et al., 2008). Despite the increased mRNA expression
level of the three aforementioned Cldns, upregulation at the protein level was only
observed for Cldn-1 (Hatakeyama et al., 2008). This study also demonstrated that the
mechanism by which IGF-I upregulates Cldn-1 expression is mediated by the MAPkinase pathway, as inhibition of this pathway diminished the increase in Cldn-1
expression (Hatakeyama et al., 2008). Recent work by our laboratory on bone cells
revealed that Cldn-18 expression is regulated by estrogen (Kim et al., 2013). In fact, the
mRNA levels of Cldn-18 were found to be reduced by 93% in bones of ovariectomized
(estrogen deficient) mice compared with sham operated animals, whereas estrogen
treatment increased Cldn-18 mRNA levels in bone cells, in vitro (Kim et al., 2013).
Furthermore, Cldn-18 is thought to be a novel estrogen target in the skeleton, as its
deletion protects from estrogen deficiency induced bone loss in mice (Kim et al., 2013).

Known Functions of Cldns
The role of individual Cldns has been investigated by employing loss or gain of
function models in cells and whole animals (Steed, Balda, & Matter, 2010). These studies
showed that KO of Cldns resulted in diverse phenotypes in different tissues as listed in
Table 2. For instance, targeted disruption of Cldn-1, -5, and -7 in mice resulted in
postnatal lethality by affecting the skin epithelial barrier, blood brain barrier, and kidney
functions, respectively (Furuse et al., 2002; Nitta et al., 2003; Tatum et al., 2010).
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Table 2. Phenotypic changes caused by Cldn gene deletions and transgenics in mice
Cldn

Phenotype

Cldn-1

KO: Skin barrier defect resulting in dehydration and neonatal lethality

Cldn-2

KO: Defect in leaky and cation selective barriers in kidney proximal tubule

Cldn-5

KO: Blood brain barrier defect and neonatal lethality

Cldn-6

Overexpressing transgenic mice: Skin barrier defect and neonatal lethality

Cldn-7

KO: Growth retardation renal salt wasting, chronic dehydration, and neonatal
lethality

Cldn-9

Mutant: Deafness

Cldn-11

KO: CNS myelin defect, male sterility, deafness

Cldn-14

KO: Deafness

Cldn-15

KO: mega-intestine

Cldn-16

KO: Renal divalent ion wasting resemble FHHNC in humans but without
nephrocalcinosis
Knock down: Renal calcium and magnesium wasting resemble FHHNC in humans

Cldn18.2

KO: Atrophic gastritis
KO: Bone loss due to direct (non-canonical) effect on osteoclast differentiation.

Cldn-19

KO: Peripheral nervous system deficit resulted in behavioral changes and
neuropathy
Knock down: Renal calcium and magnesium wasting resemble FHHNC in humans

Cldn-2/15

Double KO: Malnutrition due to decrease nutrient absorption resulting in neonatal
lethality

Cldn-11/- Double KO: CNS myelin defect, male sterility, deafness
14
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By contrast, Cldn-16 overexpression in transgenic mice resulted in postnatal
lethality, as a consequence of a defect in the skin epithelial barrier (Turksen & Troy,
2002). Several renal function defects were observed in Cldn-2, -7, -16, and -19 KO mice.
Also, the lack of Cldn-9, -11,and -14 resulted in deafness (Ben-Yosef et al., 2003; Gow et
al., 2004; Nakano et al., 2009). In addition, loss of Cldn-11 caused CNS nerve conduction
abnormalities and male sterility (Gow et al., 2004; Gow et al., 1999).
To understand the interaction between Cldns, a double KO mouse approach has
been employed. Specifically, the double Cldn-11/-14 KO phenotype was a combination
of those observed in each of the single deletion animals, including male sterility,
neurological deficits, and deafness. These findings suggest a lack of cooperation between
these two Cldns (Elkouby-Naor, Abassi, Lagziel, Gow, & Ben-Yosef, 2008). On the
other hand, Cldn-2/-15 double deletion in mice resulted in infant death as a consequence
of malnutrition (in a manner more dominant than in each of the single KOs), which
highlights a cooperative interaction between these two Cldns in maintaining nutrient
absorption in the intestine (Wada, Tamura, Takahashi, & Tsukita, 2013).
In agreement with data from mouse models, the importance of Cldns in
modulating various biological systems have been confirmed by linking mutations of Cldn
genes to human diseases. Mutations in human Cldn-1 and Cldn-14 have been found in
neonatal ichthyosis and sclerosing cholangitis (NISCH) and nonsyndromic hearing loss,
respectively (Hadj-Rabia et al., 2004; K. Lee et al., 2012; Wilcox et al., 2001). Several
mutations in human Cldn-16 and -19 are associated with a hereditary renal disease known
as familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) (Konrad
et al., 2006; Simon et al., 1999).
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With regards to the skeleton, our previous studies have shown that mice with
targeted disruption of Cldn-18 (stomach isoform) exhibited a 20-25% decrease in areal
BMD of the total body, vertebrae, and long bones (Linares et al., 2012a). Although bone
size was found not to be affected by Cldn-18 deficiency, µCT analysis revealed a 20%
reduction in cortical thickness at the femoral mid-diaphysis (Linares et al., 2012a).
Additionally, Cldn-18 KO mice exhibited a dramatic decrease in trabecular bone volume,
trabecular thickness, and trabecular number, whereas trabecular separation at both the
lumber vertebra 5 and distal femur metaphysis was increased (Linares et al., 2012a).
Histomorphometric analysis and in vitro assays of bone formation revealed that bone
formation parameters were not affected by Cldn-18 deficiency (Linares et al., 2012a). By
contrast, Cldn-18 KO mice exhibited an 87% increase in TRAP labeled osteoclast surface
in the trabecular bone, as well as an increase in osteoclast number (Linares et al., 2012a).
The increased bone resorption observed in Cldn-18 KO was also confirmed by measuring
the serum and mRNA levels of osteoclastogenic marker genes (Linares et al., 2012a). In
addition, the number of TRAP positive multinucleated cells was greater in bone marrow
macrophage cultures derived from Cldn-18 KO mice that were induced to differentiate in
the presence of RANKL and MCSF, in vitro (Linares et al., 2012a). These data clearly
demonstrate that the reduced bone mineral density reported in Cldn-18 mice was due to
increased osteoclast formation and bone resorption which highlights Cldn-18 as a novel
negative regulator of bone resorption. Interestingly, humans with a Cldn-14 variant
demonstrated a lower bone mineral density in the spine and the hip than their normal
counterparts, which provides further evidence that Cldns play an important function in
bone (Thorleifsson et al., 2009). Taken together, it is clear that while much is known
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regarding the role of Cldn-18, the skeletal phenotype of other Cldns and their
contribution to the genesis of osteoporosis is poorly defined.

Molecular Mechanisms of Cldn Action
Cldns are multifunctional proteins: they regulate paracellular transport of ions,
solutes, and water; and serve as a fence that divides apical and basolateral domains of
plasma membranes, which is known as the “canonical function”. Aside from functioning
as tight junctions, interestingly, Cldns have also been shown to participate in intracellular
signaling that controls cell proliferation and differentiation, which is known as the “noncanonical function”.
Cldns are the major determinant of paracellular permeability in epithelial and
endothelial cells, acting (canonically) as barriers or pores to decrease or increase
permeability, respectively. Several in vitro studies have demonstrated that both barrier
and pore forming Cldns are size and charge selective (Table 1) (Gunzel & Yu, 2013). In
MDCK and LLC-PK1 cell lines, while Cldn-2, -10b, -15, and -16, selectively increased
cation permeability in tight junctions, Cldn-1, -4, -5, -6, -8, -11, and -14 decrease it.
Furthermore, Cldn-7, -10a, and -17 were found to serve as anion pores, but in contrast,
Cldn-7 and -19 act as anion barriers (Gunzel & Yu, 2013; Krause et al., 2008). As
mentioned before, the Cldn carboxy-terminus possesses several phosphorylation sites for
various kinases including PKC, PKA, WNK, MLCK, MAPK, RhoK, and c-Src, which
have been implicated in regulating tight junction assembly and function (Banan et al.,
2005). In fact, several studies have reported that the barrier/pore function of Cldns can be
negatively or positively regulated by phosphorylation (Findley & Koval, 2009). It has
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been demonstrated that phosphorylation of Cldn-1 and Cldn-4 by PKC promoted their
assembly into tight junctions and increased the barrier function (Banan et al., 2004;
D'Souza, Agarwal, & Morin, 2005; French et al., 2009). Conversely, dephosphorylation
of Cldn-1 by PP2A resulted in their disassembly and decreased barrier function
(Nunbhakdi-Craig et al., 2002). As for negative regulation, Tanaka et al., reported that
phosphorylation of Cldn-4 by EphA4 decreased its integration into tight junctions and
increased paracellular permeability (Tanaka, Kamata, & Sakai, 2005). It is to be noted
though that the consequence of phosphorylation on the barrier function is rather complex
and controversial. In fact, there are kinases that can phosphorylate distinct residues on the
same Cldn with the outcome (positive or negative) depending on the external stimuli, and
the physiological, and pathological conditions (Gonzalez-Mariscal, Tapia, & Chamorro,
2008). Besides phosphorylation, it remains to be determined whether other posttranslational modifications regulate canonical functions of Cldns.
The canonical function of Cldns in regulation of the paracellular transport of ions
in bone has been suggested by several studies (Bushinsky, Chabala, & Levi-Setti, 1989;
Hatakeyama et al., 2008; Marenzana, Shipley, Squitiero, Kunkel, & Rubinacci, 2005;
Rubinacci, Benelli, Borgo, & Villa, 2000; Wongdee et al., 2010). There is substantial
evidence that osteoblast and bone lining cells form an epithelial like bone membrane to
control the paracellular ion exchange and maintain differential ion compositions between
the plasma and bone extracellular fluid (Bushinsky et al., 1989; Hatakeyama et al., 2008;
Marenzana et al., 2005; Rubinacci et al., 2000; Wongdee et al., 2008; Wongdee et al.,
2010). The expression and localization of certain Cldns in the bone lining cells support
their function as barriers, a notion that was confirmed by measuring the transepithelial

39

resistance of an osteoblast monolayer (Wongdee et al., 2008). As for regulation of the
Cldn barrier function, more work must be done to address this issue. Nonetheless, in
osteoblast like MC3T3-E1 cells, a reduction of paracellular permeability was observed as
a consequence of MAPK activation by IGF-I (Hatakeyama et al., 2008). To this end, our
previous study demonstrated that Cldn-18 disruption/overexpression did not influence
paracellular transport of calcium ions in osteoclasts, thereby supporting a potential noncanonical function of Cldns in bone cells (Linares et al., 2012a). Thus, some but not other
Cldns may exert their canonical functions in bone cells.
Besides their canonical function as a barrier, gate, and fence, Cldns have recently
started to emerge as mediators of cell signaling, e.g., proliferation and differentiation
(Table 1) (Matter et al., 2005). The non-canonical Cldn functions have been shown to
involve interaction with adaptor proteins that shuttle between the plasma membrane and
the nucleus, thereby regulating gene expression, cell proliferation, and differentiation
(Balda & Matter, 2009). As mentioned earlier, Cldns have the capacity to interact with
other PDZ domain containing cytoplasmic scaffolding proteins such as ZO-1/2/3, via
their carboxy- terminus PDZ-binding motif (Angelow et al., 2008; Krause et al., 2008).
Although much remains to be investigated regarding the physiological significance of
this interaction, research to date indicates that the interaction between Cldns and PDZ
domain containing proteins is of importance in certain biological processes (Chung,
Shikano, Hanyu, & Li, 2002; Guillemot, Paschoud, Pulimeno, Foglia, & Citi, 2008;
Matter & Balda, 2003; Sierralta & Mendoza, 2004). Of the several adaptor proteins, ZO1, the first tight junction protein identified, has been extensively studied (Stevenson,
Siliciano, Mooseker, & Goodenough, 1986). ZO-1 has three PDZ and SH3 domains that
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have been implicated in the regulation of cell proliferation (Laing, Chou, & Steinberg,
2005). The negative effect of ZO-1 on cell proliferation is thought to be mediated by its
SH3 domain interaction with the Y-BOX transcription factor ZONAB (Balda, Garrett, &
Matter, 2003). The resultant cytoplasmic sequestration of ZONAB was found to reduce
its interaction with important cell cycle regulators and cell cycle target genes (e.g., CK4,
and cyclin D) (Balda et al., 2003; Balda & Matter, 2000; Matter & Balda, 2007;
Sourisseau et al., 2006). Cldns have been also implicated in regulating cell differentiation
(S. K. Lee et al., 2005). For example, overexpression of Cldn-1 in intestinal epithelium
was found to activate Notch-signaling, and in turn inhibit goblet cell differentiation (Pope
et al., 2013).
In the recent studies, we found that Cldn-18 regulates RANKL-induced osteoclast
differentiation via stimulating non-canonical signaling (Linares et al., 2012a). We found
that overexpression of Cldn-18 resulted in a dramatic inhibition of RANKL induced
osteoclast differentiation in vitro, while bone marrow-derived macrophage precursorsderived from Cldn-18 KO mice formed fewer osteoclasts in the presence of MCSF and
RANKL, thus suggesting that Cldn-18 is a negative regulator of osteoclast differentiation
(Linares et al., 2012a). In terms of mechanisms for Cldn-18 action in osteoclasts, we
found that overexpression of full-length Cldn-18 but not a mutant form of Cldn-18 with a
deleted C-terminal PDZ binding motif had an effect on RANKL induced
osteoclastogenesis, thus suggesting that the biological effects of Cldn-18 on osteoclasts is
mediated by the PDZ binding motif (Linares et al., 2012a). Of the several PDZ domainbinding proteins reported to directly bind to the C-terminal YV sequence of several
Cldns, ZO-2 was found to be highly expressed and significantly upregulated by RANKL
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in osteoclasts (Linares et al., 2012a). Consistent with this data, the Cldn-18 and ZO-2
interaction was confirmed by immunoprecipitation (Linares et al., 2012a). Importantly,
overexpression of Cldn-18 reduced ZO-2 nuclear translocation induced by RANKL, and
this effect was abrogated with the deletion of the Cldn-18 C-terminal PDZ binding motif
(Linares et al., 2012a). Thus, we concluded that the negative effect of Cldn-18 on
osteoclasts is mediated via sequestering ZO-2 in the membrane complex. Furthermore,
we found that shRNA knockdown of ZO-2 inhibited RANKL-induced osteoclast
differentiation, in vitro. Consistent with this prediction, there is a significant body of
evidence that ZO-2 has nuclear localization signals and that nuclear translocation is
associated with increased gene expression (Betanzos et al., 2004; Islas, Vega, Ponce, &
Gonzalez-Mariscal, 2002; Traweger et al., 2003; Traweger et al., 2008). In this regard,
ZO-2 knockdown in an osteoclast like cell line resulted in reduction of RANKL induced
TRAP and cathepsin k expression, and inhibition of NF-κB and NFAT transcriptional
activity (Linares et al., 2012a). Collectively, we believe that the non-canonical effect of
the loss of Cldn-18 in the regulation of RANKL-induced osteoclast differentiation is
mediated by disruption of the interaction with ZO2, resulting in increased nuclear
translocation of ZO2. In turn, this translocation increases the expression of important
transcription factors involved in RANKL-induced osteoclast differentiation, which
ultimately leads to increased bone resorption.
While our studies have laid down a foundation for the non-canonical function of
Cldn-18 in regulating bone homeostasis, whether other Cldn family members are also
expressed and exhibit a function during osteoblastogenesis and osteoclastogenesis
remains to be investigated. Based on the role of Cldn-18 in regulating bone metabolism

42

and the established importance of Cldn family members in the development of various
tissues, we hypothesize that Cldns are important regulators of bone cell function.
Our long term goal is to characterize the role of specific Cldns in skeletal growth

and maintenance. The following specific aims are designed to address the above
hypothesis:
1- Investigate whether the osteopenia phenotype in Cldn-18 KO mice is due to
disruption of Cldn-18 in tissues other than bone, i.e., stomach.
2- Investigate the expression profile of Cldn family members during osteoblast
and osteoclast differentiation.
3- Examine the role of Cldn-1 in the regulation of osteoblast proliferation and
differentiation, in vitro.

Rationale and Hypothesis
AIM 1: Investigate Whether The 0steopenia Phenotype in Cldn-18 KO Mice is
Due to Disruption of Cldn-18 in Tissues Other Than Bone, i.e., Stomach
Our earlier studies utilized Cldn-18 that was globally disrupted, and this Cldn is
known to be expressed in tissues separate from bone (Linares et al., 2012a; Tureci et al.,
2011). Thus, the purpose of this aim is to investigate the possibility that the osteopenia
phenotype of Cldn-18 KO mice is mediated in part by its disruption in other tissues, i.e.,
the stomach (Krause et al., 2008; Tureci et al., 2011). In this connection, it has previously
been found that Cldn-18 is the predominant form of Cldns in the stomach, and plays a
critical function in paracellular transport of small molecules including H+ (Hayashi,
Tamura, Tanaka, Yamazaki, Watanabe, Suzuki, Sentani, et al., 2012; A. Tamura et al.,
2012). Moreover, deletion of Cldn-18 in mice resulted in abnormalities in gastric mucosa
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and atrophic gastritis via decreasing paracellular barrier against H+ in the stomach
epithelium (Hayashi, Tamura, Tanaka, Yamazaki, Watanabe, Suzuki, Sentani, et al.,
2012). It is noteworthy that the role of gastric acidity in calcium absorption/metabolism
has received more attention recently (Boyce, 2009; Wright, Proctor, Insogna, &
Kerstetter, 2008). Also, calcium solubilization is thought to be prerequisite for its
absorption in the small intestine, with the stomach’s acidic environment inducing the
dissolution of calcium salts and the release of ionized calcium (Bo-Linn et al., 1984;
Sipponen & Harkonen, 2010). Interestingly, several clinical studies have shown that
gastric acidity is important for calcium absorption in the small intestine (Wright et al.,
2008). In this regard, we observed that levels of serum PTH (whose reduced levels are an
indicator of calcium deficiency) were elevated in Cldn-18 KO mice fed a normal calcium
diet compared to control mice fed a normal calcium diet (Linares et al., 2012a). Thus, this
data suggests that Cldn-18 KO mice may be calcium deficient. Based on these findings,
we hypothesize that the loss of Cldn-18 decreases gastric acidity, and the osteopenia
phenotype observed in Cldn-18 KO mice is partly a consequence of decreased calcium
absorption due to the low gastric acidity.
The findings pertaining to this Aim are summarized in Chapter 2.

AIM 2: Investigate the Expression Profile of Cldn Family Members
During Osteoblast and Osteoclast Differentiation
Cldns exhibit complex patterns of expression that is tissue/cell type and
developmental stage specific (Alshbool & Mohan, 2014; Gunzel & Yu, 2013). While
much is known regarding the expression patterns and function(s) of many Cldn family
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members in several tissues, little is known about their expression and role in bone. There
is evidence that a number of Cldns are expressed in osteoblasts; however their differential
expression during osteoblast differentiation is still not well defined. In addition, aside
from Cldn 18, nothing is known about the expression of other Cldns in osteoclasts. Based
on the above consideration, we hypothesize that the expression of Cldns is differentiation
stage and cell type specific in bone.
The findings pertaining to this Aim are summarized in Chapter 3.

AIM 3: Examine The Role of Cldn-1 in The Regulation of
Osteoblast Proliferation and Differentiation, in Vitro
Cldn-1 plays important roles in the development of various biological systems. In
fact, targeted disruption of Cldn-1 in mice resulted in postnatal lethality immediately
after birth (Furuse et al., 2002). Furthermore, there is substantial evidence that Cldn-1
participates in intracellular signaling that controls cell proliferation and differentiation
(H. Fujita et al., 2011; Hoshino et al., 2008; Pope et al., 2013). It has also been found that
Cldn-1 expression in MC3TE-E1 mouse osteoblasts is regulated by IGF-I, a key bone
formation regulator (Hatakeyama et al., 2008). While Cldn-1 is known to be expressed in
osteoblasts, little is known about its regulation and role during osteoblastogenesis
(Wongdee et al., 2008). In this regard, our data demonstrated an interesting differential
expression pattern of Cldn-1 during osteoblastogenesis (i.e., upregulation of Cldn-1
during early stages of osteoblast differentiation, as opposed to downregulation during late
stages). On this basis, we hypothesize that Cldn-1 modulates osteoblast proliferation and
differentiation.
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The findings pertaining to this Aim are summarized in Chapter 3.
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CHAPTER TWO
A HIGH CALCIUM DIET FAILED TO RESCUE AN OSTEOPENIA
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Abstract
We have recently demonstrated that mice with disruption of claudin-18 (Cldn-18)
gene exhibited osteopenia due to increased bone resorption (BR). In this study, we found
that gastric pH was significantly higher in Cldn-18 knockout (KO) mice compared to
heterozygous control mice at 10 wks of age. To test the possibility that the increased BR
in the Cldn-18 KO mice fed a normal Ca diet is a consequence of decreased Ca
absorption caused by increased stomach pH, we subjected KO and control mice to a
normal Ca and high Ca diet at birth. Serum Ca levels were significantly lower in Cldn-18
KO mice compared to control mice at a normal Ca diet but not at high Ca diet. DEXA
revealed that a high Ca diet significantly increased lumbar BMD but had no effect on
femur/tibia BMD in both Cldn-18 KO and control mice compared to a normal Ca diet.
While a high Ca diet did not affect volumetric BMD, trabecular, and cortical parameters
of the lumbar vertebrae (LV) as measured by uCT, the size of the LV did increase, in
both genotypes due to reduced BR. Comparison of the skeletal phenotype of high Ca
Cldn-18 KO and control mice revealed that an osteopenia phenotype seen at a normal Ca
diet was still maintained at different skeletal sites in the KO mice till 10 weeks of age. In
conclusion, our findings suggest that increased BR is likely caused by direct effects of a
lack of Cldn-18 on osteoclasts rather than gastric pH changes.
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Introduction
Osteoporosis is a major clinical problem in which loss of bone strength leads to
skeletal fractures (13). Osteoporosis mediated bone fragility can result from failure to
produce optimal bone mass and/or the imbalance between bone formation and bone
resorption during bone remodeling (25). It is well known that bone resorption is
dependent on the number and activity of osteoclasts, which is in turn regulated by a
number of local and systemic factors including macrophage colony stimulating factor
(MCSF) and receptor activator of nuclear factor kappa B ligand (RANKL). While the
MCSF and RANKL are sufficient for inducing osteoclast activity and function, the role
of other regulatory molecules and their signaling pathways has not been determined (6,
18).
Tight junctions (TJs) play important roles in different biological systems (10).
Claudins (Cldns) comprise a major group of TJ proteins and consist of 27 members in
mice and humans (20, 23, 24). Cldns serve as a multifunctional complex: they regulate
paracellular transport of ions, solutes, and water; and serve as a fence that divides apical
and basolateral domains of plasma membranes. Moreover, Cldns act non-canonically by
regulating a variety of signaling molecules that control cell differentiation, proliferation,
and polarity (10, 20, 23, 30). Given that Cldns have major functions in different
biological systems, the role of individual Cldns has been investigated by employing loss
of function models in vivo, and by transgenic studies in cells in vitro (14). However, the
role of Cldns in bone homeostasis is still poorly defined. Nonetheless, we have recently
demonstrated that one of the Cldns, namely, Cldn-18 is expressed in bone and that
targeted disruption of Cldn-18 in mice resulted in markedly decreased total body bone
mineral density, trabecular volume, and cortical thickness (22).
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In our previous studies, we provided the first evidence that Cldn-18 is expressed
in osteoclasts and that the underlying cause of decreased bone mass observed in Cldn-18
KO mice was increased bone resorption, but not impaired bone formation (22). We
investigated the mechanism by which loss of Cldn-18 increased bone resorption and
found that osteoclast differentiation was increased by regulating RANKL signaling (22).
The non-canonical effect of the loss of Cldn-18 on RANKL actions was shown to be
mediated by disruption of the interaction with a scaffold protein called zonula occludens
(ZO)-2 that resulted in increased nuclear translocation of ZO2 (22). In turn, this
translocation increased the expression of important transcription factors involved in
RANKL-induced osteoclast differentiation (22). Since Cldn-18 was globally disrupted
and Cldn-18 is expressed in other tissues, the purpose of this study was to investigate the
possibility that the osteopenia phenotype of Cldn-18 KO mice is mediated in part by
disruption of Cldn-18 in other tissues, i.e., the stomach (20, 32).
It has been found that Cldn-18 is the predominant form of Cldns in the stomach,
and has been shown to play a major role in the physiology and pathology of the stomach
epithelial barrier (16, 31). The expression level of stomach Cldn-18 is significantly down
regulated in atrophic gastritis and gastric cancer in humans (26). Moreover, targeted
disruption of Cldn-18 in mice resulted in abnormalities in gastric mucosa and atrophic
gastritis via decreasing paracellular barrier against H+ in stomach epithelium (16).
Interestingly, several clinical studies have shown that gastric acidity is important for
calcium absorption in the small intestine (35). In this regard, we observed that serum
parathyroid hormone (PTH) levels were elevated in Cldn-18 KO mice fed a normal
calcium diet compared to control mice, thus suggesting that Cldn-18 KO mice may be
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calcium deficient. Based on these findings, we undertook studies to characterize the
impact of a lack of cldn-18 on the gastric pH and serum calcium levels, and whether a
dietary manipulation of calcium homeostasis can rescue the osteopenia phenotype in the
Cldn-18 KO mice. Collectively, our findings revealed that a high calcium diet failed to
rescue an osteopenia phenotype in Cldn-18 KO mice.

Materials and Methods
Animals
The generation of Cldn-18 deficient mice by homologous recombination and
genotyping was previously described (22). Since we did not observe any apparent
differences in the skeletal phenotype between heterozygous and wild type animals, we
opted to use the heterozygous littermates as control mice. Homozygous Cldn-18 KO and
heterozygous littermate controls were generated by breeding heterozygous with
homozygous Cldn-18 KO. Mice were housed at Jerry L. Pettis Memorial VA Medical
Center Medical Unit (Loma Linda, CA, USA) under standard approved laboratory
conditions. All animal experiments were performed in compliance with and approved by
the Institutional Animal Care and Use Committee.

Experimental Design
Cldn-18 KO and heterozygous control mice were subjected to either normal
calcium diet or high calcium diet by feeding their mothers the indicated diet at birth.
After weaning, Cldn-18 KO and heterozygous control mice were kept on their respective
diets until 10 weeks of age. The normal calcium diet (TD.04200, containing 0.6%
calcium carbonate and 0.4% phosphate by weight) and the high calcium diet (TD.96348,
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containing 2% calcium carbonate and 1.25% phosphate by weight) were purchased from
Harlan Teklad (Madison, WI, USA).

Measurement of Gastric pH
Gastric pH was assessed in 10 week old mice fed a normal calcium diet using a
modified method of Waisberg et al., (34). After the mice were euthanized, the stomach
was clamped at the esophageocardial and pylorodoudenal junctions, before being
removed, and 0.5 ml sterile water injected into the gastric lumen. The stomach fluid
contents were then collected, and gastric pH was measured using a PHR-146
microcombination pH electrode.

Total Calcium Serum Measurement
The level of total serum calcium was determined in 10 week old mice fed either a
normal calcium or a high calcium diet using Stanbio Total Calcium LiquiColor©
(Arsenazo III) kit as per manufacturer`s instructions (STANBIO, lab, Boerne, TX,
USA).

Bone Densitometry
Total and multiple skeletal site bone mineral density (BMD) was measured by
dual energy X-ray absorptiometry with a PIXImus instrument (Lunar-Corp, Madison,
WI, USA) at 3, 6, and 10 weeks of age as previously described (38). To obtain bone mass
parameters of the total body, a region of interest (ROI) rectangle was moved and re-sized
to cover the whole body, and the animal’s head was set as an exclusion zone. Femur,
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tibia, and lumbar vertebrae 5 BMD were obtained by moving the ROI rectangle to the
specific region and resized to cover the assigned area. The precision for the BMD was ±
1% for repeat measurements of the same bone several times.

Micro-CT Analysis
Micro-CT analysis of lumbar vertebrae 5 was carried out using a “vivaCT 40”
microCT system (Scanco Medical, Bassers-drof, Switzerland). Transverse slices were
acquired for the entire vertebra body, as previously described (15). Trabecular bone was
evaluated in a region 0.3 mm below the cranial and above the caudal growth region. The
cortical parameters and cross sectional areas were evaluated for 100 slices by delineating
a region of interest around the entire vertebral body. The thresholds were set at 220 for
trabecular bone, and 260 for cortical bone. The length of lumbar vertebrae 5 was recorded
at the time of scanning.

Dynamic Calcein Labeling and Histomorphometry
Cldn-18 KO and heterozygous control mice were injected intraperitoneally with
calcein 8 days (20 mg/kg of body weight) and 2 days prior to euthanization in order to
label mineralized bone surfaces. Lumbar vertebrae 5 were fixed in 10% formalin
overnight, the bones were washed, dehydrated, and embedded in methyl methacrylate for
sectioning. The sections were stained for tartrate resistant acid phosphatase (TRAP), and
the cortical bone and trabecular bone that adjacent to the growth plate were excluded.
The trabecular surface and TRAP labeled surface were measured using the OsteoMeasure
software (Osteometric, Inc. Decatur, GA) (36)
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Cell Culture
Primary osteoclast precursors or bone marrow macrophages (BMMs) were
isolated from femurs and tibias of Cldn-18 KO and heterozygous control mice, as
described previously (7), and maintained in α-MEM supplemented with 10% fetal bovine
serum (FBS), penicillin (100 units/ml), streptomycin (100 ug/ml), and macrophage
colony stimulating factor (MCSF; 25 ng/ml). Twenty four hours later, non-adherent cells
(BMMs) were collected and treated with MCSF (50 ng/ml) and receptor activator of
nuclear factor kappa B ligand (RANKL; 100 ng/ml) for 6 days; with fresh differentiation
media added every 3 days. MCSF and RANKL were obtained from R&D Systems
(Minneapolis, MN, USA).

RNA Extraction and Gene Expression Analysis
RNA was extracted using Trizol and chloroform, and isolation was completed
using E.Z.N.A.® RNA Isolation Kits (Omega Bio -Tek). The expression was determined
by real-time RT-PCR. The housekeeping gene peptidylpropyl isomerase A (PPIA) was
used as internal control in the PCR reaction and the ΔΔCT method was used for relative
quantification of gene expression. Values are presented as fold change of control
heterozygous mice.

Statistical Analysis
Data were expressed as the mean ± SEM and were analyzed using Student`s t-test
or ANOVA (Statistica software).
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Results
Cldn-18 Deficiency Affects Gastric pH
In order to determine the effect of Cldn-18 on gastric acidity, the stomach pH
was measured in both 10 week old Cldn-18 KO and heterozygous control mice. We
found that the lack of Cldn-18 dramatically increased the gastric pH (pH= 6.1) compared
to heterozygous control mice (pH=2.6) (Table. 3).

The Effect of Dietary Calcium on Serum Calcium Levels in 10 Week
Old Cldn-18 KO and Heterozygous Control Mice
To determine the effect of Cldn-18 KO on serum calcium levels and verify the
effectiveness of giving high calcium in the diet to correct calcium deficit in Cldn-18 KO
mice, we measured total serum calcium levels in Cldn-18 KO and heterozygous control
animals. Expectedly, the high calcium diet significantly increased serum calcium levels
in both Cldn-18 KO and heterozygous control mice (Table. 3). Interestingly, serum
calcium levels were found to be lower in Cldn-18 mice fed a normal calcium diet
compared to heterozygous control mice fed the same diet (Table. 3). However, serum
calcium levels were not different between Cldn-18 KO and heterozygous control mice on
a high calcium diet (Table. 3).
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Table 3. The effect of dietary calcium on gastric pH, serum calcium, and lumbar
vertebrae 5 trabecular and cortical morphology in 10 week old Cldn-18 KO and
heterozygous control mice.
Normal calcium
diet

High
calcium diet

P value

Control

Cldn-18
KO

Control

Cldn-18
KO

Control
High vs.
Control
Normal

KO
High vs.
KO
Normal

Gastric pH

2.56±
0.08

6.11±
0.05

N.D.

N.D.

N.D.

Serum Ca
(mg/dl)

9.61±
0.13

9.26±
0.06

10.01±
0.07

9.98±
0.1

*

BV/TV

0.34±0.
01
215.54±
12.15

0.29±0.
006
187.38±
5.57

Trabecular Bone
0.33±0.
0.28±
N.S.
01
0.007
223.79± 204.98±
N.S.
8.51
8

6.14±
0.19
0.057±
0.0008
0.171±
0.005

5.46±
0.11
0.054±
0.0008
0.188±
0.004

6.16±
0.18
0.056±
0.001
0.169±
0.005

347.91±
6.09
960.91±
1.81

323.55±
3.69
941.19±
1.66

333.74±
6.95
954.19±
3.92

0.073±
0.0001

0.066±
0.001

0.071±
0.001

Connectivity
density
(mm-3)
Tb.N
(1/mm)
Tb.Th(mm)
Tb.Sp (mm)

Total vBMD
(mg/cm3)
Cortical
vBMD
(mg/cm3)
Cort. Th
(mm)

KO
High vs.
Control
High

N.D.

KO
Normal
vs.
Control
Normal
***

***

*

N.S.

N.S.

***

***

N.S.

*

*

N.S.

N.S.

**

**

N.S.

N.S.

**

**

N.S.

N.S.

*

*

311.605
±4.66
935.27±
3.02

N.S.

N.S.

**

*

N.S.

N.S.

***

**

0.064±
0.001

N.S.

N.S.

***

***

5.45±
0.13
0.052±
0.009
0.187±
0.005
Cortical Bone

N.D.

Data represents the mean ±SEM. n= 15-17/group
BV/TV: bone volume/total volume; Tb.N: trabecular number; Tb.Th: trabecular
thickness; Tb.Sp: trabecular separation; vBMD: volumetric BMD; Cort. Th: cortical
thickness; N.S.: not significant; N.D.: not determined. *: p<0.05; **: p<0.01; and ***:
p<0.001.
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The Effect of Dietary Calcium on Bone Mineral Density (BMD) of
The Cldn-18 KO and Heterozygous Control Mice at Different
Skeletal Sites
We have previously reported a decrease in bone mass and an increase in bone
resorption in Cldn-18 KO mice (22). To evaluate whether these observations are a
consequence of decreased calcium absorption due to low gastric acidity, Cldn-18 KO and
heterozygous control mice were subjected to either a high calcium (2%) or normal
calcium (0.6%) diet at birth, that was continued until 10 weeks of age. First, and as
expected, the body weight and animal length increased with age in both genotypes (Fig. 5
A, B). However, neither body weight nor body length was significantly different between
Cldn-18 KO and heterozygous control mice fed either a normal or high calcium diet (Fig.
5 A, B). The high calcium diet increased total areal BMD in heterozygous control mice
compared to a normal calcium diet at 3 and 6 weeks of age, by 8% and 5%, respectively
(Fig. 6 A). A similar trend was observed in the Cldn-18 KO mice, as a high calcium diet
increased whole body areal BMD compared to a normal calcium diet at all ages (Fig. 6
A). Expectedly, the total areal BMD was decreased significantly in Cldn-18 KO mice fed
a normal diet in comparison to heterozygous control mice fed a normal calcium diet (Fig.
6 A). Moreover, total body areal BMD was significantly lower in the high calcium Cldn18 KO group compared to the high calcium heterozygous control group at 6 and 10
weeks. Therefore, this data suggests that the high calcium diet did not rescue the reduced
whole body BMD phenotype in the KO mice (Fig. 6 A). Phenotypic differences due
gender-genotype-diet interaction were not observed and, therefore, data from both
genders were pooled for analyses. Evaluation of BMD at different skeletal sites revealed
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A

B

Figure 5. The effect of dietary calcium on body weight and length of Cldn-18 KO
and heterozygous control mice. (A) Body weight of 3, 6, and 10 week old Cldn-18 KO
and heterozygous control mice (n=13-19/group). (B) Body length of 3, 6, and 10 week
old Cldn-18 KO and heterozygous control mice (n=13-19/group, mixed gender).
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Figure 6. The effect of high calcium diet on areal BMD of Cldn-18 KO and
heterozygous control mice at different ages. (A) Total body BMD as determined by
DXA at 3, 6, and 10 weeks of age. (B) Tibia BMD. (C) Femur BMD. (D) Lumbar
vertebrae BMD (n=13-19/group, mixed gender). A=p< 0.05 versus heterozygous control
mice (normal calcium diet), B=p<0.05 versus heterozygous control mice (high calcium
diet), C=p<0.05 versus KO mice (normal calcium diet).
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that the high calcium diet had no significant effect on femur and tibia BMD in both Cldn18 KO and heterozygous control mice compared to mice on a normal calcium diet, at any
age (Fig. 6 B, C). However and as previously documented, Cldn-18 KO mice exhibited a
significant decrease in tibia and femur BMD compared to heterozygous control mice on a
normal calcium diet (Fig. 6 B, C). Moreover, Cldn-18 KO mice treated with a high
calcium diet exhibited a significantly lower femur and tibia BMD compared to
heterozygous control mice treated with a high calcium diet at 3 and 6 weeks of age (Fig.
6 B, C). By contrast, the lumbar BMD increased significantly in the high calcium
heterozygous control group by 44%, 42%, and 27% at 3, 6, and 10 week of age,
respectively, compared to the normal calcium heterozygous control group (Fig. 6 D). The
same trend was observed in Cldn18 KO mice fed a high calcium diet compared to a
normal calcium diet (Fig. 6 D). Even though lumbar BMD was lower in normal calcium
fed Cldn-18 KO mice compared to heterozygous control mice, the difference was not
significant until the mice reached 10 week of age (Fig. 6 D). However, lumbar BMD was
significantly lower in the high calcium Cldn-18 KO group compared to the high calcium
heterozygous control group at 6 and 10 weeks (Fig. 6 D). Analysis of variance indicated
that the genotype alone had a significant effect on areal BMD and the age alone had a
significant effect on areal BMD (Table. 4). Furthermore, areal BMD was significantly
affected by diet alone (Table. 4). However, there was no significant genotype-diet-age
interaction for total areal BMD and skeleton-specific BMD (Table. 4).
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Table 4. The effects of genotype, diet, and age on areal BMD using ANOVA
analysis.

Grouping
Variable

Total areal
BMD

Tibia BMD

Femur BMD

Lumbar BMD

Genotype
Diet
Age
Genotype+ diet
Genotype +age
Diet + age
Genotype + diet
+age

<0.001
<0.001
<0.001
N.S.
N.S.
<0.05
N.S.

<0.001
<0.001
<0.001
N.S.
N.S.
<0.05
N.S.

<0.001
<0.001
<0.001
N.S.
N.S.
N.S.
N.S.

<0.001
<0.001
<0.001
N.S.
N.S.
N.S.
N.S.

Data represent p values of the interaction of y- axis variables with x –axis parameters
calculated using ANOVA.
Areal BMD was measured in 3, 6, and 10 week old Cldn-18 KO and heterozygous
control mice fed either a normal or a high calcium diet using Piximus. N.S.: not
significant.
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The Effect of Dietary Calcium on Lumbar Vertebrae 5 Bone Mass Parameters
of 10 Week Old Cldn-18 KO and Heterozygous Control Mice
To further characterize the effect of the calcium diet on the lumbar vertebrae, trabecular
and cortical bone parameters were evaluated at lumbar vertebrae 5 from 10 week old
Cldn-18 KO and heterozygous control mice using uCT. The high calcium diet had no
significant effect on trabecular bone parameters compared to the normal calcium diet in
heterozygous control mice (Table. 3, Fig. 7). A similar finding was observed in the Cldn18 KO mice, as a high calcium diet had no effect on trabecular parameters compared to a
normal calcium diet (Table. 3, Fig. 7). However and as expected, the trabecular bone
parameters were found to have significantly deteriorated in Cldn-18 KO compared to
heterozygous control mice fed a normal calcium diet (Table. 3, Fig. 7). Moreover, Cldn18 KO mice treated with a high calcium diet exhibited a significantly deteriorated
trabecular architecture compared to heterozygous control mice under similar dietary
conditions. The same trend was observed for cortical bone parameters (Table. 3). Thus,
these data provide further evidence that a high calcium diet failed to rescue the
osteopenia phenotype at lumbar vertebrae 5 (Table. 3).

The Effect of Dietary Calcium on Lumbar Vertebrae 5 Bone Size Parameters of
10 Week Old Cldn-18 KO and Heterozygous Control Mice
Since areal BMD is influenced by size parameters, the length of lumbar vertebrae 5 was
measured to see if the change in lumbar BMD observed with piximus data is due to a size
difference. The length of lumbar vertebrae 5 was increased by 5% (P<0.05) in the high

62

Figure 7. The effect of dietary calcium on lumbar vertebrae 5 trabecular
morphology. Three-dimensional μ-CT images of lumbar trabecular bone from 10 week
old Cldn-18 KO and heterozygous control mice
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calcium heterozygous control group compared to the normal calcium heterozygous
control group. A similar increase was also seen in the Cldn-18 KO mice (Fig. 8
A).Furthermore, the cross sectional area of lumbar vertebrae 5 was also increased
significantly in both Cldn-18 KO and heterozygous control mice fed with high dietary
calcium compared to normal dietary calcium (Fig. 8 B).

The Effect of Dietary Calcium on Histomorphometric Parameters of Lumbar
Vertebrae 5 of 10 Week Old Cldn-18 KO and Heterozygous Control Mice
Since the lumber BMD was dramatically increased in both Cldn-18 KO and heterozygous
control mice fed a high Ca diet and the lack of Cldn-18 was previously reported to affect
bone resorption, we performed histomorphometric analysis at lumbar vertebrae 5 and
measured TRAP stained surfaces of the trabecular bone. Our analysis showed that the
osteoclast surface to bone surface (Oc.S/BS) was decreased significantly in the high
calcium Cldn-18 KO group compared to the normal calcium Cldn-18 KO group (Fig. 9).
A similar trend was observed in the heterozygous control mice, as a high calcium diet
decreased Oc.S/BS compared to a normal calcium diet; however, this reduction in
Oc.S/BS was not statistically significant which could be due to either the low baseline
resorption of control animals, or the small sample size examined (Fig. 9). Expectedly,
Oc.S/BS was increased significantly in Cldn-18 KO mice fed a normal diet in comparison
to heterozygous control mice fed a normal calcium diet (Fig. 9). Moreover, Oc.S/BS was
significantly higher in the high calcium Cldn-18 KO group compared to the high calcium
heterozygous control group. Therefore, these findings suggest that the high calcium diet
did not rescue the increased bone resorption observed in the KO mice.
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Figure 8. The effect of dietary calcium on bone size parameters of lumbar vertebrae
5 (LV5) in 10 week old Cldn-18 KO and heterozygous control mice. (A) The length of
lumbar vertebrae 5. (B) The cross sectional area (CSA) calculated in the middle region of
lumbar vertebrae 5 using the uCT (n=12-17/group, mixed gender). *: p<0.05; **: p<0.01;
and ***: p<0.001.
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Figure 9. The effect of dietary calcium on lumbar vertebrae 5 TRAP labeled
trabecular surface of Cldn-18 KO and heterozygous control mice at 10 weeks of age.
(A) Osteoclast surface to bone surface (Oc.S/BS) was measured at trabecular bone of
lumbar vertebrae 5 (n= 5-6/group, mixed gender). (B) Representative micrograph of
lumbar vertebrae 5 sections stained with TRAP (10X). *: p<0.01; and **: p<0.001.
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The Effect of Cldn-18 Deficiency on Acid Secretion by Osteoclasts
To test the possibility that increased bone resorption observed in Cldn-18 KO mice is
due to increased acid secretion from mature osteoclasts, we measured mRNA levels of
carbonic anhydrase II, chloride channel-7 (CLC-7), and H+ pump in primary osteoclasts
derived from Cldn-18 KO and heterozygous control mice. The expression levels of
carbonic anhydrase II, CLC-7, and H+ pump was up regulated in Cldn-18 KO compared
to heterozygous control mice (Fig. 10). Because the number of TRAP positive
multinucleated cells was greater in RANKL/MCSF treated BMM cultures-derived from
Cldn-18 KO mice (21), we normalized mRNA levels in carbonic anhydrase II, CLC-7,
and H+ pump to that of TRAPC5b mRNA, a well-established marker of osteoclast
number. Upon normalization to expression levels of TRAPC5b, no significant change
was observed in these “normalized” values between Cldn-18 KO and heterozygous
control mice (Fig. 10). Additionally, the expression of calcitonin receptor was also not
significantly different between the two genotypes after normalization to TRAPC5b
mRNA levels (Fig. 10).
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Figure 10. The effect of Cldn-18 deficiency on the expression of osteoclastic acid
secreting machinery. The expression levels of carbonic anhydrase II (CA II), CLC-7, H+
pump, calcitonin receptor (CalcR), and TRAPC5b were determined by real -time RTPCR of mature osteoclasts derived from Cldn-18 KO and heterozygous control mice.
Values are presented as fold change of control heterozygous mice (n=4-5/group). *:
p<0.05; and **: p<0.01 versus heterozygous control mice.
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Discussion
In this study, we found that the loss of Cldn-18 negatively affected gastric acidity
in adult mice. Consistent with this observation, Sanada et al., have reported that Cldn-18
was down regulated in gastric cancer and atrophic gastritis (26). Furthermore, Hayashi et
al., have recently demonstrated that Cldn-18 deficient mice developed atrophic gastritis
and the gastric pH was significantly higher in Cldn-18 KO mice compared to WT mice at
day 14 postnatally (16). Additionally, these authors found that the H+ leakage into the
submucosal layer of gastric tissues was higher in Cldn-18 KO mice compared to WT
mice, and was associated with the up-regulation of pro- inflammatory cytokines which in
turn induced gastritis (16, 31). Furthermore, the expression of H+-K+ ATPase was found
to be down regulated in Cldn-18 KO mice, which is caused by a decrease in the total
number of well differentiated parietal and chief cells (16). Because Cldn-18 is a novel
negative regulator of bone resorption, we tested the possibility that Cldn-18 deficiency
affects acid secretion machinery in osteoclasts. We did not find significant differences in
the expression levels of any of the three markers of acid secretion between Cldn-18 KO
and heterozygous control mice after adjustment for differences in osteoclast number
using TRAPC5b mRNA levels. Based on these and published data, it appears that the
increased gastric pH (due to less acid secretion) observed in Cldn-18 KO mice is due to a
defect in the H+ resistant paracellular barrier between gastric epithelial cells and a
decrease in the total number of parietal cell induced by inflammation while the increased
bone resorption in Cldn-18 KO mice is due to MCSF/RANKL signaling-induced increase
in osteoclast number and not due to increased acid secretion per se per osteoclast. Further
studies are, however, needed to verify these conclusions.
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It is noteworthy that the role of gastric acidity in calcium absorption/metabolism
has received more attention recently (5, 35). Calcium solubilization is thought to be
prerequisite for calcium absorption in the small intestine, with the stomach’s acidic
environment inducing the dissolution of calcium salts and the release of ionized calcium
(3, 29). To this end, several clinical studies reported a positive association between the
long term use of acid suppressing agents and bone fractures (17, 33, 37). Moreover, short
and long term use of acid suppressing agents decreased bone mineral density (1, 19).
Although there is limited experimental evidence regarding the mechanism of acid
suppressing agent-induced bone loss, it seems to be more related to the inhibitory effect
of acid on calcium absorption (35). Recently, Schinke et al., have reported that mice
deficient in cholecystokinin B-gastrin receptor that affects acid secretion by parietal cells,
exhibited an osteoporotic phenotype, mediated by an alteration in calcium homeostasis
(27). These authors also found that a high calcium diet fully rescued hypo-chlorhydria
induced bone loss in these mice. Similarly, a high calcium diet is routinely used in the
literature to correct calcium deficit induced by gene mutations (2, 11, 27). The efficacy of
the dietary approach we employed in this study was in fact reported and validated in
several animals model studies in which calcium absorption and homeostasis were
perturbed. For example, the bone phenotype of vitamin D receptor deficient mice was
completely rescued by feeding them a high calcium diet (2, 11). Additionally, several
studies have demonstrated that feeding pregnant mothers with a high calcium diet
significantly increases calcium content in the milk, thereby providing an effective means
to correct calcium deficiency in the pups (8, 28). Furthermore, our data that areal BMD of
vertebra is increased in high calcium diet groups of both genotypes and that serum
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calcium levels were significantly higher in high calcium diet groups compared to normal
calcium diet groups are in support of the notion that the approach that we used was
effective in correcting calcium deficit in the Cldn-18 KO mice.
In agreement with our previous studies in which the serum PTH levels were found
to be elevated in Cldn-18 KO mice fed a normal calcium diet compared to control mice,
we found the serum calcium levels were lower in Cldn-18 KO mice compared to
heterozygous control mice fed a normal calcium diet. In addition, the serum calcium
levels were significantly higher in Cldn-18 KO mice fed a high calcium diet compared to
a normal calcium diet. Moreover, bone resorption (Oc.S/BS) was lower in high calcium
diet fed groups compared to normal calcium diet fed groups. Together these results
suggest that Cldn-18 KO mice may be calcium deficient and are in support of the
possibility that the high systemic calcium achieved by high calcium diet was effective in
correcting the calcium deficit in Cldn-18 KO mice. Importantly, the finding that the high
dietary calcium did not rescue the osteopenia phenotype in Cldn-18 KO mice supports
the idea that low gastric acidity may not be responsible for the Cldn-18 deficiency
mediated bone loss. In this regard, we have recently obtained evidence suggesting that
the low BMD observed in Cldn-18 KO mice may derive from the lack of Cldn-18 in bone
cells. Specifically, we have shown that Cldn-18 is expressed in osteoclasts and that lack
of Cldn-18 increased osteoclast differentiation and bone resorption (22). Taken together,
future studies will elucidate the direct role of Cldn-18 on bone cells using mice with a
conditional disruption of Cldn-18 in osteoclasts.
We also found that various skeletal sites respond differently to increased dietary
calcium. Thus, a high calcium diet increased lumbar BMD in both Cldn-18 KO and
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heterozygous control mice compared to their corresponding genotypes on a normal
calcium diet, whereas tibia and femur BMD were unaffected by dietary calcium in both
genotypes. Consistent with our finding, Datta et al., showed an increase in lumbar
vertebrae 5 BMD in both WT and phosphorylation deficient PTH1R knock-in mice fed a
high calcium diet starting at 4 week of age that was stopped at 8 week of age compared to
the genotype matched mice fed a normal calcium diet (12). On the other hand, these
authors observed that femur BMD was unaffected by a high calcium diet in both of these
genotypes (12). To our knowledge, our study is the first to document a positive
association between spine BMD and a high calcium diet that is started at birth, in mice. In
contrast to our results, it has been previously reported that tibia BMD increased in 3 week
old WT and parathyroid hormone deficient mice fed by dams who received a high
calcium diet compared to those on a normal calcium diet (8, 28). Skeletal site selectivity
in response to calcium supplementation is well documented in human studies during
childhood and adolescence, but the mechanism of this site specific effect remains to be
elucidated (4, 9).
Although lumbar BMD increased significantly in response to a high calcium diet
in both Cldn-18 KO and heterozygous control mice, we did not find a significant change
in either the trabecular or cortical bone parameters at lumbar vertebrae 5, as measured by
uCT. One explanation is the size difference in the lumbar vertebrae 5 between the high
calcium diet group and the normal calcium diet. We also found that the loss of Cldn-18 in
mice fed a normal calcium diet decreased the total body BMD, trabecular, and cortical
bone parameters which was consistent with our previous report on the Cldn-18 deficient
mice bone phenotype (22). However, increased dietary calcium intake in Cldn-18
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deficient mice did not rescue this phenotype at different skeletal sites. Furthermore, the
lumbar bone resorption (Oc.S/BS) was still significantly higher in Cldn-18 KO mice fed a
high calcium diet compared to heterozygous control mice fed a high calcium diet.
Collectively, correction of serum calcium deficit did not correct decreased BMD and
increased bone resorption observed in Cldn-18 KO mice, thus ruling out the possibility
that gastric abnormalities contributed to the osteopenia phenotype in these mice. While
these data suggest a direct role of Cldn-18 in osteoclasts, more direct evidence from the
use of osteoclast-specific Cldn-18 KO mice are warranted to convincingly demonstrate a
non-canonical role of Cldn-18 in osteoclasts.
The limitations of this study are as follows. First, we did not measure the impact
of changes in gastric pH in Cldn-18 KO mice on calcium absorption by directly
measuring dietary calcium uptake using calcium isotopic tracers. Second, we used
heterozygous mice lacking one functional allele of Cldn-18 based on the earlier finding
that skeletal phenotype was not different between wild type and heterozygous mice (20)
and based on the homozygous KO X heterozygous breeding strategy which yielded 50%
KO and 50% heterozygous mice that were used as control. Third, we have not provided
direct evidence using mice with conditional KO of Cldn-18 in osteoclasts to rule out any
role for Cldn-18 expressed in the stomach for the osteopenia phenotype in Cldn-18 KO
mice. Fourth, we did not measure serum PTH and calcitonin levels to check whether the
enhanced lumber BMD and decreased bone resorption observed in both genotypes in
response to high dietary calcium were due to either suppression of PTH and/or due to
secretion of calcitonin. In this regard, the calcitonin receptor expression was not different
after adjustment for differences in TRAP positive osteoclasts between the two genotypes.
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In conclusion, we demonstrated that Cldn-18 deficiency negatively affects gastric
acidity. In addition, we found that a high calcium diet increased lumbar BMD and
decreased bone resorption in both Cldn-18 KO and heterozygous control mice, whereas
correcting the deficit in serum calcium in Cldn-18 KO by feeding a high calcium diet did
not correct the osteopenia phenotype and the increase in bone resorption. Therefore, these
data suggest that the osteopenia phenotype observed in Cldn-18 KO mice is related to the
changes in bone resorption rather than a deficit in calcium absorption.
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Abstract
Claudins (Cldns), a family of 27 transmembrane proteins, represent major
components of tight junctions. Aside from functioning as tight junctions, Cldns have
emerging roles as regulators of cell proliferation and differentiation. While Cldns are
known to be expressed and have important functions in various tissues, their expression
and function in bone cells is ill-defined. In this study, the expression of Cldns was
examined during osteoblast and osteoclast differentiation. The expression of Cldn-1, -7, 11, and -15 was downregulated during early stages of osteoclast differentiation, whereas
Cldn-6 was upregulated. Moreover, the expression of several Cldns increased 3-7 fold in
fully differentiated osteoclasts. As for osteoblasts, the expression of several Cldns was
found to increase more than 10-fold during differentiation, with some peaking at early,
and others at late stages. By contrast, only expression of Cldn-12, and -15 decreased
during osteoblast differentiation. In subsequent studies, we focused on the role of Cldn-1
in osteoblasts as its expression was increased by more than 10 fold during osteoblast
differentiation and was found to be regulated by multiple osteoregulatory agents
including IGF-1 and Wnt3a. We evaluated the consequence of lentiviral shRNAmediated knockdown of Cldn-1 on osteoblast proliferation and differentiation using
MC3T3-E1 mouse osteoblasts. Cldn-1 knockdown caused a significant reduction in
MC3T3-E1 cell proliferation and ALP activity. Accordingly, expression levels of
cyclinD1 and ALP mRNA levels were reduced in Cldn-1 shRNA knockdown cells. We
next determined if Cldn-1 regulates the expression of Runx-2 and osterix, master
transcription factors of osteoblast differentiation, and found that their levels were reduced
significantly as a consequence of Cldn-1 knockdown. Moreover, knocking down Cldn-1
reduced β-catenin level. In conclusion, the expression of Cldn family members during
80

bone cell differentiation is complex and involves cell type and differentiation stagedependent regulation. In addition, Cldn-1 is a positive regulator of osteoblast
proliferation and differentiation.
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Introduction
Osteoporosis is a major public health problem in the U.S. that is characterized by
low bone mass and structural deterioration of bone tissue, resulting in increased bone
fragility [1,2]. It can result from failure to produce optimal bone mass during active
growth periods and/or the imbalance between bone formation and bone resorption during
bone remodeling processes [2]. It is well known that bone formation is mediated by
osteoblasts, which are derived from mesenchymal stem cells [3]. On the other hand, bone
resorption is mediated by osteoclasts, which are generated from hematopoietic stem cells
derived from a macrophage/monocyte lineage [4,5]. In terms of osteoblast and osteoclast
differentiation, such processes are divided into multiple stages and regulated by temporal
and sequential expression of several genes [6-8]. Although a number of systemic
hormones and local regulatory factors have been shown to regulate bone formation and
resorption, our understanding of the molecular pathways that modulate the formation and
function of osteoblasts and osteoclasts is, to date, still limited. Thus, the identification of
novel genes that participate in regulating osteoblast and osteoclast differentiation and
functions is imperative for advancing our understanding of the pathogenesis of
osteoporosis.
Tight junctions, which are composed of several types of transmembrane proteins
including Claudins (Cldns), junctional adhesion molecule, occludin, and tricellulin [9],
are important in the development and maintenance of various tissues [10]. It is
noteworthy that there is significant evidence suggesting that Cldns are the principal
proteins responsible for the formation of tight junction strands [9-11]. The Cldn family of
proteins is comprised of 27 members in mouse and human cells with a molecular weight
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ranging from 20-34 kDa [10,12], and are divided into two major groups, i.e., “classic”
and “non-classic” according to sequence analysis and functional properties of the mouse
variants [13]. Moreover, Cldns exhibit complex patterns of expression that is tissue/cell
type and developmental stage specific [10,14], where certain tissues/cells express several
Cldns, and others express only one or two [10,15]. Interestingly, Cldns expression varies
within the same tissue in a developmental/ differentiation stage dependent fashion [16].
In terms of their regulation, it has been demonstrated that the expression and function of
Cldns is controlled by several transcription factors, hormones, and cytokines [14]. As for
their function, Cldns act canonically as barriers/pores to regulate paracellular
permeability of ions and small molecules, and serve as a fence that divides apical and
basolateral domains of plasma membranes [14]. Recently, a distinct role for Cldns has
emerged, in which they were shown to serve as mediators of cell signaling. Thus, a “noncanonical function” for Cldns was observed, as they were found to control cell
proliferation and differentiation [14,17]. Even though progress has been made, our
knowledge of the expression patterns and function(s) of many Cldn family members in
various tissues, their expression, regulation, and role in bone remains ill defined.
It has been shown that bone cells (osteoblasts and osteocytes) form tight
junctional structures [18-20], and that rat osteoblasts express several Cldns at the mRNA
level [21]. Furthermore, recent work by our laboratory have documented that osteoclasts
express Cldn-18 and that its deletion, in mice, results in an osteopenia phenotype, i.e.,
markedly decreased total body bone mineral density, cortical thickness, and trabecular
volume [22]. Interestingly, the negative effect of a lack of Cldn-18 on the skeleton was
found to be independent of tight junction functions and mediated by increased bone
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resorption and osteoclast differentiation [23,24]. While our studies have laid down the
foundation for the non-canonical function of Cldn-18 in regulating bone homeostasis,
whether other Cldn family members are expressed and have a function during
osteoblastogenesis and osteoclastogenesis remains to be investigated. We, therefore,
undertook studies to evaluate the expression of Cldn family members during osteoblast
and osteoclast differentiation at the mRNA level, and to examine the regulation and
function of selected Cldns. Our findings demonstrate that both osteoblasts and osteoclasts
express several Cldns and that their expression levels vary depending on cell type and
differentiation stage. We have also determined Cldn-1 to be a positive regulator of
osteoblast proliferation and differentiation, and is regulated by several osteoregulatory
factors. In addition, knocking down Cldn-1 reduced β-catenin level, suggesting that it
may be involved in Cldn-1 regulation of osteoblastogenesis.

Materials and Methods
Reagents
Ascorbic acid (AA) and β-glycerophosphate (βGP) were purchased from Sigma
Chemicals (St. Louis, MO). Minimum essential medium α (α-MEM) and AA free αMEM were from Life Technologies (Carlsbad, CA). Calf serum (CS) was purchased
from Hyclone (Logan, UT). Fetal bovine serum (FBS) was purchased from Atlanta
Biologicals (Norcross, GA). Wnt3a, recombinant macrophage colony stimulating factor
(M-CSF), and receptor activator of nuclear factor kappa B ligand (RANKL) were from
R&D systems (Minneapolis, MN, USA). IGF-1 was a gift from Upjohn pharmacia
(Stockholm, Sweden). Cldn-1 specific polyclonal antibody was from cell signaling
technology (Danvers, MA). Antibodies to β-actin and β-catenin, and the MISSION
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shRNA lentiviral particles against Cldn-1 and control non-target short-hairpin RNA
(shRNA) lentiviral particles were purchased from Sigma-Aldrich (St. Louis, MO).

Cell Culture
Primary osteoclast precursor or bone marrow macrophages (BMMs) were
isolated from femurs and tibias of C57BL/6J mice, as described previously [25], and
maintained in α-MEM supplemented with 10% FBS, P/S, and MCSF (25 ng/ml). Twenty
four hours later, non-adherent cells (BMMs) were collected and treated with M-CSF (25
ng/ml) and RANKL (50 ng/ml) for different time periods (0, 1, and 6 days); with fresh
differentiation media added every 3 days. Primary calvarial osteoblasts were isolated
from the calvarias of 3 days old C57BL/6J mice, as previously described [26]. To induce
differentiation, calvarial osteoblasts were incubated with AA free α-MEM supplemented
with 10% CS, penicillin (P, 100 units/ml), streptomycin (S, 100 ug/ml), βGP (10 mM),
and AA (100 ug/ml) for different time periods (0, 4, 6, 8, 13, 19, and 24 days); with fresh
differentiation media added every 3 days. All mice were housed in VA Loma Linda
Health Care System VMU (Loma Linda, CA, USA) under standard approved laboratory
conditions. All animal experiments were performed in compliance with and approved by
the Institutional Animal Care and Use Committee. MC3T3-E1 mouse preosteoblast cells
were grown in AA free α-MEM supplemented with 10% CS, and P/S. Twenty four hours
prior to treatment, cells were incubated in a serum free medium containing AA free αMEM, 0.1% bovine serum albumin (BSA), and P/S. Cells were then treated with
different osteoregulatory agents (BMP-7, IGF-1, vitamin-D3, and Wnt3a) for 72 hrs. All
the treatments were made in AA free α-MEM, 0.1% (BSA), and P/S. Both control short-
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hairpin RNA (shRNA) and Cldn-1 shRNA MC3T3-E1 cells were grown in AA free αMEM supplemented with 10% CS, and P/S. Prior to treatment, cells were incubated in a
serum free medium containing AA free α-MEM, 0.1% bovine serum albumin (BSA), and
P/S for 24 hrs. Subsequently cells were treated with βGP (10 mM) and AA (100 ug/ml)
for 24 hrs and 6 days.

RNA Extraction and Gene Expression Analysis
RNA was extracted from primary cultures and MC3T3-E1 cells using Trizol and
chloroform, and isolation was completed using E.Z.N.A.® RNA Isolation Kits (Omega
Bio –Tek, Norcross, GA). The purity of RNA was determined by the ratio of the
absorbance at 260 and 280 nm. Reverse transcription was accomplished using
SuperScript® II Reverse Transcriptase (Invitrogen, Carlsbad, CA) and the cDNA were
used for real-time RT-PCR. The housekeeping gene peptidylpropyl isomerase A (PPIA)
was used as an internal control in the PCR reaction and the fold change compared to
control was calculated according to the formula 2-ΔΔCt. Primers used for real-time RTPCR are listed in Table. 5.

Protein Extraction and Western Blotting
Primary calvarial osteoblasts were isolated from 3 days old mice and incubated
with AA free α-MEM +10% CS+P/S+ βGP ± AA (100 ug/ml) for 6 days. Both control
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Table 5. Primer sequences used in real-time RT-PCR
Gene

Forward (5’-3’)

Reverse (5’-3’)

Ref

PPIA

CCATGGCAAATGCTGGACCA

TCCTGGACCCAAAACGCTCC

[46]

ALP

ATGGTAACGGGCCTGGCTACA

AGTTCTGCTCATGGACGCCGT

[47]

Cyclin-D1

AATGTACTCTGCTTTGCTGAA

ATGAGACCACTAGAGGTCG

[24]

Osteocalcin

CTCTCTCTGCTCACTCTGCT

TTTGTAGGCGGTCTTCAAGC

[24]

Osterix

AGAGGTTCACTCGCTCTGACGA

TTGCTCAAGTGGTCGCTTCTG

[46]

Runx-2

AAAGCCAGAGTGGACCCTTCCA

ATAGCGTGCTGCCATTCGAGGT

[46]

TRAP
Cldn-1

CACTCAGCTGTCCTGGCTCAA

CTGCAGGTTGTGGTCATGTCC

[24]

GATGTGGATGGCTGTCATTG

CGTGGTGGGTAAGAGGT

[48]

Cldn-2

ATGTCCTCGCTGGCTTGTATTAT

GCCATGAAGATTCCAAGCAACTG

[49]

Cldn-3

CAGTGTACCAACTGCGTACAAGAC

ACCGGTACTAAGGTGAGCAGAG

[49]

Cldn-4

TCGTGGGTGCTCTGGGGAT

GCGGATGACGTTGTGAGCG

[49]

Cldn-5

GCTGGCGCTGGTGGCACTCTTT

GCGAACCAGCAGAGCGGCAC

[49]

Cldn-6

TGCCCACTCTATCATCCAGGACTTC

AGGCCTGAGGCTGCCCAG

[50]

Cldn-7

TTTCATTGTGGCAGGTCTTG

CCAGAAGGACCAGAGCAGAC

[51]

Cldn-8

GGCAACCTACGCTCTTCAAA

CAGGGAGTCGTAGACCTTGC

[51]

Cldn-9

AAGAGAGAACTGGGGGCTTC

AACGGGAAGGGATGGAGTAG

[51]

Cldn-10

ATCTGCGTTACCGATTCCAC

GATCTGAGCCTCCGACTTTG

[52]

Cldn-11

CTGCCGAAAAATGGACGAACTG

TGCACGTAGCCTGGAAGGATGA

[50]

Cldn-12

ACTGCTCTCCTGCTGTTCGT

TGTCGATTTCAATGGCAGAG

[51]

Cldn-13

TAGTGTTGGCCTTCTGATGC

AGCCAAGCAATGGGTTAAAG

[53]

Cldn-14

GCTCCTAGGCTTCCTGCTTA

CTGGTAGATGCCTGTGCTGT

[53]

Cldn-15

CATCTTTGAGAACCTGTGGTACAGC

GATGGCGGTGATCATGAGAGC

[54]

Cldn-16

ATTCATCACCCTGCTCCTTG

AGAGGAGCGTTCGACGTAAA

[51]

Cldn-17

TCGTTCTGATTCCAGTGTCC

TCCTCCAAGTTCTCGCTTCT

[53]

Cldn-19

CCCAGCACTCCTGTCAATG

GTGCAGCAGAGAAAGGAACC

[55]

Cldn-20

GGTACACCAAGGAGATCATAGCG

TACAGGGCTCCTCCAGGTTCATA

[54]

Cldn-22

CTTCCGAACGGCAACGCA

CCTCCCGACTTCCTCCTGG

[56]

Cldn-23

ACAGGGACACCAGCAAGCTCAA

CGGAGTCACAGGGCAGCGAA

[53]
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shRNA and Cldn-1 shRNA MC3T3-E1 cells were grown in AA free α-MEM
supplemented with 10% CS, and P/S. Prior to treatment, cells were incubated in a serum
free medium containing AA free α-MEM, 0.1% bovine serum albumin (BSA), and P/S
for 24 hrs. Subsequently, cells were treated with βGP (10 mM) and AA (100 ug/ml) for
48 hrs. Whole cell extracts were prepared as previously described [24]. Equivalent
amounts of protein were resolved on 10% SDS polyacrylamide gel under denaturing
conditions and were transferred to a PVDF membrane (Millipore, Billerica, MA).
Membranes were blocked with 10% non-fat dry milk dissolved in Tris buffered saline
with 0.1% Tween-20 overnight with rotation at 4°C. The following day, membranes were
probed with Cldn-1, β-catenin, and β-actin antibodies for 1 hr at room temperature. The
membranes were washed and probed with appropriate horseradish peroxidase conjugated
secondary antibody (1:15,000; Sigma-Aldrich; St. Louis, MO). Chemiluminescent
substrate (Thermo Fisher Scientific, Waltham, MA) was used to detect the bands.

Lentivirus Transduction
MC3T3-E1 cells were transduced with control shRNA or Cldn-1 shRNA
lentiviral particles using a multiplicity of infection (MOI) of 10 in the presence of
hexadimethrine bromide (8ug/ml), as previously described [27]. The following day, the
lentiviral particles containing media was changed with fresh media, followed by
puromycin selection (10 ug/ml) for 7 days. The knockdown efficiency was evaluated by
real-time RT-PCR and western blot.
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Proliferation Assay
Cells were plated at 3,000 cells/well in 96-well plates with α-MEM (AA free) +
10% CS +P/S. The following day, the medium was changed to serum free α-MEM (AA
free) + 0.1% BSA for 24 hrs, before the cells were treated with βGP ± AA for 48 hrs,
rinsed with PBS and frozen at -80C°. Cell proliferation was assessed using a
CYQUANT© cell proliferation kit as per the manufacturer`s instructions (Life
Technologies, Carlsbad, CA). Fluorescence measurements were made using a microplate
reader with excitation at 485 nm and emission detection at 530 nm.

Alkaline Phosphatase (ALP) Activity Assay
Cells were plated at 5,000 cells/well in 96-well plates with α-MEM (AA free) +
10% CS +P/S. The following day, the medium was changed to serum free α-MEM (AA
free) + 0.1% BSA for 24 hrs. The cells were then treated with βGP ± AA for 72 hrs,
before being rinsed with PBS and permeabilized with ALP activity buffer containing
0.1% triton X-100 in 250 mM NaHCO3. Protein concentration was determined by the
BCA method (Thermo Fisher Scientific; Waltham, MA) and ALP activity was detected
as previously described [28].

ALP Staining
Cells were incubated with AA free α-MEM +10% CS+P/S+ βGP ± AA (100
ug/ml) for 6 days. Cells were washed with PBS, fixed with 10% formalin for 20 minutes
at room temperature, and incubated at 37C° for 30 min in staining buffer containing 50
mM Tris-HCL, pH 8.6, 100 mM NaCl, 5 mM KCl, 1 mM MgCl2, 0.8 mg/ml naphthol

89

AS-TR phosphate, and 0.6 mg/ml fast red violet LB diazonium (Sigma Aldrich, St.
Louis, MO). Quantification of ALP-stained areas was measured with ImageJ software.

Statistical Analysis
Data are expressed as the mean ± SEM (n=4-8) and were analyzed using one-way
ANOVA (GraphPad Prism6) for the expression of Cldns during osteoblast and osteoclast
differentiation and the Student`s t test (Microsoft Excel) for all other experiments.
Newman- Keuls was used as a post hoc test.

Results
Expression Profiles of Cldn Family Members During Osteoclast
Differentiation
To examine the expression of Cldns during osteoclast differentiation, we used
primary osteoclast precursors isolated from bone marrow (i.e., BMMs) and treated them
with MCSF and RANKL for different time periods (0, 1, and 6 days). Firstly, osteoclast
differentiation was verified by measuring the bone resorption marker gene, TRAP, which
is known to increase as osteoclasts differentiate (Fig. 11) [4]. Our findings indicated that
some of the “Classic” Cldns including Cldns-1, -7, and -15 were downregulated during
early stages (day 1) of osteoclast differentiation, whereas Cldn-6 was upregulated. As for
the expression of “Classic” Cldns, several of them (i.e., -1, -2, -3, -5, -6, -15, and -17),
were found to be increased 3-7 fold in fully differentiated osteoclasts compared to
undifferentiated osteoclasts (day 6 vs. day 0; Fig. 12). As for the remaining “Classic”
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Figure 11. The expression level of tartrate resistant acid phosphatase (TRAP), an
osteoclastogenic marker gene, during RANKL induced osteoclast differentiation.
The expression level of TRAP during primary osteoclast differentiation was evaluated by
real time RT-PCR, at different time points (0, 1, and 6 days). Values are (means ± SEM;
n = 4) presented as fold change from day 0 (untreated cells); data were analyzed using
one-way ANOVA (GraphPad Prism6). A = < 0.05 (from day 0), and B = < 0.05 (from
day 1).
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Figure 12. The expression level of “classic” Cldns during RANKL induced
osteoclast differentiation. The expression level of “classic” Cldns (Cldn 1-8, -14, -15,
and -17) during primary osteoclast differentiation was evaluated by real time RT-PCR, at
different time points (0, 1, and 6 days). Values (means ± SEM; n = 4) are presented as
fold change from day 0 (untreated cells) ), data were analyzed using one-way ANOVA
(GraphPad Prism6). A = < 0.05 (from day 0), and B = < 0.05 (from day 1).
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Cldns (-4,-8, and -14), no significant change in their expression levels was observed (Fig.
12). Of the “non-classic” Cldns, Cldn-11 was downregulated during the early stage (day
1) of osteoclast differentiation; Cldn-12, -13, and -22 were upregulated during late stages
(day 6); while no changes in Cldn-20 and -23 mRNA levels were detected (Fig. 13).
Taken together, these findings suggest that Cldns are differentially expressed and highly
regulated during osteoclast differentiation.

Expression Profiles of Cldn Family Members During Osteoblast
Differentiation
To investigate the expression of Cldns during osteoblast differentiation, primary
osteoblasts were isolated from calvarias of 3 days old mice and differentiated with AA
for different time periods (0, 4, 6, 8, 13, 19, and 24 days). The expression of Cldns was
then evaluated by real-time RT-PCR. We first confirmed osteoblast differentiation by
measuring osteoblast marker genes such as ALP and osteocalcin, which are known to
increase, in a time-dependent manner, as osteoblasts differentiate (Fig. 14) [29]. Given
that Cldns are divided into “classic” and “non-classic” groups [13], for the sake of
simplicity and ease of comprehension, the “classic” ones were subdivided into three
clusters based on their phylogenetic tree close proximity, as follows: (1) Cluster A, which
includes Cldn-3, -4, -5, -6 , -8, -9, and -17; (2) Cluster B, which includes Cldn-1, -2, -7, 14, and -19; and (3) Cluster C, which includes Cldn-10 and -15. On the other hand, the
less similar/related Cldns were classified as “non-classic”, and include Cldn-11, -12, -13,
-16, -18, -20, -22, and -23. Our results revealed that the expression levels of all “Classic”
Cldns were upregulated during osteoblast differentiation, except Cldn-15 which was
found to be downregulated (Fig. 15A, B, C). Interestingly, expression levels of Cldn-1,-2,
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Figure 13. The expression level of “non-classic” Cldns during RANKL induced
osteoclast differentiation. The expression level of “non-classic” Cldns (Cldn 11-13, -20,
-22, and -23) during primary OC differentiation was evaluated by real time RT-PCR, at
different time points (0, 1, and 6 days). Values (means ± SEM; n = 4) are presented as
fold change from day 0 (untreated cells), data were analyzed using one-way ANOVA
(GraphPad Prism6). A = < 0.05 (from day 0), and B = < 0.05 (from day 1).
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B

Figure 14. The expression level of osteoblastogenic marker genes during ascorbic
acid induced osteoblast differentiation. A) The expression of alkaline phosphatase
(ALP), an early stage maker gene of osteoblast differentiation, as determined by real time
RT-PCR. B) The expression of osteoclacin, a late stage maker gene of osteoblast
differentiation, as determined by real time RT-PCR. Values (means ± SEM; n = 6) are
presented as fold change from day 0 (untreated cells), data were analyzed using one-way
ANOVA (GraphPad Prism6). A= < 0.05 (from day 0), B = < 0.05 (from day 4), C = <
0.05 (from day 6), D = < 0.05 (from day 8), E = < 0.05 (from day 13), and F = < 0.05
(from day 19).
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B
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C

Figure 15. The expression level of “classic” Cldns during ascorbic acid induced
osteoblast differentiation. The expression level of “classic” Cldns during primary
osteoblast differentiation was measured by real time RT-PCR, at different time points (0,
4, 6, 8, 13, 19, 24 days). A) The expression level of cluster A of the “classic” Cldns,
which includes Cldn-3, -4, -5, -6 , -8, -9, and -17. B) The expression level of cluster B of
the “classic” Cldns, which includes Cldn-1, -2, -7, -14, and -19. C) The expression level
of cluster C of the “classic” Cldns, which includes Cldn-10 and -15. Values (means ±
SEM; n = 6) are presented as fold change from day 0 (untreated cells) , data were
analyzed using one-way ANOVA (GraphPad Prism6). A = < 0.05 (from day 0), B = <
0.05 (from day 4), C = < 0.05 (from day 6), D = < 0.05 (from day 8), E = < 0.05 (from
day 13), and F = <0.05 (from day 19).
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-5, -7 to -10, and -19 were increased significantly during early stages of osteoblast
differentiation, i.e., peaked between day 6 and 8, whereas the mRNA levels of Cldn-3, -4,
-6, -14, and -17 peaked at late stages (Fig. 15A, B, C). It is noteworthy that several
“classic” Cldns were found to be upregulated by more than 10 fold, at certain stages of
osteoblast differentiation, including Cldn-1, -2, -4, -5, -8, -10, -14, -17, and -19 (Fig.
15A, B, C).
Regarding the “non-classic Cldns”, our results indicate that they exhibit a diverse
expression profile. While the expression levels of Cldn-11, -13, -22, and -23 were
increased significantly during osteoblast differentiation and peaked during either early or
late stages (Fig. 16), those of Cldn-12 decreased significantly (Fig. 16). Moreover, no
change in the expression level of Cldn-20 was observed during osteoblast differentiation
(Fig. 16). Of note, the mRNA of Cldn-16 was found to be undetectable by real-time RTPCR, at least under our experimental conditions. Collectively, these data suggest that the
regulation of expression of Cldns during osteoblast differentiation is complex and
differentiation stage dependent.
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Figure 16. The expression level of “non-classic” Cldns during ascorbic acid induced
osteoblast differentiation. The expression level of “non-classic” Cldns during primary
osteoblast differentiation was evaluated by real time RT-PCR at different time points (0,
4, 6, 8, 13, 19, 24 days). Values (means ± SEM; n = 6) are presented as fold change from
day 0 (untreated cells), data were analyzed using one-way ANOVA (GraphPad Prism6).
A = < 0.05 (from day 0), B = < 0.05 (from day 4), C = < 0.05 (from day 6), D = < 0.05
(from day 8), E = < 0.05 (from day 13), and F = < 0.05 (from day 19).

99

Regulation of Cldn-1 Expression
Among the several Cldns expressed in osteoblasts, Cldn-1 is of particular interest
because it is known to be regulated by the key bone formation regulator IGF-1 [30], and
its expression, as shown by our data, increased by more than 10 fold during osteoblast
differentiation (Fig. 15B). We next sought to confirm that the increase in mRNA level of
Cldn-1 during early stages (between day 6 and 8) of osteoblast differentiation was
commensurate with an increase at the protein level using western blot analysis. Figure 17
shows that AA treatment for 6 days caused a 2-fold increase in Cldn-1 protein levels in
newborn mouse calvarial osteoblasts. Osteoblasts are known to produce a number of
growth factors which act in an autocrine/paracrine manner to regulate proliferative and
differentiative functions [8]. In order to determine if bone growth factors regulate Cldn-1
expression, Cldn-1 mRNA level was measured after treating MC3T3-E1 mouse
preosteoblast cells with different osteoregulatory agents (BMP-7, IGF-1, vitamin-D3, and
Wnt3a) for 72 hours. As expected and previously reported, IGF-1 (30 ng/ml) treatment
increased the expression of Cldn-1 in MC3T3-E1cells [30], whereas treatment with
Wnt3a (10 ng/ml) decreased Cldn1 expression by 80% (Fig. 18). On the other hand,
Cldn-1 expression was not affected by BMP-7 (30 ng/ml) or vitamin-D3 (10 nM)
treatment (Fig. 18).

The Effect of Knocking Down Cldn-1 Expression on MC3T3-E1 Cell
Proliferation and Differentiation

Cldn-1 is known to regulate cell proliferation and differentiation in a variety of
cell types [31-33]. Therefore, the role of Cldn-1 in regulating osteoblast proliferation and
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Figure 17. Cldn-1 protein levels during early stages of ascorbic acid induced
osteoblast differentiation. Primary osteoblasts isolated from calvarias were treated with
βGP ± AA for 6 days, before Cldn-1 expression was evaluated by western blotting.
Values (means ± SEM; n = 4). A = < 0.05 vs. untreated cells (βGP alone).
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Figure 18. The regulation of Cldn-1 expression. MC3T3-E1 cells were treated with
vehicle, BMP-7, IGF-1, vitamin-D3 (Vit-D3), and Wnt3a for 72 hrs, before the
expression level of Cldn-1 was examined by real time RT-PCR. Values (means ± SEM; n
= 4) are represented as % vehicle-treated control. A = < 0.05 vs. vehicle control.
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differentiation was determined by knocking it down, using lentivirus shRNA, in MC3T3E1 cells. First, we confirmed that MC3T3-E1 cells express Cldn-1 and that its expression
was increased by 3 fold (P<0.01) by AA treatment at day 6 (data not shown). It was
observed that Cldn-1expression was significantly decreased at both the mRNA and
protein levels, in cells expressing Cldn-1 shRNA compared to control shRNA (Fig. 19A,
B). It was found that cell proliferation was reduced by 18% and 13%, compared to
control shRNA cells, when treated with βGP or AA, respectively (Fig. 19C). Moreover,
in agreement with reduced cell proliferation in Cldn-1 shRNA cells, the expression of the
osteoblast proliferation marker gene cylcin-D1 was reduced by 41% (Fig 19D).
Given that Cldn-1 expression is upregulated during early stages of osteoblast
differentiation, we examined whether it plays a role in regulating expression of osteoblast
differentiation markers. Knockdown of Cldn-1 expression in MC3T3-E1 cells reduced
ALP activity by 61% (Fig. 20A). AA treatment caused a 4-fold increase in ALP activity
in control shRNA treated cells, as expected. However, the effect of AA on ALP activity
was reduced by 80% upon Cldn-1 knockdown (Fig. 20A). Consistent with these data,
inhibition of Cldn-1 reduced ALP staining, in cells treated with AA (Fig. 20B).
To further characterize the positive effect of Cldn-1 on osteoblast differentiation,
mRNA levels of osteoblast specific differentiation markers were determined in control
and Cldn-1 shRNA cells, treated with or without AA. While the mRNA levels of ALP
and bone sialoprotein were not found to be significantly decreased in Cldn-1 shRNA
compared to control 24 hrs after AA treatment, their levels were decreased by 92% 6
days after AA treatment (Fig. 20C). Even though knocking down Cldn-1 appeared to
reduce osteoclacin expression (a late osteoblast differentiation marker gene) at these time
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Figure 19. The effect of Cldn-1 knockdown on osteoblast proliferation in MC3T3-E1
cells: A) Cldn-1 expression in MC3T3-E1 cells transduced with control shRNA or Cldn1 shRNA as determined by real time RT-PCR. Values (means ± SEM; n = 4). A = <
0.0001 vs. control shRNA. B) Cldn-1 protein level in MC3T3-E1 cells transduced with
control shRNA or Cldn-1 shRNA as determined by western blot using whole cell lysates.
C) Cell proliferation: MC3T3-E1 cells transduced with control or Cldn-1 shRNA and
treated with βGP ± AA for 48 hrs, before cell proliferation was assessed using the
CYQUANT© cell proliferation kit by measuring fluorescence after excitation at 485 nm
and by emission detection at 530 nm. Values (means ± SEM; n = 8). A = < 0.05 vs. βGP
treated, and B = <0.05 vs. control shRNA at corresponding treatment. D) The expression
of a cell proliferation marker gene (cyclin-D1) in MC3T3-E1 cells transduced with
control shRNA or Cldn-1 shRNA and treated with βGP ± AA for 24 hrs, as determined
by real time RT-PCR. Values (means ± SEM; n = 4) are presented as % of control
shRNA. A=<0.05 vs. control shRNA cells.
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Figure 20. The effect of Cldn-1 knockdown on osteoblast differentiation in MC3T3E1 cells: A) ALP activity was determined in MC3T3-E1 cells transduced with control or
Cldn-1 shRNA and treated with βGP ± AA for 72 hrs. Values (means ± SEM; n = 8). A =
< 0.05 vs. βGP treated, and B = < 0.05 vs. control shRNA at the corresponding treatment.
B) ALP staining was determined on MC3T3-E1 cells transduced with control or Cldn-1
shRNA and treated with βGP ± AA for 6 days, followed by ALP activity staining. Values
(means ± SEM; n = 5) are represented as % ALP stained area. A = < 0.05 vs. βGP
treated, and B = < 0.05 vs. control shRNA at the corresponding treatment. C) The
expression of osteogenic master transcription factor genes (osterix and Runx-2) and
osteogenic marker genes ( ALP, bone sialoprotein (BSP), and osteocalcin) was evaluated
in control and Cldn-1 shRNA MC3T3-E1 treated β-glycerophosphate (βGP) with or
without ascorbic acid (AA) for 24 hrs and 6 days using real time RT-PCR. Values (means
± SEM; n = 4) are presented as % of control shRNA. A=<0.05 vs. control shRNA cells.
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points, the difference did not reach statistical significance (Fig. 20C). Finally, the
expression levels of transcription factors that are required for osteoblast differentiation
was evaluated in control and Cldn-1 shRNA cells. We found that down regulating Cldn-1
expression reduced the expression of both osterix and Runx-2 mRNA levels, by 33% and
45% respectively, when treated with AA for 24 hrs (Fig. 20C). This effect was still
maintained in the Cldn-1 shRNA cells, even after 6 days of AA treatment, albeit to a
lower extent (Fig. 20C).

The Effect of Knocking Down Cldn-1 Expression on β-catenin
Levels
To gain more insight into the molecular pathway(s) underlying Cldn-1 function in
osteoblasts, we tested the effect of its knockdown on β-catenin signaling. This is based on
β-catenin’s established importance in regulating osteoblastogenesis [34,35], as well as
reports that inhibition and overexpression of Cldn-1 in a colon cancer cell line leads to a
reduction and activation of β-catenin signaling, respectively [36,37]. Thus, β-catenin
protein level was evaluated in Cldn-1 shRNA compared to control shRNA cells, treated
with AA for 48 hrs. Indeed, we found that β-catenin protein level decreased by 28% as a
consequence of Cldn-1 knockdown (Fig 21), suggesting that it may be involved in Cldn-1
regulation of osteoblastogenesis.
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Figure 21. The effect of Cldn-1 knockdown on β-catenin. Control shRNA or Cldn-1
shRNA MC3T3-E1 cells were treated with AA for 48 hrs, then β-catenin expression was
evaluated by western blotting using whole cell lysates. Values (means ± SEM; n = 4).
A=<0.05 vs. control shRNA cells.
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Discussion
This study provides the first comprehensive investigation of the expression of
Cldn family members during bone cell differentiation, in mice. Specifically, we report for
the first time that primary mouse osteoclasts differentially express several Cldns in a time
dependent manner. Furthermore, Cldns were found to be differentially expressed and
highly regulated during primary osteoblast differentiation In an attempt to decode the
function of Cldns in regulating skeletal development and maintenance, we focused on the
role of Cldn-1 during osteoblastogenesis. We determined that Cldn-1 expression is
regulated by several osteoregulatory agents such as IGF-1 and Wnt3a and that Cldn-1 is a
positive regulator of osteoblast proliferation and differentiation. In addition, knockdown
of Cldn-1 in osteoblasts leads to a reduction in β-catenin protein levels, suggesting that
this pathway is possibly involved in Cldn-1-mediated modulation of osteoblastogenesis.
In agreement with the complex expression patterns of Cldns reported in different
tissues, we found that Cldns also exhibit cell type and differentiation stage specific
patterns of expression, during bone cells differentiation. As for osteoclasts, we were the
first to provide evidence that Cldns, specifically Cldn-18, are expressed in osteoclasts
[24]. Aside from Cldn-18, the expression profile of other Cldn family members has not
been previously reported in the literature. In this regard, the current study demonstrates,
for the first time, that several Cldns were expressed in primary osteoclasts, in a
differentiation stage dependent fashion. Furthermore, three distinct expression profiles
were observed during osteoclast differentiation: 1. upregulation or downregulation during
early stages, suggesting that these Cldns may have potential functions during the
proliferation stage; 2. up regulation during late stages, supporting possible roles in
regulating osteoclast function and activity; and 3. no apparent change in the expression of
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some Cldns, which may indicate a lack of a role during osteoclastogenesis. Regarding
their function, Cldn-18 is the only family member shown to play a role in
osteoclastogenesis [24]. While these studies clearly document a critical non-canonical
role for Cldn-18 in regulating osteoclast differentiation, the current study suggests that
other Cldn family members may also have potential roles in regulating these processes. In
addition, the issue of whether Cldn-18 interacts with other Cldns to regulate bone
resorption remains to be elucidated.
As for osteoblasts, their differentiation processes in vitro are divided into several
stages and regulated by differential and sequential expression of several genes [7,8].
While rat osteoblasts are known to express several Cldns [20,21], the consequence of
cellular differentiation on Cldn expression has not been documented. Our study revealed
for the first time that the expression pattern of Cldns may be osteoblast differentiation
stage-dependent. Many Cldns showed an increase in their expression levels, some were
found to be downregulated, and others exhibited no change, indicating possible diverse
roles for Cldns during different stages of osteoblastogenesis. Consistent with our finding,
it has been shown that the expression of Cldn-1 and -2 was higher in osteoblast like
MC3T3-E1 cells compared to osteocyte-like MLO-Y4 cells [30]. By contrast, an earlier
study showed that Cldn-1 and Cldn-2 mRNA levels were upregulated during the
mineralization stage compared to the proliferation stage [20]. While expression levels of
several Cldns seem to vary depending on differentiation stage of osteoblasts, we have not
determined whether these changes are biologically significant. Therefore, our future
experiments will evaluate the biological role of the various Cldn family members in
regulating osteoblast proliferation/differentiation to determine if their differentiation
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stage-dependent expression has physiological relevance. In-line with differentiation stage
dependent patterns of Cldns expression, it has been shown that other cells of
mesenchymal origin differentially express Cldns [38,39]. For example, Cldn-6 was found
to be upregulated and plays an important role during adipocyte differentiation [38].
Moreover, our findings that all “classic” Cldns mRNA levels were increased during
osteoblast differentiation suggest that these closely related Cldns may exert
similar/redundant functions, and possibly regulated in a similar manner. By contrast, the
diverse expression patterns observed with the “non-classic” Cldns supports the idea that
they may have district functions, and may, therefore, be regulated differently. Thus, even
though these data suggest potential roles of Cldn family members in regulating
osteoblastogenesis, our future studies will examine their role in skeletal development and
maintenance, by employing both gain and loss of function experiments in vivo and in
vitro.
In terms of the regulation of Cldn expression, multiple studies in other tissues
have shown that Cldn expression and function is regulated by a host of growth factors,
hormones, and cytokines [14]. The observed complex expression patterns of Cldns during
osteoblast differentiation appear to indicate that Cldn expression is tightly regulated.
Thus, these tight regulation processes of Cldn expression during AA induced osteoblast
differentiation could be explained by either direct effects of AA treatment and/or indirect
effects. The latter could be mediated by growth factors and/or bone matrix proteins
secreted during osteoblast differentiation, which, in turn, act in an auto/paracrine fashion.
In order to better understand the regulation and function of Cldns in bone, our efforts
focused on Cldn-1 based on its interesting differential expression pattern, (i.e.,
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upregulation of Cldn-1 during early stages of osteoblast differentiation, whereas
downregulation during late stages); and its established importance in tissue development
as mice with targeted disruption of the Cldn-1 gene failed to survive after birth [40].
Consistent with an important role for Cldn-1 are our findings that its expression is
regulated by IGF-1 and Wnt3a. The increased expression of Cldn-1 following IGF-1
treatment is similar to a previous report in which IGF-1 was found to upregulate Cldn-1
expression, via a MAPK dependent pathway (25). On other hand, Wnt3a, a known
stimulator of bone formation, significantly decreased the expression of Cldn-1.
Interestingly however, an opposite regulation pattern was observed in colon cancer cells
supporting the notion that Cldns regulation by Wnt signaling may be tissue/cell type
specific [41,42].
Regarding Cldn-1 function, it has been shown that Cldn-1 acts canonically as a
cation restrictive barrier in epithelial as well as endothelial tissues [10,43]. Aside from
this function, there is substantial evidence that Cldn-1 participates in intracellular
signaling that controls cell proliferation and differentiation [31-33]. While the canonical
function of Cldn-1 in bone cells has been suggested in the literature, virtually nothing is
known about its non-canonical function, i.e., as a mediator of cell signaling, in such cells
[30]. Consequently, knocking down Cldn-1 reduced osteoblast proliferation and the
expression of the cell proliferation marker gene cyclin-D1, indicating that Cldn-1
promotes osteoblast proliferation. In addition, several studies in other cell types have
demonstrated that Cldn-1 is a promoter, inhibitor, or has no effect on cell proliferation,
thereby supporting the notion that the “proliferative” function of Cldn-1 is cell typedependent [32,33,36]. Besides regulating proliferation, Cldn-1 appears to play an
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important role in regulating early stage osteoblast differentiation as revealed by data from
Cldn-1 knockdown experiments. In agreement with the observed upregulation of Cldn-1
during early stages of osteoblast differentiation, Cldn-1 deficiency had no significant
effect on the expression of the late stage osteogenic marker gene osteocalcin. In addition,
previous studies demonstrated that Cldn-1 can modulate the expression of transcription
factors in various tissues [37,44,45]. Accordingly, we determined if Cldn-1 regulates the
expression of Runx-2 and osterix, master transcription factors of osteoblast
differentiation, and found their levels to be reduced significantly as a consequence of
Cldn-1 knockdown. It seems that Cldn-1 regulates the expression of transcription factors
during early time points, which seems to be consistent with their consequent regulation of
the expression of osteogenic marker genes. The finding that the effect of Cldn-1
knockdown on expression of osteogenic transcription factors was maintained after 6 days,
suggests that Cldn-1 deficiency inhibits osteoblast differentiation. However, the issue
whether inhibition of Cldn-1 prevents or delays differentiation will be addressed in future
studies. Together these findings underscore Cldn-1 as a positive regulator of (early)
osteoblastogenesis, which is consistent with its reported function in early dentinogenesis
[31]. On the contrary, it has been reported that Cldn-1 inhibits differentiation of other cell
types [33], thereby, providing evidence that its regulation of differentiation is cell type
and stage dependent.
In terms of potential mechanism(s) for Cldn-1 actions, we evaluated the effect of
Cldn-1 knockdown on β-catenin, which is a major pathway known to be critical for
osteoblastogenesis [34,35]. We found that knockdown Cldn-1 in osteoblasts leads to a
reduction in β-catenin protein levels. In support of our findings, it has been reported that
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inhibition and overexpression of Cldn-1 in a colon cancer cell line leads to reduction and
activation of β-catenin signaling, respectively [36,37]. However, the detailed mechanism
by which Cldn-1 modulates β-catenin signaling remains to be determined, and the cause
and effect relationship between reduced β-catenin level and reduction in
proliferation/differentiation caused by Cldn1 knockdown in osteoblasts will be the focus
of future experiments. Nonetheless, one of the potential mechanisms may be through
phosphorylation/inactivation of GSK3, which normally results in β-catenin degradation.
Another possible mechanism is by direct binding, which will make β-catenin less
accessible to the destruction complex [36]. On the other hand, Cldn-1 itself has been
found to be a target for β-catenin signaling in colon cancer [41]. Therefore, we cannot
exclude the possibility that β-catenin signaling is also upstream of Cldn-1 and/or there
exists some kind of cross talk or feedback loop between them in regulating
osteoblastogenesis. While our data suggests that Cldn-1 may regulate β-catenin signaling,
we cannot exclude the involvement of other pathways such as TGF-β, BMP, and Notch
signaling. Thus, the delineation of the molecular pathway(s) by which Cldn-1 acts should
advance our understanding of the regulation of osteoblast differentiation.
In conclusion, here we show for the first time that Cldn family members are
expressed and tightly regulated in both primary osteoblasts and osteoclasts, in a
differentiation stage dependent manner. Furthermore, we provide compelling evidence
that Cldn-1 is a novel positive regulator of osteoblast differentiation and proliferation,
and its regulation is complex and mediated by several osteoregulatory factors.
Collectively, the observed complexity in the expression patterns of Cldns during bone
cells differentiation, and the finding that Cldn-1 regulates osteoblast differentiation
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suggests that Cldns may have potential roles in regulating bone homeostasis . Finally,
our future understanding of how Cldns regulate osteoblast and osteoclast function, and
overall bone homeostasis could lead to the development of Cldn-based drug targets for
diagnosis and therapeutic management of osteoporosis.
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CHAPTER FOUR
DISCUSSION
Osteoporosis, a major public health problem, is characterized by low bone mass
and structural deterioration of bone tissue resulting in increased bone fragility (Dempster,
2011; Raisz, 2005). The imbalance between bone formation and resorption during bone
remodeling has been documented to be a major factor in the pathogenesis of osteoporosis
(Raisz, 2005). It is well known that bone mass is maintained by a well-coordinated
activity of cells of the osteoblast and osteoclast lineages, in what is known as the basic
multicellular unit (BMU), which carry out resorption of old bone and formation of new
bone, in a sequential manner (Hou et al., 2009). While a number of systemic hormones
and local growth factors have been implicated in regulating bone formation and
resorption, our knowledge of the molecular pathways that regulate the activity of
osteoblasts and osteoclasts is, to date, still limited. Thus, it is crucial to identify novel
genes and/or novel functions for some of the known genes that regulate the formation and
activity of these cell types, which, in turn, is expected to advance our understanding of
the pathogenesis of osteoporosis, and aid in designing novel regimens for its therapeutic
management.
To this end, recent evidence suggests a significant role for the tight junction
proteins, Cldns, in the regulation of bone remodeling processes. In our previous studies,
we have demonstrated that Cldn-18 is expressed in bone cells and its targeted disruption
in mice resulted in osteopenia phenotype by increasing bone resorption (Linares et al.,
2012a). In fact, Cldn-18 was found to act non-canonically by regulating RANKL
mediated osteoclast differentiation (Linares et al., 2012b). While our previous data
suggest a direct non-canonical function in regulating osteoclast differentiation, it is
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known that Cldns act “canonically” as key determinants of paracellular permeability of
ions, solutes, and water across the plasma membrane (Gunzel & Yu, 2013). Thus, it is
possible that the phenotype of Cldn-18 KO mice is in part mediated by its canonical
function. Since Cldn 18 is known to be predominately expressed in the stomach, and it
was globally disrupted in these earlier studies (Hayashi, Tamura, Tanaka, Yamazaki,
Watanabe, Suzuki, Sentani, et al., 2012; A. Tamura et al., 2012), we tested the possibility
that the osteopenia phenotype in Cldn-18 KO mice is due to its disruption in the stomach.
In our study, we found that the loss of Cldn-18 negatively affected gastric acidity in adult
mice. Consistent with this observation, Sanada et al., have reported that Cldn-18 was
down regulated in gastric cancer and atrophic gastritis (Sanada et al., 2006a).
Furthermore, Hayashi et al., have recently demonstrated that Cldn-18 deficient mice
developed atrophic gastritis and their gastric pH was significantly higher compared to
WT mice, at day 14 postnatally (Hayashi, Tamura, Tanaka, Yamazaki, Watanabe,
Suzuki, Sentani, et al., 2012). Additionally, these authors found that the H+ leakage into
the submucosal layer of gastric tissues was higher in Cldn-18 KO mice compared to WT
mice (Hayashi, Tamura, Tanaka, Yamazaki, Watanabe, Suzuki, Sentani, et al., 2012; A.
Tamura et al., 2012). Together, these findings provide strong evidence that Cldn-18 plays
an important role in the physiology and pathology of stomach function and may provide
the paracellular barrier against H+ leakage in the stomach.
Given the documented role of gastric acidity in calcium absorption/metabolism,
as calcium solubilization by stomach’s acidic environment is thought to be prerequisite
for calcium absorption in the small intestine (Bo-Linn et al., 1984; Boyce, 2009;
Sipponen & Harkonen, 2010; Wright et al., 2008) , there is a possibility that the increased
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bone resorption in the Cldn-18 KO mice is a consequence of reduced calcium absorption
due to the increased stomach pH. To address this issue, Cldn-18 KO and control mice
were subjected to a normal or high calcium diet at birth, for a 10-week period. Serum
calcium levels were significantly lower in Cldn-18 KO mice compared to control mice on
a normal calcium diet but not on high calcium diet. This finding is consistent with our
previous studies in which the serum PTH levels (and indicator of calcium homeostasis)
were found to be elevated in Cldn-18 KO mice fed a normal calcium diet compared to
control mice (Linares et al., 2012a), suggesting that Cldn-18 KO mice may be calcium
deficient. In support of the effectiveness of the dietary approach we employed in this
study, the serum calcium levels were significantly higher in Cldn-18 KO mice fed a high
calcium diet compared to a normal calcium diet. Moreover, bone resorption was lower in
high calcium diet fed groups compared to normal calcium diet fed groups. Consistent
with our previous report on the Cldn-18 deficient mice bone phenotype, we also found
that these mice exhibited decreased total body BMD, trabecular, and cortical bone
parameters when fed a normal calcium diet (Linares et al., 2012b). However and
importantly, increased dietary calcium intake in Cldn-18 deficient mice did not rescue
this phenotype at different skeletal sites. Furthermore, the lumbar bone resorption was
still significantly higher in Cldn-18 KO mice fed a high calcium diet compared to control
mice fed a high calcium diet. Collectively, correction of serum calcium deficit did not
rescue decreased BMD and increased bone resorption observed in Cldn-18 KO mice; thus
ruling out the possibility that gastric abnormalities contributed to the osteopenia
phenotype in these mice. Therefore, these findings and our previous study support a
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direct non-canonical role for Cldn-18 in regulating osteoclast differentiation and bone
resorption (Linares et al., 2012b).
While our studies have laid down the foundation for the non-canonical function of
Cldn-18 in regulating bone homeostasis, whether other Cldn family members are
expressed and modulate osteoblastogenesis and osteoclastogenesis remains to be
investigated. Cldns exhibit complex patterns of expression that are tissue/cell type and
developmental stage specific (Alshbool & Mohan, 2014; Gunzel & Yu, 2013). Some
tissues/cells such as the epidermis express several Cldns (Brandner et al., 2002), whereas
others such as Sertoli cells express only one or two Cldns (C. M. Van Itallie & Anderson,
2006). Interestingly, Cldn expression also varies within the same tissue. For example, in
mouse kidney, at least 15 Cldns are expressed with distinct expression patterns in every
segment of the nephron (Elkouby-Naor & Ben-Yosef, 2010). Thus, while the proximal
tubules express Cldn-1, -2, -10, -11, -12, and -14, the distal tubules express Cldn-3, -7, -8,
-10, and -11 (Elkouby-Naor & Ben-Yosef, 2010). There is also increasing evidence that
the expression of Cldns is developmental stage specific (Gunzel & Yu, 2013). In the
mouse jejunum, the expression of several Cldns is increased or decreased during neonatal
development (Holmes et al., 2006). For example, the expression of Cldn-19 was
predominant in 2 week old mouse jejunum and was no longer detected after 4 weeks
(Holmes et al., 2006). While much is known regarding the expression patterns of many
Cldn family members in several tissues, little is known about their expression in bone. In
the present study, we provide the first experimental evidence that several Cldns are
expressed in bone, in a complex, cell type and differentiation stage-dependent fashion.
Specifically, several Cldns were found to be expressed in primary osteoclasts, in a
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distinct differentiation stage dependent fashion, including: upregulation or
downregulation during early stages, and upregulation during late stages. On the other
hand, some exhibited no apparent changes in their expression profile. The
aforementioned three distinct expression profiles observed during osteoclast
differentiation suggest that some Cldns have potential roles in regulating osteoclast
proliferation and/or osteoclast activity and function; whereas others might have no role.
As mentioned above, while Cldn-18 is the only family member with an established role
in regulating osteoclastogenesis (Linares et al., 2012a), the current study suggests that
other Cldn family members may also have potential roles in regulating these processes. It
would be interesting to determine whether Cldn-18 interacts with other Cldns or tight
junction proteins to regulate bone cell functions. One might find that Cldn-18 or other
Cldns act in concert or independently in regulating osteoclast function. It is noteworthy
that the double KO mouse approach has served as a powerful tool in understanding the
interaction between Cldns in different tissues. Therefore, our future studies will examine
the interaction between Cldn-18 and other candidate Cldns in regulating
osteoclastogensis, by employing this double loss of function approach, both in vivo and in
vitro.
As for osteoblasts, multiple Cldns have been shown to be expressed in rat
osteoblasts (Prele et al., 2003; Wongdee et al., 2008), however the consequence of
changes in Cldn expression on cellular differentiation has not yet been documented. Our
study has revealed that, similar to osteoclasts, their expression pattern is osteoblast
differentiation stage dependent in which many Cldns exhibited an increase in their
expression levels, either during early or late stages of differentiation; and some were
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found to be downregulated, whereas others did no change. The observed differentiation
stage dependent patterns of expression, such as early upregulation of Cldn-1, -2, -5, -7 to
-11, and -19 suggests that these Cldns modulate early stages of osteoblast differentiation.
Conversely, upregulation of Cldn-3, -4, -6, -13, -14, -17, -22, and -23 during terminal
(mineralization) stages, in which osteoblasts are converted into osteocytes or inactive
bone lining cells, appears to indicate a function during late stages of osteoblast
differentiation. Consistent with this finding, it has been shown that the expression of
Cldn-1 and -2 was higher in osteoblast like MC3T3-E1 cells compared to osteocyte-like
MLO-Y4 cells (Hatakeyama et al., 2008). In contrast, an earlier study showed that Cldn-1
and Cldn-2 mRNA levels are upregulated during the mineralization stage compared to the
proliferation stage (Prele et al., 2003). In-line with differentiation stage dependent
patterns of Cldns expression, it has been shown that other cells of mesenchymal origin
differentially express Cldns (Hong et al., 2005; L. Wang et al., 2012). For example, Cldn6 was found to be upregulated and to play an important role during adipocyte
differentiation (Hong et al., 2005). Collectively, the observed changes in the expression
profile of Cldns are consistent with the notion that they potentially play important roles
during osteoblastogenesis. However, the issue of why multiple Cldns are expressed and
whether they have redundant, overlapping, or distinct functions remains to be
investigated. In epithelial tissue, it was found that a combination of Cldns determines the
characteristics and functionality of the resulting tight junction (Elkouby-Naor & BenYosef, 2010). In fact, some Cldns need another Cldn (e.g., Cldn-16 and -19) to
translocate into tight junction and become functional, which in turn highlights a
cooperative interaction between them (Gunzel & Yu, 2013; Hou et al., 2009; Hou et al.,

125

2008). On the other hand, a lack of interaction between Cldns was observed in other cell
systems, for example; the phenotype of double Cldn-11/-14 KO was a combination of
those observed in each of the single deletion animals which suggests redundant functions
(Elkouby-Naor et al., 2008). To this end, our findings that mRNA levels of all “classic”
Cldns were increased during osteoblast differentiation suggest that the closely related
Cldns exert similar/redundant functions in regulating bone formation, and may even be
regulated in a similar manner. By contrast, the diverse expression patterns observed in the
“non-classic” Cldns supports the notion that they have district functions during osteoblast
differentiation, and may, therefore, be regulated differently. Taken together, the observed
complexity in the expression patterns of Cldns in osteoblasts suggests potential common
and member-specific functions among various Cldns. This notion remains to be
investigated by manipulating the expression of Cldn family members individually or in
combination, in vivo and in vitro.
Based on the functions of Cldns known to date, it appears that Cldns do not
follow a simple functional paradigm in various tissues including bone. Cldns act
canonically as a major determinant of paracellular permeability in epithelial and
endothelial cells; and serve as a fence that divides apical and basolateral domains of
plasma membranes. For example, it has been found that Cldn-18 (stomach isoform) acts
canonically as paracellular barriers against cations, such as sodium and hydrogen in the
stomach (Hayashi, Tamura, Tanaka, Yamazaki, Watanabe, Suzuki, Suzuki, et al., 2012;
Jovov et al., 2007). In addition, Cldn-18 was found to be downregulated in gastric cancer,
in which it was assumed that the loss of cell polarity contributes to tumorigenesis (Sanada
et al., 2006b). On the other hand, our previous study demonstrated that Cldn-18
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disruption/overexpression did not influence paracellular transport of calcium ions in
osteoclasts, thereby supporting the concept that Cldn-18 function is cell type specific
(Linares et al., 2012a). Thus, some but not other Cldns may exert their canonical
functions in bone cells. In this connection, there is evidence that osteoblast and bone
lining cells form an epithelial like bone membrane to control the paracellular ion
exchange and maintain differential ion compositions between the plasma and bone
extracellular fluid (Bushinsky et al., 1989; Hatakeyama et al., 2008; Marenzana et al.,
2005; Rubinacci et al., 2000; Wongdee et al., 2008; Wongdee et al., 2010). The
expression and localization of certain Cldns in the bone lining cells suggests that they
function as barriers, a notion that was confirmed by measuring the transepithelial
resistance of an osteoblast monolayer (Wongdee et al., 2008). Although a canonical
Cldns function in controlling paracellular transport of ions across the bone lining cells
has been suggested in the literature, compelling evidence for this function is still thus far
lacking. This field is still in its infancy with many intriguing questions remaining
unanswered: 1) What is/are the identity of ion restrictive/permeable Cldns in bone
barriers? 2) Do they resemble the same functions documented in epithelial tissues? 3)
Given the large number of Cldn proteins, how do these multiplicities influence their
barrier function? and 4) What is the interaction between these Cldns in regulating
paracelluar permeability?
Beyond functioning as a tight junction, it is now clear that Cldns exert noncanonical functions by regulating cell signaling; which is becoming an emerging area of
research. The non-canonical Cldn functions have been shown to involve interaction with
adaptor proteins that shuttle between the plasma membrane and the nucleus, thereby
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regulating gene expression, cell proliferation, and differentiation (Balda & Matter, 2009).
As mentioned earlier, Cldns have the capacity to interact with other PDZ domain
containing cytoplasmic scaffolding proteins such ZO-1/2/3, via their carboxy- terminus
PDZ-binding motif (Angelow et al., 2008; Krause et al., 2008). For example, the noncanonical effect of the loss of Cldn-18 in the regulation of RANKL-induced osteoclast
differentiation is mediated by disruption of the interaction with ZO2, resulting in
increased nuclear translocation of ZO2 (Linares et al., 2012a). In turn, this translocation
increases the expression of important transcription factors involved in RANKL-induced
osteoclast differentiation, which ultimately leads to increased bone resorption. In line
with the novel and emerging functions of Cldn-18, a number of studies have shown that
Cldn-18 is upregulated in various types of cancers, which suggests that its role in the
regulation of cancer cell behavior extends beyond just forming tight junctions (Halimi et
al., 2013; Sahin et al., 2008). Moreover, it has been recently demonstrated that
suppression of Cldn-18 promotes the proliferation of gastric cancer cells (Oshima et al.,
2013). Since little is known about the biological role of Cldn-18 in any tissues, our novel
finding that Cldn-18 has a direct non-canonical role in regulating osteoclast
differentiation is not only relevant for improving our understanding of bone biology, but
may provide fundamental and perhaps mechanistic information that may be applicable to
other tissues. In terms of the non-canonical functions of other Cldn family members, it is
noteworthy that some Cldns do not have a PDZ binding motif (e.g., Cldn-12, 19a, -12,
and -24 to-27) suggesting that not all Cldns may exert non-canonical functions or their
functions are mediated by another novel/unknown mechanism(s) (Gunzel & Yu, 2013).
While several signaling systems have been linked to Cldns non-canonical functions, we
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have just started to understand their underlying molecular mechanisms (Matter & Balda,
2003). Thus, it is crucial to understand the emerging role of Cldn family members in
bone cell signaling and biology, a knowledge that can perhaps be extrapolated to other
cell systems.
In order to better understand the function of Cldns in bone, our efforts focused on
Cldn-1. This selection was based on its interesting differential expression pattern, (i.e.,
upregulation of Cldn-1 during early stages of osteoblast differentiation, whereas
downregulation during late stages); and its established importance in tissue development
(Furuse et al., 2002). In this study we found that Cldn-1 is a positive regulator of
osteoblast differentiation and proliferation. In fact, knocking down Cldn-1 reduced
osteoblast proliferation and differentiation, and decreased the expression of osteogenic
marker genes. In agreement with our findings, there is substantial evidence that Cldn-1
participates in intracellular signaling that controls cell proliferation and differentiation in
different tissues; which is known as a “non-canonical function” (H. Fujita et al., 2011;
Hoshino et al., 2008; Pope et al., 2013). However, it appears that its “non-canonical”
function is cell type-dependent. For example, it has been demonstrated that Cldn-1 is a
promoter, inhibitor, or has no effect on cell proliferation and differentiation in other cell
types (Dhawan et al., 2005; H. Fujita et al., 2011; Hoshino et al., 2008; Pope et al., 2013).
Since Cldn-1 is also expressed in osteoclasts, there is a possibility that it may regulate
osteoclastogenesis and/or be involved in a coupling mechanism between osteoblasts and
osteoclasts during bone remodeling. Consequently, our future studies will evaluate the
skeletal phenotype of Cldn-1 deficient mice by its conditional disruption in bone cells.
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In terms of potential mechanism(s) for Cldn-1 actions, we evaluated the effect of
Cldn-1of knockdown on β-catenin, which is a major pathway known to be critical for
osteoblastogenesis (Bodine & Komm, 2006; Yavropoulou & Yovos, 2007). We found
that knockdown Cldn-1 in osteoblasts leads to a reduction in β-catenin protein levels. In
support of our findings, it has been reported that inhibition and overexpression of Cldn-1
in a colon cancer cell line leads to reduction and activation of β-catenin signaling,
respectively (Dhawan et al., 2005; Singh et al., 2011). However, the detailed mechanism
by which Cldn-1 modulates β-catenin signaling remains to be determined, and will be the
focus of future experiments. Nonetheless, one of the potential mechanisms may be
through phosphorylation/inactivation of GSK3, which normally results in β-catenin
degradation. Another possible mechanism is by direct binding, which will make β-catenin
less accessible to the destruction complex (Dhawan et al., 2005). On the other hand,
Cldn-1 itself has been found to be a target for β-catenin signaling in colon cancer (Miwa
et al., 2001). Therefore, we cannot exclude the possibility that β-catenin signaling is also
upstream of Cldn-1 and/or there exists some kind of cross talk or feedback loop between
them in regulating osteoblastogenesis. While our data suggests that Cldn-1 may regulate
β-catenin signaling, we cannot exclude the involvement of other pathways such as TGFβ, BMP, and Notch signaling. Thus, the delineation of the molecular pathway(s) by
which Cldn-1 acts should advance our understanding of the regulation of osteoblast
differentiation.
Taken together, our studies on Cldn-18 and Cldn-1 clearly document a critical
non-canonical function of Cldns in regulating bone homeostasis, which may also be
applicable in other cell systems or tissues. Given that Cldns are classically thought to
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simply function as structural elements of tight junctions, our findings clearly demonstrate
that they play a much wider role in biology. Moreover, our work opens a broad range of
avenues for research focused on understanding Cldns’ emerging role in bone cell
signaling and biology. Accordingly, Cldns are one example of proteins that have multiple
roles beyond their canonical function as tight junction molecules, which thereby argues
against the concept of protein “stereotyping”. Collectively, we hope to provide a
framework for guiding future research on understanding how Cldns modulate osteoblast
and osteoclast function and overall bone homeostasis. Such studies should provide
valuable insights into the pathogenesis of osteoporosis, and may define Cldns and/or
identify Cldn-based agents for treating such disease states.

Summary and Conclusions
1) In the study described in chapter 2, we demonstrated that Cldn-18 deficiency
negatively affects gastric acidity. In addition, we provide evidence that serum
calcium levels were lower in Cldn-18 KO mice compared to heterozygous control
mice fed a normal calcium diet suggesting that these mice may be calcium
deficient. Moreover, we found that a high calcium diet increased lumbar BMD
and decreased bone resorption in both Cldn-18 KO and heterozygous control
mice, whereas correcting the deficiency in serum calcium in Cldn-18 KO by
feeding a high calcium diet did not correct the osteopenia phenotype and the
increase in bone resorption. In conclusion, the failure to rescue the osteopenia
phenotype by high calcium diet in Cldn-18 KO mice suggests that increased bone
resorption is likely to be due to direct effects of lack of Cldn-18 on osteoclasts and
not due to gastric pH changes caused by its loss in the stomach.
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2) In the study described in chapter 3, we provide the first comprehensive
investigation of the expression of Cldn family members during bone cell
differentiation, in mice. We report for the first time that primary mouse
osteoclasts differentially express several Cldns in a differentiation-stage
dependent manner. Furthermore, Cldns were found to be differentially expressed
and highly regulated during primary osteoblast differentiation. In addition, we
provide compelling evidence that Cldn-1 is a novel positive regulator of osteoblast
differentiation and proliferation, and that its regulation is complex and mediated
by several osteoregulatory factors such as IGF-1 and Wnt3a. In addition, knocking
down Cldn-1 reduced β-catenin level, suggesting that it may be involved in Cldn1 regulation of osteoblastogenesis. Therefore, our data suggest that Cldns have a
potential role in regulating bone homeostasis.

Future Directions
1) In our study on Cldn-18, the failure to rescue the osteopenia phenotype by high
calcium diet in Cldn-18 KO mice suggests that increased bone resorption is likely
to be due to direct effects of lack of Cldn-18 on osteoclasts and not due to gastric
pH changes caused by lack of Cldn-18 in the stomach. However, more direct
evidence using mice with conditional KO of Cldn-18 in osteoclasts are warranted
to convincingly demonstrate a local non-canonical function of Cldn-18.
2) While our previous and current findings are consistent with the important role of
Cldn-18 in regulating bone resorption, the issue whether Cldn-18 also affects
bone formation needs to be evaluated. In this regard, bone formation was found
not to be affected by Cldn-18 deficiency under resting/normal conditions (Linares
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et al., 2012a), but this does not exclude a potential role for Cldn-18 in regulating
bone formation. In fact, Cldn-18 was found to be expressed in osteoblasts,
suggesting that it may regulate bone formation under conditions when bone
formation rates are severely compromised (Wongdee et al., 2008). Thus, future
studies will elucidate the direct role of Cldn-18 in the skeleton, using mice with a
conditional disruption of Cldn-18 under pathological conditions.
3) Besides Cldn-18, the finding that several Cldns are expressed in osteoclasts in a
differentiation stage dependent manner suggests potential roles of other Cldn
family members in regulating osteoclastogenesis. Thus, the issue of whether
Cldn-18 interacts with other Cldns to regulate bone resorption remains to be
elucidated. Our future studies will examine the interaction between Cldn-18 and
other candidate Cldns in regulating osteoclastogensis, by employing double loss
of function approach in vivo and in vitro. Of note, the skeletal phenotype of Cldn18/-11 double KO mice is currently under investigation.
4) The observed complexity in the expression patterns of Cldns during osteoblast
differentiation is consistent with both common and Cldn-specific functions among
various Cldns. Our strategy to decode the role of candidate Cldns in skeletal
development and maintenance is by employing both gain and loss of function
experiments in vivo and in vitro.
5) In our studies on Cldn-1, we found that it is a positive regulator of osteoblast
proliferation and differentiation. Additionally, knocking down Cldn-1 reduced βcatenin level, suggesting that it may be involved in Cldn-1 regulation of
osteoblastogenesis. While our in vitro studies suggest a non-canonical function
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for Cldn-1 in regulating osteoblastogenesis, the detailed mechanism by which
Cldn-1 modulates bone cell functions remains to be determined. Therefore, our
future studies will determine the direct non-canonical function and delineate
signaling pathways of Cldn-1, by employing transgenic overexpression or
knockdown of gene expression, in vitro and in vivo.
6) Finally, an important issue that needs to be addressed is the involvement of Cldns
in the pathogenesis of bone related diseases, such as osteoporosis. As mentioned
earlier, a sequence variant of human Cldn-14 was found to be associated with a
lower bone mineral density in the spine and hip of affected individuals. However,
wheteher sequence polymorphisms in other Cldns contribute to variation in the
skeletal phenotype remains to be evaluated.
In conclusion, the results of this dissertation start to unravel novel roles of Cldns in
bone biology, and open a broad range of avenues for research focused on understanding
such emerging role(s) in bone cell signaling. We believe that a better understanding of
the role and molecular mechanisms of Cldn function in bone could lead to the
identification of novel targets for diagnosis and treatment of metabolic bone diseases
including osteoporosis.

134

REFERENCES
Abboud, S. L., Woodruff, K., Liu, C., Shen, V., & Ghosh-Choudhury, N. (2002). Rescue
of the osteopetrotic defect in op/op mice by osteoblast-specific targeting of
soluble colony-stimulating factor-1. Endocrinology, 143(5), 1942-1949. doi:
10.1210/endo.143.5.8775
Abrahamsen, B., van Staa, T., Ariely, R., Olson, M., & Cooper, C. (2009). Excess
mortality following hip fracture: a systematic epidemiological review. Osteoporos
Int, 20(10), 1633-1650. doi: 10.1007/s00198-009-0920-3
Abuazza, G., Becker, A., Williams, S. S., Chakravarty, S., Truong, H. T., Lin, F., &
Baum, M. (2006). Claudins 6, 9, and 13 are developmentally expressed renal tight
junction proteins. Am J Physiol Renal Physiol, 291(6), F1132-1141. doi:
10.1152/ajprenal.00063.2006
Agarwal, R., D'Souza, T., & Morin, P. J. (2005). Claudin-3 and claudin-4 expression in
ovarian epithelial cells enhances invasion and is associated with increased matrix
metalloproteinase-2 activity. Cancer Res, 65(16), 7378-7385. doi: 10.1158/00085472.CAN-05-1036
Agarwal, R., Mori, Y., Cheng, Y., Jin, Z., Olaru, A. V., Hamilton, J. P., . . . Meltzer, S. J.
(2009). Silencing of claudin-11 is associated with increased invasiveness of
gastric cancer cells. PLoS One, 4(11), e8002. doi: 10.1371/journal.pone.0008002
Alexandre, M. D., Jeansonne, B. G., Renegar, R. H., Tatum, R., & Chen, Y. H. (2007).
The first extracellular domain of claudin-7 affects paracellular Cl- permeability.
Biochem Biophys Res Commun, 357(1), 87-91. doi: 10.1016/j.bbrc.2007.03.078
Alexandre, M. D., Lu, Q., & Chen, Y. H. (2005). Overexpression of claudin-7 decreases
the paracellular Cl- conductance and increases the paracellular Na+ conductance
in LLC-PK1 cells. J Cell Sci, 118(Pt 12), 2683-2693. doi: 10.1242/jcs.02406
Aliprantis, A. O., Ueki, Y., Sulyanto, R., Park, A., Sigrist, K. S., Sharma, S. M., . . .
Glimcher, L. H. (2008). NFATc1 in mice represses osteoprotegerin during
osteoclastogenesis and dissociates systemic osteopenia from inflammation in
cherubism. J Clin Invest, 118(11), 3775-3789. doi: 10.1172/JCI35711
Alshbool, F. Z., & Mohan, S. (2014). Emerging multifunctional roles of Claudin tight
junction proteins in bone. Endocrinology, en20141173. doi: 10.1210/en.20141173
Amasheh, S., Meiri, N., Gitter, A. H., Schoneberg, T., Mankertz, J., Schulzke, J. D., &
Fromm, M. (2002). Claudin-2 expression induces cation-selective channels in
tight junctions of epithelial cells. J Cell Sci, 115(Pt 24), 4969-4976.
Angelow, S., Ahlstrom, R., & Yu, A. S. (2008). Biology of claudins. Am J Physiol Renal
Physiol, 295(4), F867-876. doi: 10.1152/ajprenal.90264.2008
135

Angelow, S., El-Husseini, R., Kanzawa, S. A., & Yu, A. S. (2007). Renal localization and
function of the tight junction protein, claudin-19. Am J Physiol Renal Physiol,
293(1), F166-177. doi: 10.1152/ajprenal.00087.2007
Angelow, S., Schneeberger, E. E., & Yu, A. S. (2007). Claudin-8 expression in renal
epithelial cells augments the paracellular barrier by replacing endogenous
claudin-2. J Membr Biol, 215(2-3), 147-159. doi: 10.1007/s00232-007-9014-3
Anh, D. J., Dimai, H. P., Hall, S. L., & Farley, J. R. (1998). Skeletal alkaline phosphatase
activity is primarily released from human osteoblasts in an insoluble form, and the
net release is inhibited by calcium and skeletal growth factors. Calcif Tissue Int,
62(4), 332-340.
Arabzadeh, A., Troy, T. C., & Turksen, K. (2006). Role of the Cldn6 cytoplasmic tail
domain in membrane targeting and epidermal differentiation in vivo. Mol Cell
Biol, 26(15), 5876-5887. doi: 10.1128/MCB.02342-05
Arana-Chavez, V. E., Soares, A. M., & Katchburian, E. (1995). Junctions between early
developing osteoblasts of rat calvaria as revealed by freeze-fracture and ultrathin
section electron microscopy. Arch Histol Cytol, 58(3), 285-292.
Arden, N. K., Baker, J., Hogg, C., Baan, K., & Spector, T. D. (1996). The heritability of
bone mineral density, ultrasound of the calcaneus and hip axis length: a study of
postmenopausal twins. J Bone Miner Res, 11(4), 530-534. doi:
10.1002/jbmr.5650110414
Asagiri, M., & Takayanagi, H. (2007). The molecular understanding of osteoclast
differentiation. Bone, 40(2), 251-264. doi: 10.1016/j.bone.2006.09.023
Aslan, D., Andersen, M. D., Gede, L. B., de Franca, T. K., Jorgensen, S. R., Schwarz, P.,
& Jorgensen, N. R. (2012). Mechanisms for the bone anabolic effect of
parathyroid hormone treatment in humans. Scand J Clin Lab Invest, 72(1), 14-22.
doi: 10.3109/00365513.2011.624631
Azuma, Y., Kaji, K., Katogi, R., Takeshita, S., & Kudo, A. (2000). Tumor necrosis
factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol
Chem, 275(7), 4858-4864.
Baker, M., Reynolds, L. E., Robinson, S. D., Lees, D. M., Parsons, M., Elia, G., &
Hodivala-Dilke, K. (2013). Stromal Claudin14-heterozygosity, but not deletion,
increases tumour blood leakage without affecting tumour growth. PLoS One, 8(5),
e62516. doi: 10.1371/journal.pone.0062516
Balda, M. S., Garrett, M. D., & Matter, K. (2003). The ZO-1-associated Y-box factor
ZONAB regulates epithelial cell proliferation and cell density. J Cell Biol, 160(3),
423-432. doi: 10.1083/jcb.200210020

136

Balda, M. S., & Matter, K. (2000). The tight junction protein ZO-1 and an interacting
transcription factor regulate ErbB-2 expression. EMBO J, 19(9), 2024-2033. doi:
10.1093/emboj/19.9.2024
Balda, M. S., & Matter, K. (2009). Tight junctions and the regulation of gene expression.
Biochim Biophys Acta, 1788(4), 761-767. doi: 10.1016/j.bbamem.2008.11.024
Banan, A., Zhang, L. J., Shaikh, M., Fields, J. Z., Choudhary, S., Forsyth, C. B., . . .
Keshavarzian, A. (2005). theta Isoform of protein kinase C alters barrier function
in intestinal epithelium through modulation of distinct claudin isotypes: a novel
mechanism for regulation of permeability. J Pharmacol Exp Ther, 313(3), 962982. doi: 10.1124/jpet.104.083428
Banan, A., Zhang, L. J., Shaikh, M., Fields, J. Z., Farhadi, A., & Keshavarzian, A.
(2004). Theta-isoform of PKC is required for alterations in cytoskeletal dynamics
and barrier permeability in intestinal epithelium: a novel function for PKC-theta.
Am J Physiol Cell Physiol, 287(1), C218-234. doi: 10.1152/ajpcell.00575.2003
Bellido, T., Ali, A. A., Plotkin, L. I., Fu, Q., Gubrij, I., Roberson, P. K., . . . Jilka, R. L.
(2003). Proteasomal degradation of Runx2 shortens parathyroid hormone-induced
anti-apoptotic signaling in osteoblasts. A putative explanation for why
intermittent administration is needed for bone anabolism. J Biol Chem, 278(50),
50259-50272. doi: 10.1074/jbc.M307444200
Ben-Yosef, T., Belyantseva, I. A., Saunders, T. L., Hughes, E. D., Kawamoto, K., Van
Itallie, C. M., . . . Friedman, T. B. (2003). Claudin 14 knockout mice, a model for
autosomal recessive deafness DFNB29, are deaf due to cochlear hair cell
degeneration. Hum Mol Genet, 12(16), 2049-2061.
Bergmann, P., Body, J. J., Boonen, S., Boutsen, Y., Devogelaer, J. P., Goemaere, S., . . .
Rozenberg, S. (2010). Loading and skeletal development and maintenance. J
Osteoporos, 2011, 786752. doi: 10.4061/2011/786752
Betanzos, A., Huerta, M., Lopez-Bayghen, E., Azuara, E., Amerena, J., & GonzalezMariscal, L. (2004). The tight junction protein ZO-2 associates with Jun, Fos and
C/EBP transcription factors in epithelial cells. Exp Cell Res, 292(1), 51-66.
Bo-Linn, G. W., Davis, G. R., Buddrus, D. J., Morawski, S. G., Santa Ana, C., &
Fordtran, J. S. (1984). An evaluation of the importance of gastric acid secretion in
the absorption of dietary calcium. J Clin Invest, 73(3), 640-647. doi:
10.1172/JCI111254
Bodine, P. V., & Komm, B. S. (2006). Wnt signaling and osteoblastogenesis. Rev Endocr
Metab Disord, 7(1-2), 33-39. doi: 10.1007/s11154-006-9002-4
Bonewald, L. F. (2011). The amazing osteocyte. J Bone Miner Res, 26(2), 229-238. doi:
10.1002/jbmr.320

137

Boyce, B. F. (2009). Stomaching calcium for bone health. Nat Med, 15(6), 610-612. doi:
10.1038/nm0609-610
Boyce, B. F. (2013). Advances in osteoclast biology reveal potential new drug targets and
new roles for osteoclasts. J Bone Miner Res, 28(4), 711-722. doi:
10.1002/jbmr.1885
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003). Osteoclast differentiation and
activation. Nature, 423(6937), 337-342. doi: 10.1038/nature01658
Brandner, J. M., Kief, S., Grund, C., Rendl, M., Houdek, P., Kuhn, C., . . . Moll, I.
(2002). Organization and formation of the tight junction system in human
epidermis and cultured keratinocytes. Eur J Cell Biol, 81(5), 253-263. doi:
10.1078/0171-9335-00244
Brixen, K. T., Christensen, P. M., Ejersted, C., & Langdahl, B. L. (2004). Teriparatide
(biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment
of osteoporosis. Basic Clin Pharmacol Toxicol, 94(6), 260-270. doi:
10.1111/j.1742-7843.2004.pto940602.x
Bruzzaniti, A., & Baron, R. (2006). Molecular regulation of osteoclast activity. Rev
Endocr Metab Disord, 7(1-2), 123-139. doi: 10.1007/s11154-006-9009-x
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., . . . Simonet,
W. S. (1998). osteoprotegerin-deficient mice develop early onset osteoporosis and
arterial calcification. Genes Dev, 12(9), 1260-1268.
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A.
(2007). Incidence and economic burden of osteoporosis-related fractures in the
United States, 2005-2025. J Bone Miner Res, 22(3), 465-475. doi:
10.1359/jbmr.061113
Bushinsky, D. A., Chabala, J. M., & Levi-Setti, R. (1989). Ion microprobe analysis of
mouse calvariae in vitro: evidence for a "bone membrane". Am J Physiol, 256(1 Pt
1), E152-158.
Chau, J. F., Leong, W. F., & Li, B. (2009). Signaling pathways governing osteoblast
proliferation, differentiation and function. Histol Histopathol, 24(12), 1593-1606.
Che, P., Tang, H., & Li, Q. (2013). The interaction between claudin-1 and dengue viral
prM/M protein for its entry. Virology, 446(1-2), 303-313. doi:
10.1016/j.virol.2013.08.009
Chen, G., Deng, C., & Li, Y. P. (2012). TGF-beta and BMP signaling in osteoblast
differentiation and bone formation. Int J Biol Sci, 8(2), 272-288. doi:
10.7150/ijbs.2929

138

Cheng, S. L., Shin, C. S., Towler, D. A., & Civitelli, R. (2000). A dominant negative
cadherin inhibits osteoblast differentiation. J Bone Miner Res, 15(12), 2362-2370.
doi: 10.1359/jbmr.2000.15.12.2362
Chiba, H., Osanai, M., Murata, M., Kojima, T., & Sawada, N. (2008). Transmembrane
proteins of tight junctions. Biochim Biophys Acta, 1778(3), 588-600. doi:
10.1016/j.bbamem.2007.08.017
Chin, K. Y., & Ima-Nirwana, S. (2012). Sex steroids and bone health status in men. Int J
Endocrinol, 2012, 208719. doi: 10.1155/2012/208719
Chow, J., Tobias, J. H., Colston, K. W., & Chambers, T. J. (1992). Estrogen maintains
trabecular bone volume in rats not only by suppression of bone resorption but also
by stimulation of bone formation. J Clin Invest, 89(1), 74-78. doi:
10.1172/JCI115588
Chung, J. J., Shikano, S., Hanyu, Y., & Li, M. (2002). Functional diversity of protein Ctermini: more than zipcoding? Trends Cell Biol, 12(3), 146-150.
Clarke, B. (2008). Normal bone anatomy and physiology. Clin J Am Soc Nephrol, 3
Suppl 3, S131-139. doi: 10.2215/CJN.04151206
Colegio, O. R., Van Itallie, C. M., McCrea, H. J., Rahner, C., & Anderson, J. M. (2002).
Claudins create charge-selective channels in the paracellular pathway between
epithelial cells. Am J Physiol Cell Physiol, 283(1), C142-147. doi:
10.1152/ajpcell.00038.2002
Colon-Emeric, C. S., & Saag, K. G. (2006). Osteoporotic fractures in older adults. Best
Pract Res Clin Rheumatol, 20(4), 695-706. doi: 10.1016/j.berh.2006.04.004
Crotti, T. N., Flannery, M., Walsh, N. C., Fleming, J. D., Goldring, S. R., & McHugh, K.
P. (2006). NFATc1 regulation of the human beta3 integrin promoter in osteoclast
differentiation. Gene, 372, 92-102. doi: 10.1016/j.gene.2005.12.012
D'Souza, T., Agarwal, R., & Morin, P. J. (2005). Phosphorylation of claudin-3 at
threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier
function in ovarian cancer cells. J Biol Chem, 280(28), 26233-26240. doi:
10.1074/jbc.M502003200
DeKoter, R. P., Walsh, J. C., & Singh, H. (1998). PU.1 regulates both cytokinedependent proliferation and differentiation of granulocyte/macrophage
progenitors. EMBO J, 17(15), 4456-4468. doi: 10.1093/emboj/17.15.4456
Dempster, D. W. (2011). Osteoporosis and the burden of osteoporosis-related fractures.
Am J Manag Care, 17 Suppl 6, S164-169.
Dhawan, P., Ahmad, R., Chaturvedi, R., Smith, J. J., Midha, R., Mittal, M. K., . . . Singh,
A. B. (2011). Claudin-2 expression increases tumorigenicity of colon cancer cells:

139

role of epidermal growth factor receptor activation. Oncogene, 30(29), 32343247. doi: 10.1038/onc.2011.43
Dhawan, P., Singh, A. B., Deane, N. G., No, Y., Shiou, S. R., Schmidt, C., . . .
Beauchamp, R. D. (2005). Claudin-1 regulates cellular transformation and
metastatic behavior in colon cancer. J Clin Invest, 115(7), 1765-1776. doi:
10.1172/JCI24543
Drissi, H., Pouliot, A., Koolloos, C., Stein, J. L., Lian, J. B., Stein, G. S., & van Wijnen,
A. J. (2002). 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1
gene promoter. Exp Cell Res, 274(2), 323-333. doi: 10.1006/excr.2002.5474
Elkouby-Naor, L., Abassi, Z., Lagziel, A., Gow, A., & Ben-Yosef, T. (2008). Double
gene deletion reveals lack of cooperation between claudin 11 and claudin 14 tight
junction proteins. Cell Tissue Res, 333(3), 427-438. doi: 10.1007/s00441-0080621-9
Elkouby-Naor, L., & Ben-Yosef, T. (2010). Functions of claudin tight junction proteins
and their complex interactions in various physiological systems. Int Rev Cell Mol
Biol, 279, 1-32. doi: 10.1016/S1937-6448(10)79001-8
Escudero-Esparza, A., Jiang, W. G., & Martin, T. A. (2012a). Claudin-5 is involved in
breast cancer cell motility through the N-WASP and ROCK signalling pathways.
J Exp Clin Cancer Res, 31, 43. doi: 10.1186/1756-9966-31-43
Escudero-Esparza, A., Jiang, W. G., & Martin, T. A. (2012b). Claudin-5 participates in
the regulation of endothelial cell motility. Mol Cell Biochem, 362(1-2), 71-85.
doi: 10.1007/s11010-011-1129-2
Findley, M. K., & Koval, M. (2009). Regulation and roles for claudin-family tight
junction proteins. IUBMB Life, 61(4), 431-437. doi: 10.1002/iub.175
Fishwick, K. J., Neiderer, T. E., Jhingory, S., Bronner, M. E., & Taneyhill, L. A. (2012).
The tight junction protein claudin-1 influences cranial neural crest cell
emigration. Mech Dev, 129(9-12), 275-283. doi: 10.1016/j.mod.2012.06.006
Fontijn, R. D., Rohlena, J., van Marle, J., Pannekoek, H., & Horrevoets, A. J. (2006).
Limited contribution of claudin-5-dependent tight junction strands to endothelial
barrier function. Eur J Cell Biol, 85(11), 1131-1144. doi:
10.1016/j.ejcb.2006.07.005
Fortier, A. M., Asselin, E., & Cadrin, M. (2013). Keratin 8 and 18 loss in epithelial
cancer cells increases collective cell migration and cisplatin sensitivity through
claudin1 up-regulation. J Biol Chem, 288(16), 11555-11571. doi:
10.1074/jbc.M112.428920

140

French, A. D., Fiori, J. L., Camilli, T. C., Leotlela, P. D., O'Connell, M. P., Frank, B. P., .
. . Weeraratna, A. T. (2009). PKC and PKA phosphorylation affect the subcellular
localization of claudin-1 in melanoma cells. Int J Med Sci, 6(2), 93-101.
Fujita, H., Chalubinski, M., Rhyner, C., Indermitte, P., Meyer, N., Ferstl, R., . . . Akdis,
C. A. (2011). Claudin-1 expression in airway smooth muscle exacerbates airway
remodeling in asthmatic subjects. J Allergy Clin Immunol, 127(6), 1612-1621
e1618. doi: 10.1016/j.jaci.2011.03.039
Fujita, H., Chiba, H., Yokozaki, H., Sakai, N., Sugimoto, K., Wada, T., . . . Sawada, N.
(2006). Differential expression and subcellular localization of claudin-7, -8, -12, 13, and -15 along the mouse intestine. J Histochem Cytochem, 54(8), 933-944.
doi: 10.1369/jhc.6A6944.2006
Fujita, H., Sugimoto, K., Inatomi, S., Maeda, T., Osanai, M., Uchiyama, Y., . . . Chiba,
H. (2008). Tight junction proteins claudin-2 and -12 are critical for vitamin Ddependent Ca2+ absorption between enterocytes. Mol Biol Cell, 19(5), 19121921. doi: 10.1091/mbc.E07-09-0973
Fujita, K., Katahira, J., Horiguchi, Y., Sonoda, N., Furuse, M., & Tsukita, S. (2000).
Clostridium perfringens enterotoxin binds to the second extracellular loop of
claudin-3, a tight junction integral membrane protein. FEBS Lett, 476(3), 258261.
Furuse, M., Hata, M., Furuse, K., Yoshida, Y., Haratake, A., Sugitani, Y., . . . Tsukita, S.
(2002). Claudin-based tight junctions are crucial for the mammalian epidermal
barrier: a lesson from claudin-1-deficient mice. J Cell Biol, 156(6), 1099-1111.
doi: 10.1083/jcb.200110122
Garnero, P., Arden, N. K., Griffiths, G., Delmas, P. D., & Spector, T. D. (1996). Genetic
influence on bone turnover in postmenopausal twins. J Clin Endocrinol Metab,
81(1), 140-146. doi: 10.1210/jcem.81.1.8550741
Gennari, L., Merlotti, D., De Paola, V., Calabro, A., Becherini, L., Martini, G., & Nuti,
R. (2005). Estrogen receptor gene polymorphisms and the genetics of
osteoporosis: a HuGE review. Am J Epidemiol, 161(4), 307-320. doi:
10.1093/aje/kwi055
Gohel, A., McCarthy, M. B., & Gronowicz, G. (1999). Estrogen prevents glucocorticoidinduced apoptosis in osteoblasts in vivo and in vitro. Endocrinology, 140(11),
5339-5347. doi: 10.1210/endo.140.11.7135
Gonzalez-Mariscal, L., Tapia, R., & Chamorro, D. (2008). Crosstalk of tight junction
components with signaling pathways. Biochim Biophys Acta, 1778(3), 729-756.
doi: 10.1016/j.bbamem.2007.08.018
Gow, A., Davies, C., Southwood, C. M., Frolenkov, G., Chrustowski, M., Ng, L., . . .
Kachar, B. (2004). Deafness in Claudin 11-null mice reveals the critical
141

contribution of basal cell tight junctions to stria vascularis function. J Neurosci,
24(32), 7051-7062. doi: 10.1523/JNEUROSCI.1640-04.2004
Gow, A., Southwood, C. M., Li, J. S., Pariali, M., Riordan, G. P., Brodie, S. E., . . .
Lazzarini, R. A. (1999). CNS myelin and sertoli cell tight junction strands are
absent in Osp/claudin-11 null mice. Cell, 99(6), 649-659.
Greenfield, E. M. (2012). Anabolic effects of intermittent PTH on osteoblasts. Curr Mol
Pharmacol, 5(2), 127-134.
Guillemot, L., Paschoud, S., Pulimeno, P., Foglia, A., & Citi, S. (2008). The cytoplasmic
plaque of tight junctions: a scaffolding and signalling center. Biochim Biophys
Acta, 1778(3), 601-613. doi: 10.1016/j.bbamem.2007.09.032
Gunzel, D., & Fromm, M. (2012). Claudins and other tight junction proteins. Compr
Physiol, 2(3), 1819-1852. doi: 10.1002/cphy.c110045
Gunzel, D., & Yu, A. S. (2013). Claudins and the modulation of tight junction
permeability. Physiol Rev, 93(2), 525-569. doi: 10.1152/physrev.00019.2012
Guo, Y., Xu, X., Liu, Z., Zhang, T., Zhang, X., Wang, L., . . . Quan, C. (2012). Apoptosis
signal-regulating kinase 1 is associated with the effect of claudin-6 in breast
cancer. Diagn Pathol, 7, 111. doi: 10.1186/1746-1596-7-111
Gupta, I. R., & Ryan, A. K. (2010). Claudins: unlocking the code to tight junction
function during embryogenesis and in disease. Clin Genet, 77(4), 314-325. doi:
10.1111/j.1399-0004.2010.01397.x
Hadj-Rabia, S., Baala, L., Vabres, P., Hamel-Teillac, D., Jacquemin, E., Fabre, M., . . .
Smahi, A. (2004). Claudin-1 gene mutations in neonatal sclerosing cholangitis
associated with ichthyosis: a tight junction disease. Gastroenterology, 127(5),
1386-1390.
Hadjidakis, D. J., & Androulakis, II. (2006). Bone remodeling. Ann N Y Acad Sci, 1092,
385-396. doi: 10.1196/annals.1365.035
Halimi, S. A., Maeda, D., Shinozaki-Ushiku, A., Koso, T., Matsusaka, K., Tanaka, M., . .
. Fukayama, M. (2013). Claudin-18 overexpression in intestinal-type mucinous
borderline tumour of the ovary. Histopathology, 63(4), 534-544. doi:
10.1111/his.12182
Harada, S., Matsumoto, T., & Ogata, E. (1991). Role of ascorbic acid in the regulation of
proliferation in osteoblast-like MC3T3-E1 cells. J Bone Miner Res, 6(9), 903-908.
doi: 10.1002/jbmr.5650060902
Harris, M., Nguyen, T. V., Howard, G. M., Kelly, P. J., & Eisman, J. A. (1998). Genetic
and environmental correlations between bone formation and bone mineral
density: a twin study. Bone, 22(2), 141-145.

142

Hatakeyama, N., Kojima, T., Iba, K., Murata, M., Thi, M. M., Spray, D. C., . . . Sawada,
N. (2008). IGF-I regulates tight-junction protein claudin-1 during differentiation
of osteoblast-like MC3T3-E1 cells via a MAP-kinase pathway. Cell Tissue Res,
334(2), 243-254. doi: 10.1007/s00441-008-0690-9
Hayashi, D., Tamura, A., Tanaka, H., Yamazaki, Y., Watanabe, S., Suzuki, K., . . .
Tsukita, S. (2012). Deficiency of claudin-18 causes paracellular H+ leakage, upregulation of interleukin-1beta, and atrophic gastritis in mice. Gastroenterology,
142(2), 292-304. doi: 10.1053/j.gastro.2011.10.040
Hayashi, D., Tamura, A., Tanaka, H., Yamazaki, Y., Watanabe, S., Suzuki, K., . . .
Tsukita, S. (2012). Deficiency of claudin-18 causes paracellular H+ leakage, upregulation of interleukin-1beta, and atrophic gastritis in mice. Gastroenterology,
142(2), 292-304. doi: 10.1053/j.gastro.2011.10.040
Hoggard, J., Fan, J., Lu, Z., Lu, Q., Sutton, L., & Chen, Y. H. (2013). Claudin-7 increases
chemosensitivity to cisplatin through the upregulation of caspase pathway in
human NCI-H522 lung cancer cells. Cancer Sci, 104(5), 611-618. doi:
10.1111/cas.12135
Holmes, J. L., Van Itallie, C. M., Rasmussen, J. E., & Anderson, J. M. (2006). Claudin
profiling in the mouse during postnatal intestinal development and along the
gastrointestinal tract reveals complex expression patterns. Gene Expr Patterns,
6(6), 581-588. doi: 10.1016/j.modgep.2005.12.001
Hong, Y. H., Hishikawa, D., Miyahara, H., Nishimura, Y., Tsuzuki, H., Gotoh, C., . . .
Roh, S. G. (2005). Up-regulation of the claudin-6 gene in adipogenesis. Biosci
Biotechnol Biochem, 69(11), 2117-2121.
Hoshino, M., Hashimoto, S., Muramatsu, T., Matsuki, M., Ogiuchi, H., & Shimono, M.
(2008). Claudin rather than occludin is essential for differentiation in rat incisor
odontoblasts. Oral Dis, 14(7), 606-612. doi: 10.1111/j.1601-0825.2007.01427.x
Hosoi, T. (2007). [Prevention and treatment of osteoporosis]. Nihon Ronen Igakkai
Zasshi, 44(3), 299-301.
Hou, J., Gomes, A. S., Paul, D. L., & Goodenough, D. A. (2006). Study of claudin
function by RNA interference. J Biol Chem, 281(47), 36117-36123. doi:
10.1074/jbc.M608853200
Hou, J., Renigunta, A., Gomes, A. S., Hou, M., Paul, D. L., Waldegger, S., &
Goodenough, D. A. (2009). Claudin-16 and claudin-19 interaction is required for
their assembly into tight junctions and for renal reabsorption of magnesium. Proc
Natl Acad Sci U S A, 106(36), 15350-15355. doi: 10.1073/pnas.0907724106
Hou, J., Renigunta, A., Konrad, M., Gomes, A. S., Schneeberger, E. E., Paul, D. L., . . .
Goodenough, D. A. (2008). Claudin-16 and claudin-19 interact and form a cation-

143

selective tight junction complex. J Clin Invest, 118(2), 619-628. doi:
10.1172/JCI33970
Hou, J., Renigunta, A., Yang, J., & Waldegger, S. (2010). Claudin-4 forms paracellular
chloride channel in the kidney and requires claudin-8 for tight junction
localization. Proc Natl Acad Sci U S A, 107(42), 18010-18015. doi:
10.1073/pnas.1009399107
Hou, J., Shan, Q., Wang, T., Gomes, A. S., Yan, Q., Paul, D. L., . . . Goodenough, D. A.
(2007). Transgenic RNAi depletion of claudin-16 and the renal handling of
magnesium. J Biol Chem, 282(23), 17114-17122. doi: 10.1074/jbc.M700632200
Ikenouchi, J., Matsuda, M., Furuse, M., & Tsukita, S. (2003). Regulation of tight
junctions during the epithelium-mesenchyme transition: direct repression of the
gene expression of claudins/occludin by Snail. J Cell Sci, 116(Pt 10), 1959-1967.
doi: 10.1242/jcs.00389
Inai, T., Kobayashi, J., & Shibata, Y. (1999). Claudin-1 contributes to the epithelial
barrier function in MDCK cells. Eur J Cell Biol, 78(12), 849-855. doi:
10.1016/S0171-9335(99)80086-7
Inman, C. L., Warren, G. L., Hogan, H. A., & Bloomfield, S. A. (1999). Mechanical
loading attenuates bone loss due to immobilization and calcium deficiency. J Appl
Physiol (1985), 87(1), 189-195.
Inoue, M., Tanaka, H., Moriwake, T., Oka, M., Sekiguchi, C., & Seino, Y. (2000).
Altered biochemical markers of bone turnover in humans during 120 days of bed
rest. Bone, 26(3), 281-286.
Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A., & Bravo, R. (1997). Osteopetrosis
in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med, 3(11), 1285-1289.
Ip, Y. C., Cheung, S. T., Lee, Y. T., Ho, J. C., & Fan, S. T. (2007). Inhibition of
hepatocellular carcinoma invasion by suppression of claudin-10 in HLE cells. Mol
Cancer Ther, 6(11), 2858-2867. doi: 10.1158/1535-7163.MCT-07-0453
Ishii, J., Kitazawa, R., Mori, K., McHugh, K. P., Morii, E., Kondo, T., & Kitazawa, S.
(2008). Lipopolysaccharide suppresses RANK gene expression in macrophages
by down-regulating PU.1 and MITF. J Cell Biochem, 105(3), 896-904. doi:
10.1002/jcb.21886
Islas, S., Vega, J., Ponce, L., & Gonzalez-Mariscal, L. (2002). Nuclear localization of the
tight junction protein ZO-2 in epithelial cells. Exp Cell Res, 274(1), 138-148. doi:
10.1006/excr.2001.5457
Janssens, K., ten Dijke, P., Janssens, S., & Van Hul, W. (2005). Transforming growth
factor-beta1 to the bone. Endocr Rev, 26(6), 743-774. doi: 10.1210/er.2004-0001

144

Jensen, E. D., Gopalakrishnan, R., & Westendorf, J. J. (2010). Regulation of gene
expression in osteoblasts. Biofactors, 36(1), 25-32. doi: 10.1002/biof.72
Jimi, E., Nakamura, I., Duong, L. T., Ikebe, T., Takahashi, N., Rodan, G. A., & Suda, T.
(1999). Interleukin 1 induces multinucleation and bone-resorbing activity of
osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res, 247(1), 8493. doi: 10.1006/excr.1998.4320
Jovov, B., Van Itallie, C. M., Shaheen, N. J., Carson, J. L., Gambling, T. M., Anderson, J.
M., & Orlando, R. C. (2007). Claudin-18: a dominant tight junction protein in
Barrett's esophagus and likely contributor to its acid resistance. Am J Physiol
Gastrointest Liver Physiol, 293(6), G1106-1113. doi: 10.1152/ajpgi.00158.2007
Kameda, T., Mano, H., Yuasa, T., Mori, Y., Miyazawa, K., Shiokawa, M., . . .
Kumegawa, M. (1997). Estrogen inhibits bone resorption by directly inducing
apoptosis of the bone-resorbing osteoclasts. J Exp Med, 186(4), 489-495.
Kassem, M., & Marie, P. J. (2011). Senescence-associated intrinsic mechanisms of
osteoblast dysfunctions. Aging Cell, 10(2), 191-197. doi: 10.1111/j.14749726.2011.00669.x
Kausalya, P. J., Amasheh, S., Gunzel, D., Wurps, H., Muller, D., Fromm, M., &
Hunziker, W. (2006). Disease-associated mutations affect intracellular traffic and
paracellular Mg2+ transport function of Claudin-16. J Clin Invest, 116(4), 878891. doi: 10.1172/JCI26323
Kawai, Y., Hamazaki, Y., Fujita, H., Fujita, A., Sato, T., Furuse, M., . . . Minato, N.
(2011). Claudin-4 induction by E-protein activity in later stages of CD4/8 doublepositive thymocytes to increase positive selection efficiency. Proc Natl Acad Sci
U S A, 108(10), 4075-4080. doi: 10.1073/pnas.1014178108
Kesavan, C., & Mohan, S. (2010). Bone mass gained in response to external loading is
preserved for several weeks following cessation of loading in 10 week C57BL/6J
mice. J Musculoskelet Neuronal Interact, 10(4), 274-280.
Kesavan, C., Mohan, S., Oberholtzer, S., Wergedal, J. E., & Baylink, D. J. (2005).
Mechanical loading-induced gene expression and BMD changes are different in
two inbred mouse strains. J Appl Physiol (1985), 99(5), 1951-1957. doi:
10.1152/japplphysiol.00401.2005
Khosla, S. (2013). Pathogenesis of age-related bone loss in humans. J Gerontol A Biol Sci
Med Sci, 68(10), 1226-1235. doi: 10.1093/gerona/gls163
Kim, H. Y., Alarcon, C., Pourteymour, S., Wergedal, J. E., & Mohan, S. (2013).
Disruption of claudin-18 diminishes ovariectomy-induced bone loss in mice. Am J
Physiol Endocrinol Metab, 304(5), E531-537. doi: 10.1152/ajpendo.00408.2012

145

Kitajiri, S. I., Furuse, M., Morita, K., Saishin-Kiuchi, Y., Kido, H., Ito, J., & Tsukita, S.
(2004). Expression patterns of claudins, tight junction adhesion molecules, in the
inner ear. Hear Res, 187(1-2), 25-34.
Kling, J. M., Clarke, B. L., & Sandhu, N. P. (2014). Osteoporosis prevention, screening,
and treatment: a review. J Womens Health (Larchmt), 23(7), 563-572. doi:
10.1089/jwh.2013.4611
Knothe Tate, M. L., Adamson, J. R., Tami, A. E., & Bauer, T. W. (2004). The osteocyte.
Int J Biochem Cell Biol, 36(1), 1-8.
Komori, T. (2010). Regulation of osteoblast differentiation by Runx2. Adv Exp Med Biol,
658, 43-49. doi: 10.1007/978-1-4419-1050-9_5
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., . . .
Kishimoto, T. (1997). Targeted disruption of Cbfa1 results in a complete lack of
bone formation owing to maturational arrest of osteoblasts. Cell, 89(5), 755-764.
Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., . . .
Penninger, J. M. (1999). OPGL is a key regulator of osteoclastogenesis,
lymphocyte development and lymph-node organogenesis. Nature, 397(6717),
315-323. doi: 10.1038/16852
Konrad, M., Schaller, A., Seelow, D., Pandey, A. V., Waldegger, S., Lesslauer, A., . . .
Weber, S. (2006). Mutations in the tight-junction gene claudin 19 (CLDN19) are
associated with renal magnesium wasting, renal failure, and severe ocular
involvement. Am J Hum Genet, 79(5), 949-957. doi: 10.1086/508617
Koo, W., & Walyat, N. (2013). Vitamin D and skeletal growth and development. Curr
Osteoporos Rep, 11(3), 188-193. doi: 10.1007/s11914-013-0156-1
Krause, G., Winkler, L., Mueller, S. L., Haseloff, R. F., Piontek, J., & Blasig, I. E.
(2008). Structure and function of claudins. Biochim Biophys Acta, 1778(3), 631645. doi: 10.1016/j.bbamem.2007.10.018
Krug, S. M., Gunzel, D., Conrad, M. P., Rosenthal, R., Fromm, A., Amasheh, S., . . .
Fromm, M. (2012). Claudin-17 forms tight junction channels with distinct anion
selectivity. Cell Mol Life Sci, 69(16), 2765-2778. doi: 10.1007/s00018-012-0949x
Krupa-Kozak, U. (2014). Pathologic bone alterations in celiac disease: etiology,
epidemiology, and treatment. Nutrition, 30(1), 16-24. doi:
10.1016/j.nut.2013.05.027
Kubota, T., Michigami, T., & Ozono, K. (2009). Wnt signaling in bone metabolism. J
Bone Miner Metab, 27(3), 265-271. doi: 10.1007/s00774-009-0064-8

146

Kwon, M. J. (2013). Emerging roles of claudins in human cancer. Int J Mol Sci, 14(9),
18148-18180. doi: 10.3390/ijms140918148
Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., . . .
Boyle, W. J. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast
differentiation and activation. Cell, 93(2), 165-176.
Laing, J. G., Chou, B. C., & Steinberg, T. H. (2005). ZO-1 alters the plasma membrane
localization and function of Cx43 in osteoblastic cells. J Cell Sci, 118(Pt 10),
2167-2176. doi: 10.1242/jcs.02329
Lane, N. E., & Yao, W. (2010). Glucocorticoid-induced bone fragility. Ann N Y Acad Sci,
1192, 81-83. doi: 10.1111/j.1749-6632.2009.05228.x
Lecanda, F., Warlow, P. M., Sheikh, S., Furlan, F., Steinberg, T. H., & Civitelli, R.
(2000). Connexin43 deficiency causes delayed ossification, craniofacial
abnormalities, and osteoblast dysfunction. J Cell Biol, 151(4), 931-944.
Lee, J. W., Hsiao, W. T., Chen, H. Y., Hsu, L. P., Chen, P. R., Lin, M. D., . . . Hsu, Y. C.
(2010). Upregulated claudin-1 expression confers resistance to cell death of
nasopharyngeal carcinoma cells. Int J Cancer, 126(6), 1353-1366. doi:
10.1002/ijc.24857
Lee, K., Ansar, M., Andrade, P. B., Khan, B., Santos-Cortez, R. L., Ahmad, W., & Leal,
S. M. (2012). Novel CLDN14 mutations in Pakistani families with autosomal
recessive non-syndromic hearing loss. Am J Med Genet A, 158A(2), 315-321. doi:
10.1002/ajmg.a.34407
Lee, S. K., & Lorenzo, J. (2006). Cytokines regulating osteoclast formation and function.
Curr Opin Rheumatol, 18(4), 411-418. doi: 10.1097/01.bor.0000231911.42666.78
Lee, S. K., Moon, J., Park, S. W., Song, S. Y., Chung, J. B., & Kang, J. K. (2005). Loss
of the tight junction protein claudin 4 correlates with histological growth-pattern
and differentiation in advanced gastric adenocarcinoma. Oncol Rep, 13(2), 193199.
Li, J., Chigurupati, S., Agarwal, R., Mughal, M. R., Mattson, M. P., Becker, K. G., . . .
Morin, P. J. (2009). Possible angiogenic roles for claudin-4 in ovarian cancer.
Cancer Biol Ther, 8(19), 1806-1814.
Linares, G. R., Brommage, R., Powell, D. R., Xing, W., Chen, S. T., Alshbool, F. Z., . . .
Mohan, S. (2012a). Claudin 18 is a novel negative regulator of bone resorption
and osteoclast differentiation. J Bone Miner Res, 27(7), 1553-1565. doi:
10.1002/jbmr.1600
Linares, G. R., Brommage, R., Powell, D. R., Xing, W. R., Chen, S. T., Alshbool, F. Z., .
. . Mohan, S. (2012b). Claudin 18 is a novel negative regulator of bone resorption

147

and osteoclast differentiation. Journal of Bone and Mineral Research, 27(7),
1553-1565. doi: Doi 10.1002/Jbmr.1600
Liu, Y., Wang, L., Lin, X. Y., Wang, J., Yu, J. H., Miao, Y., & Wang, E. H. (2012). Antiapoptotic effect of claudin-1 on TNF-alpha-induced apoptosis in human breast
cancer MCF-7 cells. Tumour Biol, 33(6), 2307-2315. doi: 10.1007/s13277-0120493-1
Liu, Y. F., Wu, Q., Xu, X. M., Ren, Y., Yu, L. N., Quan, C. S., & Li, Y. L. (2010).
[Effects of 17beta-estradiol on proliferation and migration of MCF-7 cell by
regulating expression of claudin-6]. Zhonghua Bing Li Xue Za Zhi, 39(1), 44-47.
Long, F. (2012). Building strong bones: molecular regulation of the osteoblast lineage.
Nat Rev Mol Cell Biol, 13(1), 27-38. doi: 10.1038/nrm3254
Lorenzo, J. A., Naprta, A., Rao, Y., Alander, C., Glaccum, M., Widmer, M., . . . Pilbeam,
C. C. (1998). Mice lacking the type I interleukin-1 receptor do not lose bone mass
after ovariectomy. Endocrinology, 139(6), 3022-3025. doi:
10.1210/endo.139.6.6128
Luk, J. M., Tong, M. K., Mok, B. W., Tam, P. C., Yeung, W. S., & Lee, K. F. (2004).
Sp1 site is crucial for the mouse claudin-19 gene expression in the kidney cells.
FEBS Lett, 578(3), 251-256. doi: 10.1016/j.febslet.2004.11.010
Marenzana, M., Shipley, A. M., Squitiero, P., Kunkel, J. G., & Rubinacci, A. (2005).
Bone as an ion exchange organ: evidence for instantaneous cell-dependent
calcium efflux from bone not due to resorption. Bone, 37(4), 545-554. doi:
10.1016/j.bone.2005.04.036
Marie, P. J. (2008). Transcription factors controlling osteoblastogenesis. Arch Biochem
Biophys, 473(2), 98-105. doi: 10.1016/j.abb.2008.02.030
Markov, A. G., Kruglova, N. M., Fomina, Y. A., Fromm, M., & Amasheh, S. (2012).
Altered expression of tight junction proteins in mammary epithelium after
discontinued suckling in mice. Pflugers Arch, 463(2), 391-398. doi:
10.1007/s00424-011-1034-2
Martin, T. A., Harrison, G. M., Watkins, G., & Jiang, W. G. (2008). Claudin-16 reduces
the aggressive behavior of human breast cancer cells. J Cell Biochem, 105(1), 4152. doi: 10.1002/jcb.21797
Matter, K., Aijaz, S., Tsapara, A., & Balda, M. S. (2005). Mammalian tight junctions in
the regulation of epithelial differentiation and proliferation. Curr Opin Cell Biol,
17(5), 453-458. doi: 10.1016/j.ceb.2005.08.003
Matter, K., & Balda, M. S. (2003). Signalling to and from tight junctions. Nat Rev Mol
Cell Biol, 4(3), 225-236. doi: 10.1038/nrm1055

148

Matter, K., & Balda, M. S. (2007). Epithelial tight junctions, gene expression and nucleojunctional interplay. J Cell Sci, 120(Pt 9), 1505-1511. doi: 10.1242/jcs.005975
Mazaud-Guittot, S., Meugnier, E., Pesenti, S., Wu, X., Vidal, H., Gow, A., & Le
Magueresse-Battistoni, B. (2010). Claudin 11 deficiency in mice results in loss of
the Sertoli cell epithelial phenotype in the testis. Biol Reprod, 82(1), 202-213. doi:
10.1095/biolreprod.109.078907
McGill, G. G., Horstmann, M., Widlund, H. R., Du, J., Motyckova, G., Nishimura, E. K.,
. . . Fisher, D. E. (2002). Bcl2 regulation by the melanocyte master regulator Mitf
modulates lineage survival and melanoma cell viability. Cell, 109(6), 707-718.
Meertens, L., Bertaux, C., Cukierman, L., Cormier, E., Lavillette, D., Cosset, F. L., &
Dragic, T. (2008). The tight junction proteins claudin-1, -6, and -9 are entry
cofactors for hepatitis C virus. J Virol, 82(7), 3555-3560. doi: 10.1128/JVI.0197707
Mellis, D. J., Itzstein, C., Helfrich, M. H., & Crockett, J. C. (2011). The skeleton: a multifunctional complex organ: the role of key signalling pathways in osteoclast
differentiation and in bone resorption. J Endocrinol, 211(2), 131-143. doi:
10.1530/JOE-11-0212
Milatz, S., Krug, S. M., Rosenthal, R., Gunzel, D., Muller, D., Schulzke, J. D., . . .
Fromm, M. (2010). Claudin-3 acts as a sealing component of the tight junction for
ions of either charge and uncharged solutes. Biochim Biophys Acta, 1798(11),
2048-2057. doi: 10.1016/j.bbamem.2010.07.014
Mineta, K., Yamamoto, Y., Yamazaki, Y., Tanaka, H., Tada, Y., Saito, K., . . . Tsukita, S.
(2011). Predicted expansion of the claudin multigene family. FEBS Lett, 585(4),
606-612. doi: 10.1016/j.febslet.2011.01.028
Miwa, N., Furuse, M., Tsukita, S., Niikawa, N., Nakamura, Y., & Furukawa, Y. (2001).
Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its
frequent upregulation in human colorectal cancers. Oncol Res, 12(11-12), 469476.
Miyamoto, T., Morita, K., Takemoto, D., Takeuchi, K., Kitano, Y., Miyakawa, T., . . .
Tsukita, S. (2005). Tight junctions in Schwann cells of peripheral myelinated
axons: a lesson from claudin-19-deficient mice. J Cell Biol, 169(3), 527-538. doi:
10.1083/jcb.200501154
Mohan, S., Kapoor, A., Singgih, A., Zhang, Z., Taylor, T., Yu, H., . . . Baylink, D. J.
(2005). Spontaneous fractures in the mouse mutant sfx are caused by deletion of
the gulonolactone oxidase gene, causing vitamin C deficiency. J Bone Miner Res,
20(9), 1597-1610. doi: 10.1359/JBMR.050406

149

Mohan, S., & Kesavan, C. (2012). Role of insulin-like growth factor-1 in the regulation
of skeletal growth. Curr Osteoporos Rep, 10(2), 178-186. doi: 10.1007/s11914012-0100-9
Monroe, D. G., McGee-Lawrence, M. E., Oursler, M. J., & Westendorf, J. J. (2012).
Update on Wnt signaling in bone cell biology and bone disease. Gene, 492(1), 118. doi: 10.1016/j.gene.2011.10.044
Morin, P. J. (2005). Claudin proteins in human cancer: promising new targets for
diagnosis and therapy. Cancer Res, 65(21), 9603-9606. doi: 10.1158/00085472.CAN-05-2782
Morita, K., Furuse, M., Fujimoto, K., & Tsukita, S. (1999). Claudin multigene family
encoding four-transmembrane domain protein components of tight junction
strands. Proc Natl Acad Sci U S A, 96(2), 511-516.
Morita, K., Sasaki, H., Fujimoto, K., Furuse, M., & Tsukita, S. (1999). Claudin-11/OSPbased tight junctions of myelin sheaths in brain and Sertoli cells in testis. J Cell
Biol, 145(3), 579-588.
Morrison, N. A., Qi, J. C., Tokita, A., Kelly, P. J., Crofts, L., Nguyen, T. V., . . . Eisman,
J. A. (1994). Prediction of bone density from vitamin D receptor alleles. Nature,
367(6460), 284-287. doi: 10.1038/367284a0
Mulari, M., Vaaraniemi, J., & Vaananen, H. K. (2003). Intracellular membrane
trafficking in bone resorbing osteoclasts. Microsc Res Tech, 61(6), 496-503. doi:
10.1002/jemt.10371
Mundlos, S., Otto, F., Mundlos, C., Mulliken, J. B., Aylsworth, A. S., Albright, S., . . .
Olsen, B. R. (1997). Mutations involving the transcription factor CBFA1 cause
cleidocranial dysplasia. Cell, 89(5), 773-779.
Murad, M. H., Elamin, K. B., Abu Elnour, N. O., Elamin, M. B., Alkatib, A. A.,
Fatourechi, M. M., . . . Montori, V. M. (2011). Clinical review: The effect of
vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrinol
Metab, 96(10), 2997-3006. doi: 10.1210/jc.2011-1193
Nakahama, K. (2010). Cellular communications in bone homeostasis and repair. Cell Mol
Life Sci, 67(23), 4001-4009. doi: 10.1007/s00018-010-0479-3
Nakamura, T. (2008). [Goals of treatment for osteoporosis]. Clin Calcium, 18(10), 13891395. doi: CliCa081013891395
Nakano, Y., Kim, S. H., Kim, H. M., Sanneman, J. D., Zhang, Y., Smith, R. J., . . . Banfi,
B. (2009). A claudin-9-based ion permeability barrier is essential for hearing.
PLoS Genet, 5(8), e1000610. doi: 10.1371/journal.pgen.1000610

150

Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J. M., Behringer, R. R., & de
Crombrugghe, B. (2002). The novel zinc finger-containing transcription factor
osterix is required for osteoblast differentiation and bone formation. Cell, 108(1),
17-29.
Naot, D., & Cornish, J. (2008). The role of peptides and receptors of the calcitonin family
in the regulation of bone metabolism. Bone, 43(5), 813-818. doi:
10.1016/j.bone.2008.07.003
Nishida, M., Yoshida, M., Nishiumi, S., Furuse, M., & Azuma, T. (2013). Claudin-2
regulates colorectal inflammation via myosin light chain kinase-dependent
signaling. Dig Dis Sci, 58(6), 1546-1559. doi: 10.1007/s10620-012-2535-3
Nitta, T., Hata, M., Gotoh, S., Seo, Y., Sasaki, H., Hashimoto, N., . . . Tsukita, S. (2003).
Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J
Cell Biol, 161(3), 653-660. doi: 10.1083/jcb.200302070
Nunbhakdi-Craig, V., Machleidt, T., Ogris, E., Bellotto, D., White, C. L., 3rd, & Sontag,
E. (2002). Protein phosphatase 2A associates with and regulates atypical PKC and
the epithelial tight junction complex. J Cell Biol, 158(5), 967-978. doi:
10.1083/jcb.200206114
Ohkubo, T., & Ozawa, M. (2004). The transcription factor Snail downregulates the tight
junction components independently of E-cadherin downregulation. J Cell Sci,
117(Pt 9), 1675-1685. doi: 10.1242/jcs.01004
Ohlsson, C., Borjesson, A. E., & Vandenput, L. (2012). Sex steroids and bone health in
men. Bonekey Rep, 1, 2. doi: 10.1038/bonekey.2012.3
Ohtsuki, S., Yamaguchi, H., Katsukura, Y., Asashima, T., & Terasaki, T. (2008). mRNA
expression levels of tight junction protein genes in mouse brain capillary
endothelial cells highly purified by magnetic cell sorting. J Neurochem, 104(1),
147-154. doi: 10.1111/j.1471-4159.2007.05008.x
Okugawa, T., Oshima, T., Chen, X., Hori, K., Tomita, T., Fukui, H., . . . Miwa, H.
(2012). Down-regulation of claudin-3 is associated with proliferative potential in
early gastric cancers. Dig Dis Sci, 57(6), 1562-1567. doi: 10.1007/s10620-0122043-5
Oshima, T., Shan, J., Okugawa, T., Chen, X., Hori, K., Tomita, T., . . . Miwa, H. (2013).
Down-regulation of claudin-18 is associated with the proliferative and invasive
potential of gastric cancer at the invasive front. PLoS One, 8(9), e74757. doi:
10.1371/journal.pone.0074757
Otto, F., Thornell, A. P., Crompton, T., Denzel, A., Gilmour, K. C., Rosewell, I. R., . . .
Owen, M. J. (1997). Cbfa1, a candidate gene for cleidocranial dysplasia
syndrome, is essential for osteoblast differentiation and bone development. Cell,
89(5), 765-771.
151

Panula, J., Pihlajamaki, H., Mattila, V. M., Jaatinen, P., Vahlberg, T., Aarnio, P., &
Kivela, S. L. (2011). Mortality and cause of death in hip fracture patients aged 65
or older: a population-based study. BMC Musculoskelet Disord, 12, 105. doi:
10.1186/1471-2474-12-105
Pasco, J. A., Sanders, K. M., Hoekstra, F. M., Henry, M. J., Nicholson, G. C., &
Kotowicz, M. A. (2005). The human cost of fracture. Osteoporos Int, 16(12),
2046-2052. doi: 10.1007/s00198-005-1997-y
Persy, V., & D'Haese, P. (2009). Vascular calcification and bone disease: the
calcification paradox. Trends Mol Med, 15(9), 405-416. doi:
10.1016/j.molmed.2009.07.001
Piontek, J., Winkler, L., Wolburg, H., Muller, S. L., Zuleger, N., Piehl, C., . . . Blasig, I.
E. (2008). Formation of tight junction: determinants of homophilic interaction
between classic claudins. FASEB J, 22(1), 146-158. doi: 10.1096/fj.07-8319com
Pope, J. L., Bhat, A. A., Sharma, A., Ahmad, R., Krishnan, M., Washington, M. K., . . .
Dhawan, P. (2013). Claudin-1 regulates intestinal epithelial homeostasis through
the modulation of Notch-signalling. Gut. doi: 10.1136/gutjnl-2012-304241
Prele, C. M., Horton, M. A., Caterina, P., & Stenbeck, G. (2003). Identification of the
molecular mechanisms contributing to polarized trafficking in osteoblasts. Exp
Cell Res, 282(1), 24-34.
Prince, C. W., & Butler, W. T. (1987). 1,25-Dihydroxyvitamin D3 regulates the
biosynthesis of osteopontin, a bone-derived cell attachment protein, in clonal
osteoblast-like osteosarcoma cells. Coll Relat Res, 7(4), 305-313.
Proff, P., & Romer, P. (2009). The molecular mechanism behind bone remodelling: a
review. Clin Oral Investig, 13(4), 355-362. doi: 10.1007/s00784-009-0268-2
Qu, Q., Perala-Heape, M., Kapanen, A., Dahllund, J., Salo, J., Vaananen, H. K., &
Harkonen, P. (1998). Estrogen enhances differentiation of osteoblasts in mouse
bone marrow culture. Bone, 22(3), 201-209.
Rahner, C., Mitic, L. L., & Anderson, J. M. (2001). Heterogeneity in expression and
subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and
gut. Gastroenterology, 120(2), 411-422.
Raisz, L. G. (2005). Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J
Clin Invest, 115(12), 3318-3325. doi: 10.1172/JCI27071
Ramasamy, I. (2006). Recent advances in physiological calcium homeostasis. Clin Chem
Lab Med, 44(3), 237-273. doi: 10.1515/CCLM.2006.046

152

Richards, J. B., Zheng, H. F., & Spector, T. D. (2012). Genetics of osteoporosis from
genome-wide association studies: advances and challenges. Nat Rev Genet, 13(8),
576-588. doi: 10.1038/nrg3228
Ross, F. P., & Teitelbaum, S. L. (2005). alphavbeta3 and macrophage colony-stimulating
factor: partners in osteoclast biology. Immunol Rev, 208, 88-105. doi:
10.1111/j.0105-2896.2005.00331.x
Rubinacci, A., Benelli, F. D., Borgo, E., & Villa, I. (2000). Bone as an ion exchange
system: evidence for a pump-leak mechanism devoted to the maintenance of high
bone K(+). Am J Physiol Endocrinol Metab, 278(1), E15-24.
Sahin, U., Koslowski, M., Dhaene, K., Usener, D., Brandenburg, G., Seitz, G., . . .
Tureci, O. (2008). Claudin-18 splice variant 2 is a pan-cancer target suitable for
therapeutic antibody development. Clin Cancer Res, 14(23), 7624-7634. doi:
10.1158/1078-0432.CCR-08-1547
Saitou, M., Fujimoto, K., Doi, Y., Itoh, M., Fujimoto, T., Furuse, M., . . . Tsukita, S.
(1998). Occludin-deficient embryonic stem cells can differentiate into polarized
epithelial cells bearing tight junctions. J Cell Biol, 141(2), 397-408.
Saitou, M., Furuse, M., Sasaki, H., Schulzke, J. D., Fromm, M., Takano, H., . . . Tsukita,
S. (2000). Complex phenotype of mice lacking occludin, a component of tight
junction strands. Mol Biol Cell, 11(12), 4131-4142.
Sakai, S., Takaishi, H., Matsuzaki, K., Kaneko, H., Furukawa, M., Miyauchi, Y., . . .
Toyama, Y. (2009). 1-Alpha, 25-dihydroxy vitamin D3 inhibits
osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J Bone
Miner Metab, 27(6), 643-652. doi: 10.1007/s00774-009-0084-4
Salo, J., Lehenkari, P., Mulari, M., Metsikko, K., & Vaananen, H. K. (1997). Removal of
osteoclast bone resorption products by transcytosis. Science, 276(5310), 270-273.
Sanada, Y., Oue, N., Mitani, Y., Yoshida, K., Nakayama, H., & Yasui, W. (2006a).
Down-regulation of the claudin-18 gene, identified through serial analysis of gene
expression data analysis, in gastric cancer with an intestinal phenotype. Journal of
Pathology, 208(5), 633-642. doi: Doi 10.1002/Path.1922
Sanada, Y., Oue, N., Mitani, Y., Yoshida, K., Nakayama, H., & Yasui, W. (2006b).
Down-regulation of the claudin-18 gene, identified through serial analysis of gene
expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol,
208(5), 633-642. doi: 10.1002/path.1922
Sas, D., Hu, M., Moe, O. W., & Baum, M. (2008). Effect of claudins 6 and 9 on
paracellular permeability in MDCK II cells. Am J Physiol Regul Integr Comp
Physiol, 295(5), R1713-1719. doi: 10.1152/ajpregu.90596.2008

153

Schaffler, M. B., & Kennedy, O. D. (2012). Osteocyte signaling in bone. Curr
Osteoporos Rep, 10(2), 118-125. doi: 10.1007/s11914-012-0105-4
Seeman, E. (2003). Invited Review: Pathogenesis of osteoporosis. J Appl Physiol (1985),
95(5), 2142-2151. doi: 10.1152/japplphysiol.00564.2003
Shang, X., Lin, X., Manorek, G., & Howell, S. B. (2013). Claudin-3 and claudin-4
regulate sensitivity to cisplatin by controlling expression of the copper and
cisplatin influx transporter CTR1. Mol Pharmacol, 83(1), 85-94. doi:
10.1124/mol.112.079798
Shrestha, A., & McClane, B. A. (2013). Human claudin-8 and -14 are receptors capable
of conveying the cytotoxic effects of Clostridium perfringens enterotoxin. MBio,
4(1). doi: 10.1128/mBio.00594-12
Sierralta, J., & Mendoza, C. (2004). PDZ-containing proteins: alternative splicing as a
source of functional diversity. Brain Res Brain Res Rev, 47(1-3), 105-115. doi:
10.1016/j.brainresrev.2004.06.002
Simon, D. B., Lu, Y., Choate, K. A., Velazquez, H., Al-Sabban, E., Praga, M., . . . Lifton,
R. P. (1999). Paracellin-1, a renal tight junction protein required for paracellular
Mg2+ resorption. Science, 285(5424), 103-106.
Singh, A. B., Sharma, A., Smith, J. J., Krishnan, M., Chen, X., Eschrich, S., . . . Dhawan,
P. (2011). Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin
expression in colon cancer cells. Gastroenterology, 141(6), 2140-2153. doi:
10.1053/j.gastro.2011.08.038
Sipponen, P., & Harkonen, M. (2010). Hypochlorhydric stomach: a risk condition for
calcium malabsorption and osteoporosis? Scandinavian Journal of
Gastroenterology, 45(2), 133-138. doi: Doi 10.3109/00365520903434117
Smith, D. M., Nance, W. E., Kang, K. W., Christian, J. C., & Johnston, C. C., Jr. (1973).
Genetic factors in determining bone mass. J Clin Invest, 52(11), 2800-2808. doi:
10.1172/JCI107476
Soares, A. M., Arana-Chavez, V. E., Reid, A. R., & Katchburian, E. (1992). Lanthanum
tracer and freeze-fracture studies suggest that compartmentalisation of early bone
matrix may be related to initial mineralisation. J Anat, 181 ( Pt 2), 345-356.
Sourisseau, T., Georgiadis, A., Tsapara, A., Ali, R. R., Pestell, R., Matter, K., & Balda,
M. S. (2006). Regulation of PCNA and cyclin D1 expression and epithelial
morphogenesis by the ZO-1-regulated transcription factor ZONAB/DbpA. Mol
Cell Biol, 26(6), 2387-2398. doi: 10.1128/MCB.26.6.2387-2398.2006
Steed, E., Balda, M. S., & Matter, K. (2010). Dynamics and functions of tight junctions.
Trends Cell Biol, 20(3), 142-149. doi: 10.1016/j.tcb.2009.12.002

154

Stevenson, B. R., Siliciano, J. D., Mooseker, M. S., & Goodenough, D. A. (1986).
Identification of ZO-1: a high molecular weight polypeptide associated with the
tight junction (zonula occludens) in a variety of epithelia. J Cell Biol, 103(3), 755766.
Stringer, B., Waddington, R., Houghton, A., Stone, M., Russell, G., & Foster, G. (2007).
Serum from postmenopausal women directs differentiation of human clonal
osteoprogenitor cells from an osteoblastic toward an adipocytic phenotype. Calcif
Tissue Int, 80(4), 233-243. doi: 10.1007/s00223-007-9016-2
Suh, Y., Yoon, C. H., Kim, R. K., Lim, E. J., Oh, Y. S., Hwang, S. G., . . . Lee, S. J.
(2013). Claudin-1 induces epithelial-mesenchymal transition through activation of
the c-Abl-ERK signaling pathway in human liver cells. Oncogene, 32(41), 48734882. doi: 10.1038/onc.2012.505
Sun, C., Yi, T., Song, X., Li, S., Qi, X., Chen, X., . . . Zhao, X. (2011). Efficient
inhibition of ovarian cancer by short hairpin RNA targeting claudin-3. Oncol Rep,
26(1), 193-200. doi: 10.3892/or.2011.1275
Supanchart, C., & Kornak, U. (2008). Ion channels and transporters in osteoclasts. Arch
Biochem Biophys, 473(2), 161-165. doi: 10.1016/j.abb.2008.03.029
Sweet, M. G., Sweet, J. M., Jeremiah, M. P., & Galazka, S. S. (2009). Diagnosis and
treatment of osteoporosis. Am Fam Physician, 79(3), 193-200.
Syed, F., & Khosla, S. (2005). Mechanisms of sex steroid effects on bone. Biochem
Biophys Res Commun, 328(3), 688-696. doi: 10.1016/j.bbrc.2004.11.097
Tahimic, C. G., Wang, Y., & Bikle, D. D. (2013). Anabolic effects of IGF-1 signaling on
the skeleton. Front Endocrinol (Lausanne), 4, 6. doi: 10.3389/fendo.2013.00006
Takahashi, N., Udagawa, N., & Suda, T. (2014). Vitamin D endocrine system and
osteoclasts. Bonekey Rep, 3, 495. doi: 10.1038/bonekey.2013.229
Takasu, H., Sugita, A., Uchiyama, Y., Katagiri, N., Okazaki, M., Ogata, E., & Ikeda, K.
(2006). c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and
synthesis of new analogs. J Clin Invest, 116(2), 528-535. doi: 10.1172/JCI24742
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., . . . Taniguchi,
T. (2002). Induction and activation of the transcription factor NFATc1 (NFAT2)
integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell,
3(6), 889-901.
Takeshita, S., Kaji, K., & Kudo, A. (2000). Identification and characterization of the new
osteoclast progenitor with macrophage phenotypes being able to differentiate into
mature osteoclasts. J Bone Miner Res, 15(8), 1477-1488. doi:
10.1359/jbmr.2000.15.8.1477

155

Tamura, A., Kitano, Y., Hata, M., Katsuno, T., Moriwaki, K., Sasaki, H., . . . Tsukita, S.
(2008). Megaintestine in claudin-15-deficient mice. Gastroenterology, 134(2),
523-534. doi: 10.1053/j.gastro.2007.11.040
Tamura, A., Yamazaki, Y., Hayashi, D., Suzuki, K., Sentani, K., Yasui, W., & Tsukita, S.
(2012). Claudin-based paracellular proton barrier in the stomach. Ann N Y Acad
Sci, 1258, 108-114. doi: 10.1111/j.1749-6632.2012.06570.x
Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., . . . et al.
(1993). Soluble interleukin-6 receptor triggers osteoclast formation by interleukin
6. Proc Natl Acad Sci U S A, 90(24), 11924-11928.
Tanaka, M., Kamata, R., & Sakai, R. (2005). EphA2 phosphorylates the cytoplasmic tail
of Claudin-4 and mediates paracellular permeability. J Biol Chem, 280(51),
42375-42382. doi: 10.1074/jbc.M503786200
Targownik, L. E., Bernstein, C. N., & Leslie, W. D. (2013). Inflammatory bowel disease
and the risk of osteoporosis and fracture. Maturitas, 76(4), 315-319. doi:
10.1016/j.maturitas.2013.09.009
Tatum, R., Zhang, Y., Salleng, K., Lu, Z., Lin, J. J., Lu, Q., . . . Chen, Y. H. (2010).
Renal salt wasting and chronic dehydration in claudin-7-deficient mice. Am J
Physiol Renal Physiol, 298(1), F24-34. doi: 10.1152/ajprenal.00450.2009
Thompson, P. D., Tipney, H., Brass, A., Noyes, H., Kemp, S., Naessens, J., & Tassabehji,
M. (2010). Claudin 13, a member of the claudin family regulated in mouse stress
induced erythropoiesis. PLoS One, 5(9). doi: 10.1371/journal.pone.0012667
Thorleifsson, G., Holm, H., Edvardsson, V., Walters, G. B., Styrkarsdottir, U.,
Gudbjartsson, D. F., . . . Stefansson, K. (2009). Sequence variants in the CLDN14
gene associate with kidney stones and bone mineral density. Nat Genet, 41(8),
926-930. doi: 10.1038/ng.404
Thuma, F., & Zoller, M. (2013). EpCAM-associated claudin-7 supports lymphatic spread
and drug resistance in rat pancreatic cancer. Int J Cancer, 133(4), 855-866. doi:
10.1002/ijc.28085
Tiwari-Woodruff, S. K., Buznikov, A. G., Vu, T. Q., Micevych, P. E., Chen, K.,
Kornblum, H. I., & Bronstein, J. M. (2001). OSP/claudin-11 forms a complex
with a novel member of the tetraspanin super family and beta1 integrin and
regulates proliferation and migration of oligodendrocytes. J Cell Biol, 153(2),
295-305.
Tondravi, M. M., McKercher, S. R., Anderson, K., Erdmann, J. M., Quiroz, M., Maki, R.,
& Teitelbaum, S. L. (1997). Osteopetrosis in mice lacking haematopoietic
transcription factor PU.1. Nature, 386(6620), 81-84. doi: 10.1038/386081a0

156

Traweger, A., Fuchs, R., Krizbai, I. A., Weiger, T. M., Bauer, H. C., & Bauer, H. (2003).
The tight junction protein ZO-2 localizes to the nucleus and interacts with the
heterogeneous nuclear ribonucleoprotein scaffold attachment factor-B. J Biol
Chem, 278(4), 2692-2700. doi: 10.1074/jbc.M206821200
Traweger, A., Lehner, C., Farkas, A., Krizbai, I. A., Tempfer, H., Klement, E., . . . Bauer,
H. (2008). Nuclear Zonula occludens-2 alters gene expression and junctional
stability in epithelial and endothelial cells. Differentiation, 76(1), 99-106. doi:
10.1111/j.1432-0436.2007.00227.x
Tureci, O., Koslowski, M., Helftenbein, G., Castle, J., Rohde, C., Dhaene, K., . . . Sahin,
U. (2011). Claudin-18 gene structure, regulation, and expression is evolutionary
conserved in mammals. Gene, 481(2), 83-92. doi: 10.1016/j.gene.2011.04.007
Turksen, K., & Troy, T. C. (2001). Claudin-6: a novel tight junction molecule is
developmentally regulated in mouse embryonic epithelium. Dev Dyn, 222(2),
292-300. doi: 10.1002/dvdy.1174
Turksen, K., & Troy, T. C. (2002). Permeability barrier dysfunction in transgenic mice
overexpressing claudin 6. Development, 129(7), 1775-1784.
Tveit, M., Rosengren, B. E., Nilsson, J. A., & Karlsson, M. K. (2014). Exercise in youth:
High bone mass, large bone size, and low fracture risk in old age. Scand J Med
Sci Sports. doi: 10.1111/sms.12305
Urano, T., & Inoue, S. (2014). Genetics of osteoporosis. Biochem Biophys Res Commun.
doi: 10.1016/j.bbrc.2014.07.141
Vaananen, H. K., & Laitala-Leinonen, T. (2008). Osteoclast lineage and function. Arch
Biochem Biophys, 473(2), 132-138. doi: 10.1016/j.abb.2008.03.037
Vaananen, H. K., Zhao, H., Mulari, M., & Halleen, J. M. (2000). The cell biology of
osteoclast function. J Cell Sci, 113 ( Pt 3), 377-381.
Van Itallie, C., Rahner, C., & Anderson, J. M. (2001). Regulated expression of claudin-4
decreases paracellular conductance through a selective decrease in sodium
permeability. J Clin Invest, 107(10), 1319-1327. doi: 10.1172/JCI12464
Van Itallie, C. M., & Anderson, J. M. (2006). Claudins and epithelial paracellular
transport. Annu Rev Physiol, 68, 403-429. doi:
10.1146/annurev.physiol.68.040104.131404
Van Itallie, C. M., Fanning, A. S., & Anderson, J. M. (2003). Reversal of charge
selectivity in cation or anion-selective epithelial lines by expression of different
claudins. Am J Physiol Renal Physiol, 285(6), F1078-1084. doi:
10.1152/ajprenal.00116.2003

157

Van Itallie, C. M., Rogan, S., Yu, A., Vidal, L. S., Holmes, J., & Anderson, J. M. (2006).
Two splice variants of claudin-10 in the kidney create paracellular pores with
different ion selectivities. Am J Physiol Renal Physiol, 291(6), F1288-1299. doi:
10.1152/ajprenal.00138.2006
Veshnyakova, A., Piontek, J., Protze, J., Waziri, N., Heise, I., & Krause, G. (2012).
Mechanism of Clostridium perfringens enterotoxin interaction with claudin-3/-4
protein suggests structural modifications of the toxin to target specific claudins. J
Biol Chem, 287(3), 1698-1708. doi: 10.1074/jbc.M111.312165
Wada, M., Tamura, A., Takahashi, N., & Tsukita, S. (2012). Loss of Claudins 2 and 15
From Mice Causes Defects in Paracellular Na(+) Flow and Nutrient Transport in
Gut and Leads to Death from Malnutrition. Gastroenterology. doi:
10.1053/j.gastro.2012.10.035
Wada, M., Tamura, A., Takahashi, N., & Tsukita, S. (2013). Loss of claudins 2 and 15
from mice causes defects in paracellular Na+ flow and nutrient transport in gut
and leads to death from malnutrition. Gastroenterology, 144(2), 369-380. doi:
10.1053/j.gastro.2012.10.035
Wang, B. L., Dai, C. L., Quan, J. X., Zhu, Z. F., Zheng, F., Zhang, H. X., . . . Qiu, M. C.
(2006). Parathyroid hormone regulates osterix and Runx2 mRNA expression
predominantly through protein kinase A signaling in osteoblast-like cells. J
Endocrinol Invest, 29(2), 101-108.
Wang, F., Daugherty, B., Keise, L. L., Wei, Z., Foley, J. P., Savani, R. C., & Koval, M.
(2003). Heterogeneity of claudin expression by alveolar epithelial cells. Am J
Respir Cell Mol Biol, 29(1), 62-70. doi: 10.1165/rcmb.2002-0180OC
Wang, L., Xue, Y., Shen, Y., Li, W., Cheng, Y., Yan, X., . . . Zeng, F. (2012). Claudin 6:
a novel surface marker for characterizing mouse pluripotent stem cells. Cell Res,
22(6), 1082-1085. doi: 10.1038/cr.2012.77
Wang, Z. Q., Ovitt, C., Grigoriadis, A. E., Mohle-Steinlein, U., Ruther, U., & Wagner, E.
F. (1992). Bone and haematopoietic defects in mice lacking c-fos. Nature,
360(6406), 741-745. doi: 10.1038/360741a0
Webb, P. G., Spillman, M. A., & Baumgartner, H. K. (2013). Claudins play a role in
normal and tumor cell motility. BMC Cell Biol, 14, 19. doi: 10.1186/1471-212114-19
Weilbaecher, K. N., Motyckova, G., Huber, W. E., Takemoto, C. M., Hemesath, T. J.,
Xu, Y., . . . Fisher, D. E. (2001). Linkage of M-CSF signaling to Mitf, TFE3, and
the osteoclast defect in Mitf(mi/mi) mice. Mol Cell, 8(4), 749-758.
Weinger, J. M., & Holtrop, M. E. (1974). An ultrastructural study of bone cells: the
occurrence of microtubules, microfilaments and tight junctions. Calcif Tissue Res,
14(1), 15-29.
158

Wen, H., Watry, D. D., Marcondes, M. C., & Fox, H. S. (2004). Selective decrease in
paracellular conductance of tight junctions: role of the first extracellular domain
of claudin-5. Mol Cell Biol, 24(19), 8408-8417. doi: 10.1128/MCB.24.19.84088417.2004
Wilcox, E. R., Burton, Q. L., Naz, S., Riazuddin, S., Smith, T. N., Ploplis, B., . . .
Friedman, T. B. (2001). Mutations in the gene encoding tight junction claudin-14
cause autosomal recessive deafness DFNB29. Cell, 104(1), 165-172.
Wolburg, H., Wolburg-Buchholz, K., Liebner, S., & Engelhardt, B. (2001). Claudin-1,
claudin-2 and claudin-11 are present in tight junctions of choroid plexus
epithelium of the mouse. Neurosci Lett, 307(2), 77-80.
Wongdee, K., Pandaranandaka, J., Teerapornpuntakit, J., Tudpor, K., Thongbunchoo, J.,
Thongon, N., . . . Charoenphandhu, N. (2008). Osteoblasts express claudins and
tight junction-associated proteins. Histochem Cell Biol, 130(1), 79-90. doi:
10.1007/s00418-008-0419-6
Wongdee, K., Riengrojpitak, S., Krishnamra, N., & Charoenphandhu, N. (2010). Claudin
expression in the bone-lining cells of female rats exposed to long-standing
acidemia. Exp Mol Pathol, 88(2), 305-310. doi: 10.1016/j.yexmp.2009.12.005
Wright, M. J., Proctor, D. D., Insogna, K. L., & Kerstetter, J. E. (2008). Proton pumpinhibiting drugs, calcium homeostasis, and bone health. Nutrition Reviews, 66(2),
103-108. doi: DOI 10.1111/j.1753-4887.2008.00015.x
Xing, W., Pourteymoor, S., & Mohan, S. (2011). Ascorbic acid regulates osterix
expression in osteoblasts by activation of prolyl hydroxylase and ubiquitinationmediated proteosomal degradation pathway. Physiol Genomics, 43(12), 749-757.
doi: 10.1152/physiolgenomics.00229.2010
Yamashita, T., Yao, Z., Li, F., Zhang, Q., Badell, I. R., Schwarz, E. M., . . . Boyce, B. F.
(2007). NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand
(RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation
by activating c-Fos and NFATc1. J Biol Chem, 282(25), 18245-18253. doi:
10.1074/jbc.M610701200
Yavropoulou, M. P., & Yovos, J. G. (2007). The role of the Wnt signaling pathway in
osteoblast commitment and differentiation. Hormones (Athens), 6(4), 279-294.
Yoon, C. H., Kim, M. J., Park, M. J., Park, I. C., Hwang, S. G., An, S., . . . Lee, S. J.
(2010). Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCdelta) signaling
and has a causal role in the acquisition of invasive capacity in human liver cells. J
Biol Chem, 285(1), 226-233. doi: 10.1074/jbc.M109.054189
Yoshida, H., Hayashi, S., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., . . .
Nishikawa, S. (1990). The murine mutation osteopetrosis is in the coding region

159

of the macrophage colony stimulating factor gene. Nature, 345(6274), 442-444.
doi: 10.1038/345442a0
Yu, A. S., Cheng, M. H., Angelow, S., Gunzel, D., Kanzawa, S. A., Schneeberger, E. E., .
. . Coalson, R. D. (2009). Molecular basis for cation selectivity in claudin-2-based
paracellular pores: identification of an electrostatic interaction site. J Gen Physiol,
133(1), 111-127. doi: 10.1085/jgp.200810154
Yu, A. S., Enck, A. H., Lencer, W. I., & Schneeberger, E. E. (2003). Claudin-8
expression in Madin-Darby canine kidney cells augments the paracellular barrier
to cation permeation. J Biol Chem, 278(19), 17350-17359. doi:
10.1074/jbc.M213286200
Zallone, A. (2006). Direct and indirect estrogen actions on osteoblasts and osteoclasts.
Ann N Y Acad Sci, 1068, 173-179. doi: 10.1196/annals.1346.019
Zavala-Zendejas, V. E., Torres-Martinez, A. C., Salas-Morales, B., Fortoul, T. I.,
Montano, L. F., & Rendon-Huerta, E. P. (2011). Claudin-6, 7, or 9 overexpression
in the human gastric adenocarcinoma cell line AGS increases its invasiveness,
migration, and proliferation rate. Cancer Invest, 29(1), 1-11. doi:
10.3109/07357907.2010.512594
Zhang, C. (2010). Transcriptional regulation of bone formation by the osteoblast-specific
transcription factor Osx. J Orthop Surg Res, 5, 37. doi: 10.1186/1749-799X-5-37
Zheng, A., Yuan, F., Li, Y., Zhu, F., Hou, P., Li, J., . . . Deng, H. (2007). Claudin-6 and
claudin-9 function as additional coreceptors for hepatitis C virus. J Virol, 81(22),
12465-12471. doi: 10.1128/JVI.01457-07
Zheng, J. Y., Yu, D., Foroohar, M., Ko, E., Chan, J., Kim, N., . . . Pang, S. (2003).
Regulation of the expression of the prostate-specific antigen by claudin-7. J
Membr Biol, 194(3), 187-197. doi: 10.1007/s00232-003-2038-4

160

